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Abstract 
Abstract 
There is a considerable interest in small molecules that bind to DNA because of their 
potential use in chemotherapeutics, regulators of gene expression and tools for 
molecular biology and nanotechnology. Transition metal complexes, which provide 
high stability, structural versatility and unique spectroscopic and redox properties, 
are explored largely for DNA binding studies. These metal complexes are capable of 
binding to DNA by multitude of interactions via, DNA intercalation, DNA groove 
binding or external electrostatic or covalent linkage and cleavage of DNA by virtue 
of their intrinsic chemical, electrochemical or photochemical reactivities. Metal-
nucleic acid chemistry has gained momentum after Rosenberg's discovery of 
cisplatin- cis-diamminedichloroplatinum(II) and its subsequent clinical use for 
treating solid tumors (testicular and ovarian cancers). DNA has been identified as the 
possible primary molecular target of both cisplatin and other metal based drugs. The 
clinical use of cisplatin, however, is severely limited by its toxic side effects, its 
limited applicability to relatively narrow range of tumors and acquired or inherent 
resistance. This has spurred research for the development of new non-platinum 
metal-based anticancer agents which are more efficacious, less toxic and can 
overcome resistance. Therefore, alternate strategies based on different metal ions, 
ligand ftinctionality, shape or geometric requirement and stereoselectivity were 
opted to design these new cancer drug therapeutics. In the majority of complexes 
studied, the metal usually serves as the redox center and the ligand is responsible for 
DNA recognition, nevertheless metals are also used as building blocks for well 
defined, three dimensional constructs. The modular approach of optimising the 
design by the use of coordinating ligands, which themselves are active 
pharmacophores, offers to fine-tune metals properties and in this manner tailored 
multifunctional ligand can assist to achieve target selectivity/improved solubility. 
The mechanism of cytotoxic action which is related to DNA binding affinity can 
also vary accordingly, as the biological activity is strongly dependent on structure-
activity relationship. This optimization based on shape selectivity is introduced by 
chiral ligands which interact with DNA- an inherently chiral biomolecule in a site-
specific manner. Furthermore, chirality may enhance the pharmacological behaviour 
of complexes, by adopting a specific conformation; thereby improving the DNA-
binding affinity to provide recognition elements in the metal nucleobase recognition 
process. The interaction of metal complexes with nucleobases and/or nucleotides is 
very well established, and is now known to be the basis of antitumor drug action. 
The metal complexes, which are favoured as effective drug candidates are molecules 
that; damage DNA; block DNA synthesis indirectly through inhibition of nucleic 
acid precursor biosynthesis; disrupt hormonal stimulation of cell growth; must 
recognize nucleic acid particularly in sequence specific fashion and then bind to 
DNA in a way that alters their function. 
The characterization of DNA recognition by aromatic metal complexes has been 
substantially aided by studying the DNA cleavage activity. Literature reveals that 
double strand breaks in duplex DNA are thought to be more significant sources of 
cell lethality as compared to single strand breaks, as they are less readily repaired by 
DNA repair mechanism. A number of copper(n) complexes are exceptional 
candidates for mediation of strand scission of duplex DNA. The metal complex 
DNA Interaction has been investigated using a host of biophysical methods like 
electronics absorption, fluorescence spectroscopy, cyclic voltammetry, circular 
dichroic studies, NMR dynamics with nucleotides, hydrodynamic measurements 
such as viscosity and cleavage reaction have been assayed using agarose gel 
electrophoresis. 
The present work stems from our interest to design DNA-binding drug candidates 
which can be explored as antitumor chemotherapeutics. In view of this rationale, we 
present in this thesis four series of novel metal-based drug candidates employing de 
novo synthetic strategy (by the variation of ligand scaffold and the metal ions: 
transition, copper(II)/zinc(II) and non-transition, organotin(IV) metal ions). Their in 
vitro binding studies with CT-DNA and nucleotides viz 5'-GMP, 5'-TMP, 5'-AMP. 
5'-CMP were carried out to evaluate their DNA binding potential and thereby, their 
therapeutic potency. 
The development of new heterobimetallic complexes [C6H24N406CuSn2Cl4]Cl2 and 
[C6H24N406ZnSn2Cl4]Cl2 from their monometallic analogues [C6H2oN402Cu]Ci2 and 
[C6H2oN402Zn]Cl2, incorporating both transition {copper(II) and zinc(ll)} and non-
transition {tin(IV)} metal ions, were synthesized with the aim to synergize effects of 
two metal ions possessing preferential selectivity towards biomolecules. The 
heterobimetallic complexes show novelty due to dual binding modes in comparison 
to their monometallic analogues and thus exhibit greater binding propensity with 
DNA. These complexes were thoroughly characterized by spectroscopic (IR, 'H, ' ' C 
and "^SnNMR, EPR, UV -vis., ESI-MS) and analytical methods. The comparative 
interaction of monometallic complexes and their heterobimetallic analogues with 
CT-DNA in Tris-buffer were studied by various biophysical methods such as 
electronic absorption titration, fluorescence titration, cyclic voltammetry and 
viscosity measurements. To quantify the extent binding of complexes with DNA, the 
intrinsic binding constant Kb of complexes were determined, which follows the 
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order; [C6H24N406ZnSn2Cl4]Cl2>[C6H24N406CuSn2Cl4]Cl2>[C6H2oN402Zn]Cl2> 
[C6H2oN402Cu]Cl2, thus, revealing a pronounced DNA binding of the 
heterobimetallic complexes in comparison to their respective monometallic 
analogues. Furthermore, the interaction of transition metal ions of heterobimetallic 
complexes with 5'-GMP and 5'-TMP was ascertained by absorption titration of the 
heterobimetallic complexes with these nucleotides which clearly shows selective 
preference of 5'-GMP with the copper(II) complex while zinc(ll) complex preferring 
selective interactions with 5'-TMP. The results of spectroscopic, viscometric and 
cyclic voltammetric studies of the heterobimetallic complexes with CT-DNA 
suggested electrostatic mode of binding with the phosphate backbone of DNA 
double helix. Heterobimetallic complexes [C6H24N406CuSn2Cl4]C'l2 and 
[C6H24N406ZnSn2Cl4]Cl2 when subjected to gel electrophoresis with supercoiled 
pBR322 DNA, demonstrate significant cleavage activity under physiologically 
relevant conditions. 
As a means of further exploring the chiral preference of potential drug candidates, a 
new series of chiral modulated organotin antitumor drug (S)/(R)-[Ci5H2iN03Sn] and 
(S)/(R)-[C,oHi6NOSnCl] derived from S- and R- enantiomers of [4-(2-hydroxy-l-
phenylethylimino)pent-2-ol] and 2-amino-2-phenylethanol, respectively, were 
synthesized and characterized by various physicochemical and spectroscopic 
methods. Chiral modulation of the drug is responsible for its high binding affinity 
towards DNA (primary pharmacological target) as the efficacy of most of the chiral 
drugs is based on enantioselectivity. In order to establish the enantiomeric selectivity 
in drug-DNA binding, preliminary complex-DNA interaction studies employing 
UV-visible, fluorescence, circular dichroic and viscosity measurements were 
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elucidated revealing preference of binding for S-enantiomer of the complexes 
towards the ultimate drug target DNA. Nevertheless, both isomers displa>ed higher 
Kb values than that of cisplatin drug. Furthermore, interaction studies of complex 
(S)-[C,5H2iN02Sn] with 5'-GMP using 'H and ^'P NMR again verifies electrostatic 
binding mode of the complex. The less effective cleavage pattern demonstrated by 
these complexes (S)-[Ci5H2iN02Sn] and (S)-[CioHi6NOSnCl] at micromolar 
concentration suggested a strand scission of plasmid pBR322 DNA from its 
supercoiled Form I to open circular Form II. Moreover, significant binding exhibited 
by the S-enantiomer of both the complexes [Ci5H2iN02Sn] and [CioHieNOSnCI] in 
comparison to their R-enantiomeric analogues led us to investigate their in viiro 
antitumor potential via Sulforhodamine-B (SRB) assay to assess cellular 
proliferation against five human cell lines of different histological origin viz. Hop62 
(human lung), DWD (human oral), K562 (human leukemia), DU145 (human 
prostrate) and MCF-7 (human breast). The complex (S)-[Ci5H2iN02Sn] displayed 
remarkably pronounced and specific activity for K562 (Human leukemia) while 
complex (S)-[CioHi6NOSnCl] exhibited significant activity towards Hop62 (Human 
lung), DWD (Human oral), DU145 (Human prostrate) and MCF-7 (Human breast). 
Benzimidazoles are important subunits of biologically relevant ligands ow ing to 
their broad spectrum of biological and chemotherapeutic potential. The biological 
relevance of these heterocyclic aromatic building blocks is due to their structural 
similarity with nucleobases. Additionally, benzimidazole derived drugs have 
received much attention owing to the fact that benzimidazole residue is a constituent 
of Vitamin Bn, which supports their potential use as therapeutics. Thus, the 
benzimidazole ligand [C16H14N4O2] exhibits coordination mode with an oxygen 
atom of alcohol group directed towards the metal ion and another -OH group with 
different molecular axis directed away from the metal center. These complexes, 
[Ci8Hi9N402SnCl] and [C52H42N402Sn2] exhibit a pentacoordinate geometry while 
the complex [C28H23N402SnCl] reveals hexacoordinated environment around the 
tin(IV) metal ions as evidenced by ' '^ Sn NMR studies. 
The DNA binding ability of benzimidazole ligand [C16H14N4O2] and their 
organotin(IV) complexes [Ci8Hi9N402SnCl], [C2gH23N402SnCI] and 
[C52H42N402Sn2] were examined by means of different biophysical methods. The 
effects of varying substituents of organotin(IV) metal ions both aliphatic and 
aromatic was studied as it is well known that the biological effects of organotins 
depends on both the nature and number of organic groups bound to tin(IV) cation. 
The absorption titration of the complexes with CT-DNA reveal significant 
"hyperchromic" effect together with strong bathochromic shift of 4-5 nm which infer 
substantial binding of the complexes with CT-DNA. The intrinsic binding constant 
Kb values of the complexes [C]8Hi9N402SnCl], [C28H23N402SnCI] and 
[C52H42N402Sn2] were found to be 2.16 ± 0.04xl0\ 3.47 ± 0.04x10^ and 4.60 ± 
0.04x10 M" respectively, suggesting pronounced binding of complex 
[C28H23N402SnCl] with DNA double helix, among the other complexes. These 
spectral changes reflect the different binding propensity of the complexes with CT-
DNA due to different structural constraints and suggest an electrostatic binding of 
the complexes with partial intercalative interactions. Although the cation ic core of 
tin(IV) lack base specificity in DNA binding, the hexacoordinated 
[C28H23N402SnCl] with labile CI group promotes higher binding of this complex 
towards DNA exhibiting a muhifaceted binding of the complex probably due to 
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differential conformational effects induced by planar ligands towards CT-DNA. The 
mechanism of binding of the complexes was further ascertained by the interaction 
studies of these complexes with nucleotides (5'-GMP and 5'-TMP) using absorption 
spectroscopy suggesting a clear preference for 5'-GMP binding which was further 
authenticated by NMR ( 'H and ^'P NMR) studies. 
In addition to the importance of the metal ions in DNA-binding regime, the 
optimization and structure activity relationship of various ligands with CT-DNA 
plays an eminent role in governing the DNA binding interactions. In this context, 
novel Schiff base ligand derived from the condensation reaction of 2-amino-3-
formylchromone with 2-amino-2-phenylethanol, [C|8H]6N203] was synthesized and 
characterized which involves combination element of ammine functionality and 
naturally occurring heterocyclic chromone, 4H-benzopyran-4-one compounds which 
modulates their biological activity to a large extent. Subsequently, their transition 
metal complexes [C36H34N407Cu](N03)2 and [C36H32N406Zn](N03)2 were also 
prepared. The DNA-binding studies of the ligand and complexes with CT-DNA by 
employing different biophysical methods. The UV-visible titrations of both ligand 
and complexes, exhibit concurrent increase in the absorption intensity with a red 
shift of 2-3 nm illustrate electrostatic association of the complexes with CT-DNA by 
subsequent stabilization of the DNA helical structure. This "hyperchromic effect'" 
was explained on the basis of two phenomena via, electrostatic interactions primaril> 
by groove binding and effect of the coordination geometry around the central metal 
ion on CT-DNA binding. In order to quantify the binding extent of both ligand and 
complexes, binding constant Kb values were determined which display a higher 
propensity of [C36H34N407Cu](N03)2 complex to bind with CT-DNA compared to 
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[C36H32N406Zn](N03)2 complex. Moreover, the complexes exhibit higher binding 
for CT-DNA as compared to classical cisplatin drug. Furthermore, the absorption 
studies with mononucleotides (5'-GMP, 5'-TMP, 5'-AMP and 5'-CMP) were also 
monitored to examine the base specific interactions of the transition metal complexes 
[C36H34N407Cu](N03)2 and [C36H32N406Zn](N03)2. The extent of interaction of 
nucleotides with the complexes follows the order; 5'-GMP > 5'-TMP > 5'-CMP > 
5'-AMP for [C36H34N407Cu](N03)2 and 5'-TMP > 5'-GMP > 5'-CMP > 5'-AMP for 
the [C36H32N406Zn](N03)2 complex thus, supporting a higher propensity of 
copper(II) complex towards 5'-GMP and for zinc(n) complex towards 5'-TMP. To 
further support these findings, the interaction of complex [C36H32N406Zn](N03)2 
with 5'-GMP and 5'-TMP, was ascertained by 'H and ^'P NMR studies which 
confirms higher binding propensity of the complex towards 5'-TMP as compared to 
5'-GMP. The binding studies performed using fluorescence, circular dichroism, 
viscosity further conclude a groove binding mechanism of the complexes towards 
DNA. The DNA cleavage activity of the complex [C36H34N407Cu](N03)2 using 
agarose gel electrophoresis in presence of increasing concentration of complex 
shows an excellent cleavage revealing the conversion of supercoiled Form I to open 
circular Form II and then to linearized Form III. The cleavage of DNA by the 
complex in presence of activators follows the order; H2O2 > MPA >GSH >Asc. The 
mechanistic pathway followed by the complex in the presence of various radical 
scavengers such as NaNs, DMSO, tert-butyl alcohol, NaN3 and SOD suggested 
cleave of plasmid DNA via, oxidative mechanism. Furthermore, the major groove 
binding ability of the complex was ascertained on the basis of cleavage pattern of 
plasmid in presence of minor and major groove binding agents such as DAPl and 
methyl green. 
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Abstract 
Abstract 
There is a considerable interest in small molecules that bind to DNA because of their 
potential use in chemotherapeutics, regulators of gene expression and tools for 
molecular biology and nanotechnology. Transition metal complexes, which provide 
high stability, structural versatility and unique spectroscopic and redox properties, 
are explored largely for DNA binding studies. These metal complexes are capable of 
binding to DNA by multitude of interactions via, DNA intercalation, DNA groove 
binding or external electrostatic or covalent linkage and cleavage of DNA by virtue 
of their intrinsic chemical, electrochemical or photochemical reactivities. Metal-
nucleic acid chemistry has gained momentum after Rosenberg's discovery ot 
cisplatin- cis-diamminedichloroplatinum(Il) and its subsequent clinical use for 
treating solid tumors (testicular and ovarian cancers). DNA has been identified as the 
possible primary molecular target of both cisplatin and other metal based drugs. 1 he 
clinical use of cisplatin, however, is severely limited by its toxic side effects, its 
limited applicability to relatively narrow range of tumors and acquired or inherent 
resistance. This has spurred research for the development of new non-platinum 
metal-based anticancer agents which are more efficacious, less toxic and can 
overcome resistance. Therefore, alternate strategies based on different metal ions. 
ligand functionality, shape or geometric requirement and stereoselectivity were 
opted to design these new cancer drug therapeutics. In the majority of complexes 
studied, the metal usually serves as the redox center and the ligand is responsible for 
DNA recognition, nevertheless metals are also used as building blocks for well 
defined, three dimensional constructs. The modular approach of optimising the 
design by the use of coordinating ligands, which themselves are active 
pharmacophores, offers to fine-tune metals properties and in this manner tailored 
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multiftinctional ligand can assist to achieve target selectivity/improved solubility. 
The mechanism of cytotoxic action which is related to DNA binding affinity can 
also vary accordingly, as the biological activity is strongly dependent on structure-
activity relationship. This optimization based on shape selectivity is introduced by 
chiral ligands which interact with DNA- an inherently chiral biomolecule in a site-
specific manner. Furthermore, chirality may enhance the pharmacological behaviour 
of complexes, by adopting a specific conformation; thereby improving the DNA-
binding affinity to provide recognition elements in the metal nucleobase recognition 
process. The interaction of metal complexes with nucleobases and/or nucleotides is 
very well established, and is now known to be the basis of antitumor drug action. 
The metal complexes, which are favoured as effective drug candidates are molecules 
that; damage DNA; block DNA synthesis indirectly through inhibition of nucleic 
acid precursor biosynthesis; disrupt hormonal stimulation of cell growth: must 
recognize nucleic acid particularly in sequence specific fashion and then bind to 
DNA in a way that alters their function. 
The characterization of DNA recognition by aromatic metal complexes has been 
substantially aided by studying the DNA cleavage activity. Literature reveals that 
double strand breaks in duplex DNA are thought to be more significant sources of 
cell lethality as compared to single strand breaks, as they are less readily repaired by 
DNA repair mechanism. A number of copper(II) complexes are exceptional 
candidates for mediation of strand scission of duplex DNA. The metal complex 
DNA interaction has been investigated using a host of biophysical methods like 
electronics absorption, fluorescence spectroscopy, cyclic voltammetry. circular 
dichroic studies, NMR dynamics with nucleotides, hydrodynamic measurements 
such as viscosity and cleavage reaction have been assayed using agarose gel 
electrophoresis. 
The present work stems from our interest to design DNA-binding drug candidates 
which can be explored as antitumor chemotherapeutics. In view of this rationale, we 
present in this thesis four series of novel metal-based drug candidates employing de 
novo synthetic strategy (by the variation of ligand scaffold and the metal ions; 
transition, copper(II)/zinc(II) and non-transition, organotin(IV) metal ions). Their in 
vitro binding studies with CT-DNA and nucleotides viz 5'-GMP, 5'-TMP, 5'-AMP. 
5'-CMP were carried out to evaluate their DNA binding potential and thereby, their 
therapeutic potency. 
The development of new heterobimetallic complexes [C6H24N406CuSn2Cl4]Cl2 and 
[C6H24N406ZnSn2Cl4]Cl2 from their monometallic analogues [C6H2oN402Cu]Cl2 and 
[C6H2oN402Zn]Cl2, incorporating both transition {copper(II) and zinc(II)} and non-
transition {tin(IV)} metal ions, were synthesized with the aim to synergize effects of 
two metal ions possessing preferential selectivity towards biomolecules. The 
heterobimetallic complexes show novelty due to dual binding modes in comparison 
to their monometallic analogues and thus exhibit greater binding propensity with 
DNA. These complexes were thoroughly characterized by spectroscopic (IR, 'H, 'Y^ 
and "^SnNMR, EPR, UV -vis., ESI-MS) and analytical methods. The comparative 
interaction of monometallic complexes and their heterobimetallic analogues with 
CT-DNA in Tris-buffer were studied by various biophysical methods such as 
electronic absorption titration, fluorescence titration, cyclic voltammetry and 
viscosity measurements. To quantify the extent binding of complexes with DNA, the 
intrinsic binding constant Kb of complexes were determined, which follows the 
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order; [C6H24N406ZnSn2Cl4]Cl2>[C6H24N406CuSn2Cl4]Cl2>[C6H2oN40:Zn]Cl2> 
[C6H2oN402Cu]Cl2, thus, revealing a pronounced DNA binding of the 
heterobimetallic complexes in comparison to their respective monometallic 
analogues. Furthermore, the interaction of transition metal ions of heterobimetallic 
complexes with 5'-GMP and 5'-TMP was ascertained by absorption titration of the 
heterobimetallic complexes with these nucleotides which clearly shows selective 
preference of 5'-GMP with the copper(ll) complex while zinc(II) complex preferring 
selective interactions with 5'-TMP. The resuhs of spectroscopic, viscometric and 
cyclic voltammetric studies of the heterobimetallic complexes with CT-DIMA 
suggested electrostatic mode of binding with the phosphate backbone of DNA 
double helix. Heterobimetallic complexes [C6H24N406CuSn2Cl4]C'l2 and 
[C6H24N406ZnSn2Cl4]Cl2 when subjected to gel electrophoresis with supercoiled 
pBR322 DNA, demonstrate significant cleavage activity under physiologically 
relevant conditions. 
As a means of fijrther exploring the chiral preference of potential drug candidates, a 
new series of chiral modulated organotin antitumor drug (S)/(R)-[Ci5H2iN02Sn] and 
(S)/(R)-[CioHi6NOSnCl] derived from S- and R- enantiomers of [4-(2-h>droxy-l-
phenylethylimino)pent-2-ol] and 2-amino-2-phenylethanol, respectively, were 
synthesized and characterized by various physicochemical and spectroscopic 
methods. Chiral modulation of the drug is responsible for its high binding affinity 
towards DNA (primary pharmacological target) as the efficacy of most of the chiral 
drugs is based on enantioselectivity. In order to establish the enantiomeric selectivity 
in drug-DNA binding, preliminary complex-DNA interaction studies employing 
UV-visible, fluorescence, circular dichroic and viscosity measurements were 
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elucidated revealing preference of binding for S-enantiomer of the complexes 
towards the ultimate drug target DNA. Nevertheless, both isomers displayed higher 
Kb values than that of cisplatin drug. Furthermore, interaction studies of complex 
(S)-[Ci5H2iN02Sn] with 5'-GMP using ' H and ^'P NMR again verifies electrostatic 
binding mode of the complex. The less effective cleavage pattern demonstrated by 
these complexes (S)-[Ci5H2iN02Sn] and (S)-[CioHi6NOSnCl] at micromolar 
concentration suggested a strand scission of plasmid pBR322 DNA from its 
supercoiled Form I to open circular Form II. Moreover, significant binding exhibited 
by the S-enantiomer of both the complexes [Ci5H2iN02Sn] and [CioHieNOSnCl] in 
comparison to their R-enantiomeric analogues led us to investigate their in vitro 
antitumor potential via Sulforhodamine-B (SRB) assay to assess cellular 
proliferation against five human cell lines of different histological origin viz, Hop62 
(human lung), DWD (human oral), K562 (human leukemia), DU145 (human 
prostrate) and MCF-7 (human breast). The complex (S)-[Ci5H2iN02Sn] displayed 
remarkably pronounced and specific activity for K562 (Human leukemia) while 
complex (S)-[CioHi6NOSnCl] exhibited significant activity towards Hop62 (Human 
lung), DWD (Human oral), DU145 (Human prostrate) and MCF-7 (Human breast). 
Benzimidazoles are important subunits of biologically relevant ligands owing to 
their broad spectrum of biological and chemotherapeutic potential. The biological 
relevance of these heterocyclic aromatic building blocks is due to their structural 
similarity with nucleobases. Additionally, benzimidazole derived drugs have 
received much attention owing to the fact that benzimidazole residue is a constituent 
of Vitamin B12, which supports their potential use as therapeutics. Thus, the 
benzimidazole ligand [C16H14N4O2] exhibits coordination mode with an oxygen 
atom of alcohol group directed towards the metal ion and another -OH group with 
different molecular axis directed away from the metal center. These complexes, 
[Ci8Hi9N402SnCl] and [C52H42N402Sn2] exhibit a pentacoordinate geometry while 
the complex [C28H23N402SnCl] reveals hexacoordinated environment around the 
tin(rV) metal ions as evidenced by "^Sn NMR studies. 
The DNA binding ability of benzimidazole ligand [C16H14N4O2] and their 
organotin(IV) complexes [Ci8Hi9N402SnCl], [C28H23N402SnCl| and 
[C52H42N402Sn2] were examined by means of different biophysical methods. The 
effects of varying substituents of organotin(IV) metal ions both aliphatic and 
aromatic was studied as it is well known that the biological effects of organotins 
depends on both the nature and number of organic groups bound to tin(IV) cation. 
The absorption titration of the complexes with CT-DNA reveal significant 
"hyperchromic" effect together with strong bathochromic shift of 4-5 nm which infer 
substantial binding of the complexes with CT-DNA. The intrinsic binding constant 
Kb values of the complexes [Ci8Hi9N402SnCl], [C28H23N402SnCl] and 
[C52H42N402Sn2] were found to be 2.16 ± 0.04xl0\ 3.47 ± 0.04x10'' and 4.60 ± 
0.04x10^ M"' respectively, suggesting pronounced binding of complex 
[C28H23N402SnCl] with DNA double helix, among the other complexes. These 
spectral changes reflect the different binding propensity of the complexes with CT-
DNA due to different structural constraints and suggest an electrostatic bmding of 
the complexes with partial intercalative interactions. Although the cationic core of 
tin(IV) lack base specificity in DNA binding, the hexacoordinated 
[C28H23N402SnCl] with labile CI group promotes higher binding of this complex 
towards DNA exhibiting a multifaceted binding of the complex probably due to 
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differential conformational effects induced by planar ligands towards CT-DNA. The 
mechanism of binding of the complexes was further ascertained by the interaction 
studies of these complexes with nucleotides (5'-GMP and 5'-TMP) using absorption 
spectroscopy suggesting a clear preference for 5'-GMP binding which was further 
authenticated by NMR ( ' H and ^'P NMR) studies. 
In addition to the importance of the metal ions in DNA-binding regime, the 
optimization and structure activity relationship of various ligands with CT-DNA 
plays an eminent role in governing the DNA binding interactions. In this context, 
novel Schiff base ligand derived from the condensation reaction of 2-amino-3-
formylchromone with 2-amino-2-phenylethanol, [C18H16N2O3] was synthesized and 
characterized which involves combination element of ammine functionality and 
naturally occurring heterocyclic chromone, 4H-benzopyran-4-one compounds which 
modulates their biological activity to a large extent. Subsequently, their transition 
metal complexes [C36H34N407Cu](N03)2 and [C36H32N406Zn](N03)2 were also 
prepared. The DNA-binding studies of the ligand and complexes with CT-DNA by 
employing different biophysical methods. The UV-visible titrations of both ligand 
and complexes, exhibit concurrent increase in the absorption intensity with a red 
shift of 2-3 nm illustrate electrostatic association of the complexes with CT-DNA by 
subsequent stabilization of the DNA helical structure. This "hyperchromic effect" 
was explained on the basis of two phenomena via, electrostatic interactions primarily 
by groove binding and effect of the coordination geometry around the central metal 
ion on CT-DNA binding. In order to quantify the binding extent of both ligand and 
complexes, binding constant Kb values were determined which display a higher 
propensity of [C36H34N407Cu](N03)2 complex to bind with CT-DNA compared to 
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[C36H32N406Zn](N03)2 complex. Moreover, the complexes exhibit higher binding 
for CT-DNA as compared to classical cisplatin drug. Furthermore, the absorption 
studies with mononucleotides (5'-GMP, 5'-TMP, 5'-AMP and 5'-CMP) were also 
monitored to examine the base specific interactions of the transition metal complexes 
[C36H34N407Cu](N03)2 and [C36H32N406Zn](N03)2. The extent of interaction of 
nucleotides with the complexes follows the order; 5'-GMP > 5'-TMP > 5'-CMP > 
5'-AMP for [C36H34N407Cu](N03)2 and 5'-TMP > 5'-GMP > 5'-CMP > 5'-AMP for 
the [C36H32N406Zn](N03)2 complex thus, supporting a higher propensity of 
copper(II) complex towards 5'-GMP and for zinc(II) complex towards 5'-TMP. To 
further support these findings, the interaction of complex [C36H32N406Zn](N03 (2 
with 5'-GMP and 5'-TMP, was ascertained by 'H and ^'P NMR studies which 
confirms higher binding propensity of the complex towards 5'-TMP as compared to 
5'-GMP. The binding studies performed using fluorescence, circular dichroism, 
viscosity further conclude a groove binding mechanism of the complexes towards 
DNA. The DNA cleavage activity of the complex [C36H34N407Cu](N03)2 using 
agarose gel electrophoresis in presence of increasing concentration of complex 
shows an excellent cleavage revealing the conversion of supercoiled Form 1 to open 
circular Form II and then to linearized Form III. The cleavage of DNA by the 
complex in presence of activators follows the order; H2O2 > MPA >GSH >Asc. The 
mechanistic pathway followed by the complex in the presence of various radical 
scavengers such as NaN3, DMSO, tert-butyl alcohol, NaNs and SOD suggested 
cleave of plasmid DNA via, oxidative mechanism. Furthermore, the major groove 
binding ability of the complex was ascertained on the basis of cleavage pattern of 
plasmid in presence of minor and major groove binding agents such as DAPI and 
methyl green. 
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CHAPTER I 
Introduction 
Introduction 
Medicinal inorganic chemistry - an interdisciplinary area of science emerged from 
the burgeoning field of bioinorganic chemistry which includes metal-based drugs. 
metal sequestering or mobilizing agents, metal-containing diagnostic aids, and the 
medicinal recruitment of endogenous metal ions. It combines various aspect of 
inorganic chemistry and chemical biology of living system. Because small molecules 
can affect biochemical function, there is a clear link between chemical biology. 
pharmacology and medicine [1]. While small molecules usually imply organic 
compounds [2], inorganic small molecules have long history in both biology and 
medicine. 
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Figure 1. Platinum(II) complexes in clinical use for cancer chemotherapy, ci.splatin 
(left), carboplatin (middle), oxaliplatin (right). 
The use of metal complexes as therapeutic agents can be traced back to 3500 B.C 
[3]. Copper and gold have been used since antiquity in metal based therapies |4.5]. 
Medicinal inorganic chemistry in particular, after the prototypical success story of 
cisplatin- an archetypical inorganic antitumor drug used for the treating several solid 
malignancies such as testicular, ovarian, bladder and neck cancers [6,7] (Figure 1). 
However the clinical efficacy of this drug is well established yet, it exhibits onl> a 
narrow spectrum of activity and has been associated with severe side effects such as 
nephrotoxicity, neurotoxicity, and emetogenesis as well as inherent or acquired 
resistance [8-10]. Therefore, new drug design strategies have been applied to 
inorganic metal complexes, such as finding pharmacologically active iigand 
scaffolds, attachment of intercalating agents or other ancillary functional groups and 
introduction of chiral motifs in order to modulate or optimise the detrimental 
properties of these metal complexes leading to the development of more efficacious 
drug candidates with pronounced anticancer potential acting via, specific reaction 
pathway in the biological system [11]. 
Inorganic elements play a crucial role in biological and biomedical processes [12]. 
and it is evident that many organic compounds used in medicine do not have purely 
organic mode of action; some are activated or biotransformed by metal ions 
including metalloenzymes [13], others have a direct or indirect effect on metal ion 
metabolism. Metal ions are also very important for the structure and function of 
nucleic acids. Both essential and non-essential metals can be used in therap\ and 
diagnosis. Thus, diversity of the properties of inorganic elements makes them 
versatile for many applications viz. for therapy [14], diagnosis [15], catalysis [I6J. 
molecular magnets [17], molecular light switches [18-20] etc. Brief summary of the 
general chemical properties of metals as outlined in several books of bioinorganic 
chemistry [12,21,22] is given below 
1. Charge. Metal ions are positively charged in aqueous solution, but that charge can 
be manipulated depending on the coordination environment so that a metal 
complexed by ligands can be cationic, anionic, or neutral. 
2. Interactions with ligands. Metal ions bind to ligands via, interactions that are 
often strong and selective. The ligands impart their own functionality and can fine 
tune properties of the overall complex that are unique from those of the individual 
Iigand or metal. 
3. Structure and bonding. Metal ligand complexes span a range of coordination 
geometries that give them unique shapes compared with organic molecules. The 
bond lengths, bond angles, and number of coordination sites can vary depending on 
the metal and its oxidation state. 
4. Lewis acid character. Metal ions with high electron affinity can significantly 
polarize groups that are coordinated to them, facilitating hydrolysis reactions. 
5. Partially filled d-shell. For the transition metals, the variable number of electrons 
in the d-shell orbitals imparts interesting electronic and magnetic properties to 
transition metal complexes. 
6. Redox activity. Coupled with the variability of electrons in the d-shcll is the 
ability for many transition metals to undergo one-electron oxidation and reduction 
reactions. 
Transition metal complexes stand out as exceptional candidates for artificial 
nucleases of DNA due to their ability to recognize and react selectively with 
individual target sites [23-28]. Stable, inert, water soluble, versatile structures as 
well as spectroscopically and electrochemically active metal centers constitute the 
unique signatures of transition metal complexes, which make them sensitive 
diagnostic agents [29]. 
Additionally, transition metal complexes exhibit significant modulation effects. 
which can tune the mode of binding and their reactivity towards biomolecules. A 
vast number of ligands can be readily 'plugged' in and out of a wide variety of metal 
centers. This unique attribute of metal complexes provides system that utilizes 
strength of both synthetic organic chemistry and transition metal complexes. Any 
metal ion or complex is subject to the potential limitations in the Bertrand diagram. 
(Figure 2) which is usually used in discussing the essentiality of elements [30]. 
deficiency toxidty 
benefit 
Figure 2. Bertrand diagram indicating the relationship between benefit/detriment 
from an element and its concentration. Great variations are found in each region 
depending on the nature of the element. 
The area of optimum physiological response vary greatly according to the element. 
its speciation, oxidation state and the biochemistry of the specific compound in 
which it is found. Therefore, the areas of deficiency, toxicity and optimum 
physiological response can be dramatically varied by considering a combination of 
these variables, as well as design features of the potential ligand which may be 
altered to facilitate the delivery of that metal ion into the biological system [31]. 
Thus, the refinement of biological properties of metal complexes by well-tailored. 
multifunctional ligands offer exciting possibilities and play a substantial role in 
muting the potential toxicity of the metallodrug to deliver a positive impact in area 
of diagnosis and therapy [32]. 
Metal ions can be introduced into the biological system either for 
therapeutic or diagnostic aids. Alternatively, these metal ions can be removed from 
the biological system by the judicious use of metal binding molecules (termed as 
ligands). Ligands are most often but not limited to organic compounds that binds to 
metal ions, thus modifying the physical and chemical properties of the ions. Ligands 
can modify the reactivity, lipophilicity, oral/systematic bioavailability of metal ions. 
stabilization of oxidation state, and substitutional inertness depending on the 
requirements for chemotherapy [33,34]. They ensure protection of tissues from toxic 
metal ion or in a contrasting strategy, enhance uptake of pharmacological beneficial 
metal ion [35]. It has been well documented in literature that carrier amine ligands of 
cisplatin analogues appear to modulate the antitumor properties of this class of drug 
[36,37]. The antitumor activity is usually lost or diminished if the primary or 
secondary amines on platinum are replaced by tertiary amines [38]. In addition, the 
carrier ligands may also affect bio-distribution and recognition of DNA adducts b\ 
repair enzymes, regulatory and DNA binding proteins. A notable class of amine 
ligands is l,3-diamino-2-propanol as many amino alcohol derivatives have been 
extensively used as chemotherapeutic agents [39]. Besides this, a relatively large 
number of natural products contain amino alcohol functionality [40]. Keppler and 
Hartinger et al. [41] have demonstrated binding of 5'-GMP with platinum(II) 
cytotoxic complexes derived from amino alcohols. A judicious variation of ligand 
structure resulted in a series of platinum complexes bearing amino alcohol 
(Figure 3). These compounds were distinguished by the capability of eventually 
administered form to open intramolecular rings under the action of variable pH and 
chloride concentration giving rise to species more reactive towards 5'-GMP and 
possessing higher cytotoxicity. Another important feature of amino alcohol 
platinum(II) complexes is the ability of hydroxyl group as well as alcoholato oxygen 
atom in ring closed species, to form hydrogen bonds with nucleobases. This 
hydrogen bonding is expected to play a crucial role in the binding of platinum 
compound to DNA [42]. 
Figure 3. Structural formulae of (SP-4-2)-bis-[(R)-(-)-2-aminobutanol-kN]-
dichloroplatinum(II) 1, (SP-4-2)-bis-[(R)-(-)-2-aminobutanolato-k-N, OJ-
platinum(II) 2, (SP-4-2)-bis-[2-aminoethanol-kN)]-dichloroplatinum(n) 3. (SP-4-2)-
bis-[2-ammoethanolato-k^N, 0]-platinum(II)4, and (SP-4-2)-bis-[4-
aminobutanolato-KN,O]-dichloroplatinum(II) 5. 
Bermejo et al. [43] have studied the versatility of potentially heptadentate ligand 
N,N-bis(3-hydroxysalicyldene)-l,3-diaminopropanol. The presence of four phenolic 
groups results in high nuclearity as it can simultaneously coordinate upto five metal 
centers in different ways resulting in complex structures. Nickel and copper centres 
in these polynuclear complexes possess distorted tetrahedral or square pyramidal 
geometry while zinc(II) was found to be hexacoordinated in the mononuclear 
complexes. 
The condensation of primary amines with carbonyl compounds was first reported by 
Schiff and since then condensation products are referred to as Schiff bases [44]. The 
Schiff bases are widely studied because of increasing recognition of their role in 
biological systems [45]. The anti-microbial and anti-proliferative activities of Schiff 
base copper(lI) complexes [46] are not attributed to coordinated ligands alone but 
also to the physicochemical, structural and electronic properties that arise due to the 
coordination [47-49]. The effect of copper(II) Schiff base complexes of the type 
[Cu(dienXX)Y]Y with iodine or bromine {where (dienXX) = Schiff dibase of 
diethylenetriamine and Y=C1, Br} on the single stranded, double stranded and pDNA 
was examined by DNA-binding spectroscopic studies and DNA electrophoretic 
mobility to study the structure-activity relationship [50]. Schiff base ligands derived 
from acetylacetone are widely employed in coordination chemistry because of their 
convenient tuning of steric and electronic properties [51-53] 
Chohan et al. [51] have synthesized ligands (L1-L5) (Figure 4) obtained by the 
condensation reaction of amino acids (glycine, phenylalanine, alanine, valine or 
histidine) and acetylacetone for exploring metal-based bacteriostatic and 
carcinostatic pharmaceuticals with a high efficacy and low toxicity. All these ligands 
along with their metal complexes {cobalt(II), copper(ll), nickel(II) and zinc(II)} 
were screened for their in vitro antibacterial activity against Gram-negative (E. coli. 
S. flexenari, P. aeruginosa, and S. typhi) and Gram-positive (B. subtilis and S. 
aureus) bacterial strains. 
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Figure 4. Proposed structure of the ligands (Li-Ls). 
These compounds demonstrated not only good antibacterial and antifungal activity 
but also proved to be a new class of compound for metal-based drug therapies. 
Increasing attention has also been devoted to SchifFbase complexes of organotin(lV) 
moieties in view of their potential applications in medicinal chemistry and 
biotechnology [54-58]. Baul et al. [59] have reported series of new amino acetate 
functionalized Schiff base organotin(IV) complexes [Ph3SnLH]n and |Ph2SnL]. 
These organotin(IV) complexes were characterized by IR, NMR ( H, C, " Sn) 
spectroscopic techniques and were screened against A498, EVSA-T, H226- IGROV. 
Ml9 MEL, MCF7 and WIDR human tumor cell lines. Among the studied complexes 
[Ph3SnL'H]n, [Ph3SnL^H]n, [PhjSnL J^n, [Ph2SnL^H]n, triphenyltin(lV) compound 
[PhsSnL J^n exhibited a much higher ID50 values (35 ng/ml) compared to previousK 
known drugs doxorubicin, cisplatin, 5-fluorouracil and etoposide and offers its 
promising candidature for ftirther development as an anti-cancer agent. 
M. Nath et al. [60] have synthesized and characterized organotin(IV)-amino acid 
Schiff bases derived from the condensation of 2-hydroxy-l-naphthaldehyde or 
acetylacetone with Gly, L-Ala, DL-Val, DL-4-aminobutyric acid, L-Met, L-Leu and 
PhGly with a general formula Bu2SnL (L=dianion of tridentate Schiff base) (Figure 
5). The central tin(IV) ions in all these complexes are pentacoordinated with a 
monodentate carboxylic group. An attempt was made to prove the structure of 
resulting complexes on the basis of elemental analysis, conductance measurement 
and electronic IR, multinuclear magnetic resonance ( 'H, '^C and "''Sn) and "''Sn 
Mossbauer spectral studies. 
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Figure 5. Structures ofBu2SnL with different Schiffbase ligands. 
The in vitro cytotoxicity of the complexes against a panel of seven tumor cell lines, 
viz. MCF-7, EVSA-T, WiDr, IGROV, Ml9 MEL, A498 and H226 was found to be 
higher than those observed for cisplatin and carboplatin (Table 1). 
Complex 
Bu,Sn-J(I) 
BujSnL-2(I) 
Bu,SnL-6(n) 
PhjSnL-Ul) 
Ph,SnL-2(I) 
Carboplacin" 
Cisplatin'' 
1D|^ , (ng mP ' ) against*: 
MCF-7 
75 
20 
60 
170 
600 
10 500 
1400 
EVSA-T 
35 
17 
120 
70 
150 
4500 
320 
WiDr 
480 
114 
420 
490 
1750 
3500 
1550 
IGROV 
75 
27 
130 
no 480 
2400 
230 
MI9 MEL 
90 
71 
70 
530 
620 
5500 
780 
A498 
170 
62 
130 
230 
690 
18000 
1200 
H226 
IW 
\(0 
200 
350 
1100 
25 000 
31M) 
Table 1. ID50 values (in ng mt') of selected diorganotin derivatives of Schiffbase 
derived from amino-acids, and of some reference compounds. 
Benzimidazoles represent one of the largest groups of heterocyclic compounds and 
have attracted a great deal of interest over the decades due to their wide potential 
biological activities. Bis-benzimidazoles have potent activity against a number of 
microorganism including those that lead to AIDS-related infections [61], these 
compounds bind to DNA at AT-rich sequences and have been extensively studied as 
potential therapeutic agents owing to the fact that benzimidazole residue is a 
constituent of Vitamin B12 [62,63]. Benzimidazole sometimes called 1,3-
dideazapurine and its derivatives can serve as model compounds for purine due to 
their structural similarity [64,65]. Among the other biologically active ligands, 
benzimidazole has been found to play important roles in several DNA minor groove 
binding agents such as Hoechst 33258 and Hoechst 33342 [66,67]. 
Williams et al. [68] reported the synthesis and coordination chemistry of versatile 
chiral, tridentate facially coordinating l,2-bis-(lH-benzimidazol-2-yl)-l,2-ethanediol 
ligands (Figure 6). The ligands were prepared by simple Phillips reaction [69-71] 
from tartaric acid with the appropriate 1,2-diaminobenzene. The copper(ll) 
complexes exhibited 4+2 coordination with benzimidazole moiety occupying 
equatorial sites and alcohol functions weakly binding in the axial sites. In view of 
the fact that benzimidazole derivatives have displayed a wide range of biological 
activities including inhibition of DNA topoisomerase I, antitumor and antiparasitic 
activity [72,7'3], our research group has previously synthesised new chiral and 
achiral macrocyclic complexes [l,2-bis(lH-benzimidazol-2yl)-l-(l,8-dihydro-
1,3,5,8,10,12-hexaazacyclotetradecane)-2-hydroxyethanolate]copper(n)perchlorate 
and [ 1,2-bis( 1 H-benzimidazol-2yl)-1 -(1,8-dihydro-1,3,5,8,10.12-
hexaazacyclotetradecane)-2-hydroxyethanolate]nickeI(II) perchlorate exhibiting a 
pentacoordinated environment around the metal center [74] (Figure 6a). The 
comparative DNA-binding studies of the chiral complex [l,2-bis(lH-benzimidazol-
2yl)-1 -(1,8-dihydro-1,3,5,8,10,12-hexaazacyclotetradecane)-2-
hydroxyethanolate]copper(II)perchlorate with achiral macrocycle (1,8-dihydro-
l,3,5,8,10,12-hexazacyclotetradecane)copper(II) were performed by absorption. 
fluorescence spectral studies, circular dichroism, cyclic voltammetric and viscosity 
measurements. The results suggested a partial intercalation mode that is different 
from the parent achiral complex as revealed by the absorption titrations of the 
II 
complex with DNA (Figure 7). The binding constants Kb for the achiral and chiral 
complexes bound to DNA was found out to be 2.7x10"* M"' and 6.6x10^ M ', 
respectively. 
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Figure 6. Proposed structures of complexes (a) [l,2-bis(lH-benzimidarol-2vl)-l-
(1,8-dihydro-l, 3,5,8,10,12-hexaazacyclotetradecane) -2-
hydroxyethanolate]copper(II)perchlorate (b) stannoxane capping nuicrocyclic 
complex. 
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Figure 7. Absorption spectral traces of complex (a) (1,8-dihydro-l,3.5,8,10,12-
hexazacyclotetradecane)copper(ll) (b) [l,2-bis(lH-benzimidazol-2-yI)-l-(l,8-
dihydro-1,3,5,8,10,12-hexaazacyclotetradecane) -2-
hydroxyethanolateJcopper(II)perchlorate in tris-HCl buffer upon addition of CT 
DNA. Inset: Plots of[DNA]/\sa-Sf \ vs. [Complex]=1.5 x 10"' M. 
Furthermore, circular dichroic studies of the chiral complex have also been found to 
be consistent with the other spectral studies. The introduction of chirality has shown 
a pronounced effect on DNA binding event of macrocyclic metal complex which is 
witnessed by strong binding affinity of the benzimidazole modulated complex 
towards DNA. 
In another attempt, comparative DNA binding studies of benzimidazole derived 
N~N~0 donor tridentate chiral dinuclear stannoxane complex (Figure 6b) and its 
modulated copper macrocyclic complex were carried out by various biophysical 
methods [75]. This stannoxane capping creates interesting differences in space, 
configuration and electronic structure. Chirality enhances extent of inhibition at the 
target site DNA in a stereoselective manner at the molecular level. It further tunes 
the reactivity and facilitates the modulation of the macrocycle by exhibiting unique 
electronic and kinetic effects. 
Chromones (l-benzopyran-4-one) are ubiquitous in nature, especially in plants 
which were exploited since long as potential therapeutic agents due to the high anti-
tumor activity and low toxicity. These natural products possess potential anticancer 
activity since they stimulate or inhibit a wide variety of enzyme s\ stems as 
pharmacological agents [76,77]. Their biological and physiological activities also 
include antimycobacterial, antifungal, anticonvulsant, antimicrobial, mushroom 
tyrosinase inhibition activities [78,79]. Flavonoid-related chromone (Figure 8a) and 
its derivatives {Hormothamnione (Figure 8b) and 6-desmethoxyhormothamnione 
(Figure 8c)} are well known naturally occurring heterocyclic compounds with 
oxygen as heteroatom [80]. They possess antibacterial antifungal, anticancer, anti-
HIV, spasmolytic and antiviral properties [81,82]. Flavonoids are effective metal ion 
chelators and play a key role in the initiation of free radical processes by acting on 
two antioxidant pathways: (1) direct reactions with free radicals, (2) chelating of 
metal ions involved in production of reactive oxygen pathways. Thus, experimental 
data indicate that the chelated compounds are more effective free radical scavengers 
than flavonoids alone [83]. 
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Figure 8. Structures of (a) chromone (4H-benzopyran-4-one), (b) hormothamnione, 
(c) 6-desmethoxyhormothamnione. 
Recently E. Budzisz et al. [84] described some coumarin complexes with excellent 
cytotoxic activity obtained from the reaction of chromone derivatives. Starting from 
2-methyl-4-oxo-chromone-3-carboxylic acid, new coumarin derivatives 3-[l-
(alkylamino)-ethylidene]-chroman-2,4-dione were synthesized which displayed 
excellent cytotoxic activity against HL-60, NALM-6 cell lines. Another chromone 
derivative namely 2-methyl-4-oxo-4H-chromone-3-carboxylate also exhibited in 
vitro activity against human cancer cell lines A549, K562 and HeLa. 
The DNA-binding properties of chromone complexes were also exploited by Yang et 
al. [85]. They have synthesized and characterized of novel glycine SchifT bases 
sodium salt, 6-hydroxychromone-3-methylidyneiminoacetate (LNa), derived from 
chromone and their complexes [CuL(H20)3lN03H20 and [NiLH20]N03-2H20 
(Figure 9a-b). 
(a) 
Figure 9. Speculated structures of (a) fCuL(H20)s]NOrH20 (b) 
[NiLH20]NOr2H20. 
14 
Their DNA-binding properties have been elucidated by means of UV-visible 
spectroscopy, fluorescence spectroscopy, and viscosity measurement studies 
revealing an intercalative mode of interaction of these complexes. The interaction of 
[CuL-(H20)3]N03H20 and [NiLHjOlNOa^HjO with DNA was investigated by 
electronic absorption spectroscopy which revealed 50% hypochromism in the 
absorption band with a bathochromic shift of 3-10 nm for [CuL-(H20)3]N03H20 
while the [NiL-H20]N03-2H20 exhibited 42% hypochromism with a bathochromic 
shift of 6 nm. These results were suggestive of either the electrostatic effect or 
intercalative association of the complexes with DNA (Figure 10). 
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Figure 10. (a) Electronic spectra of [CuL(H20)3]N03H20 (10 nM) (h) Electronic 
spectra of [Nil •H20]NOy2H20 (10 juM) in presence of increasing amounts of DNA : 
[DNA] = 0-35 fuM. The arrow indicates the absorbance changes upon increasing 
DNA concentration. 
Spectrofluorimetric titration of [CuL-(H20)3]N03-H20 and [NiL-H20]N03-2H20 
with DNA displayed an enhancement in the fluorescence intensity of the complexes 
which agrees well with those observed for intercalators [86]. The relative association 
constant of [CuL(H20)3]N03H20 and [NiL-H20]N03-2H20 were 6.08x10' and 
2.75x10^ M'' which suggest that the binding strength of [CuL-(H20)3]N03-H20 was 
higher in magnitude than [NiL-H20]N03-2H20 complex (Figure 1 la-b). 
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Figure 11. The emission enhancement spectra of (a) [CuL(H20)3]N03H20 (10 /.iMj 
(b) [NiL-(H20)3]N03-H20 (10 fjM) in the presence of increasing concentration of 
DNAfrom 0, 2.5, 5, 7.5, 10, 12.5, 15 and 17.5 nM. 
Recently, Yang et al. [87] have described the synthesis, characterization and DNA 
binding properties of novel fluorescent zinc(Il) and nickel(ll) complexes of (6-
ethoxy chromone-3-carbaldehyde benzoyl hydrazone) ligand (Figure 12). The 
comparative interaction of the ligand (L) and [ZnLNOsJNOs with DNA were carried 
out using UV-visible, fluorescence, circular dichroic methods and viscosity 
measurements. It was found that the zinc(II) complex strongly binds DNA 
presumably by an intercalative mode. 
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Figure 12. Proposed structure of complexes (a) [ZnLN03]N03 complex and (b) 
[NiLN03]N03.H20 complex. 
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Amongst various metal ions, Lewis acid metal centers such as copper(II). zinc(il) 
and tin(IV) are chemically well suited to influence fundamental biological processes 
at the cellular level owing to their high affinity for basic nitrogen and oxygen donor 
ligands and their capability to accommodate larger aromatic architectures capable of 
nucleic acid recognition. Their ability to directly hydrolyze phoshodiester linkages as 
well as redox chemistry of the metal center or generate reactive oxygen-derived 
species further accentuates their natural aptitude for participation in cellular 
functions involving nucleic acids. Because binding and cleavage of nucleic acid lies 
at the heart of cellular transcription and translation, these substrates are ultimate 
targets for therapeutic intervention and development of diagnostic probes of nucleic 
acid structures. Transition metals are compatible in the biological system in contrast 
to platinum based anticancer agents, which are non-specific, resulting in significant 
toxicity [88]. The oxidation state of metal ions dictate particular geometries, hence 
limiting appropriate binding for different ligand sets [89]. 
Among the first row transition metal ions, copper(ll) complexes are attractive 
scaffold for metal based drug research as they possess biologically accessible redox 
potentials with relevant oxidation state +1 and +2. Due to the plasticity and 
participation of copper as an integral part of the active site of metalloproteins 
familiarize its coordination with the human body's functions. Copper was found to 
bind DNA by coordination to the electron-rich nucleobases with high affinity than 
any other divalent cation, thus, promoting DNA oxidation [90]. Copper(ll) 
complexes selectively coordinate to the N7 position of guanine residue of DNA 
double helix [27,91,92] and are therefore, selective at the molecular target site. The 
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selectivity of copper ions to specific sites modifies the conformational structure of 
DNA, polynucleotides and biomembranes [93]. The binding is dependent on the size 
of the copper ions, charge, electron affinity and geometry of the formed adduct. 
Copper complexes which exhibit strong binding with DNA are also capable to 
induce a hydrolytic cleavage of DNA [94,95] therefore, a number of copper based 
synthetic nucleases have also been reported [96-100]. Among the copper complexes 
explored so far, the copper(II) complexes of 1,10-phenanthroline described by 
Sigman et al. [101] have attracted great attention due to their high artificial 
nucleolytic activity, as these complexes are able to break the DNA double helix in 
presence of H2O2 and reducing agents [102], have found application as foot printing 
agents of both proteins and DNA [103], probes of the dimensions of the minor 
groove of duplex structures [104], identifiers of transcription starting sites [105]. 
In the recent past, A. Kumbhar et al. [106] have described a series of crystalline 
mononuclear mixed ligand copper(II) malonate complexes [Cu(L)(maltol)] where 
L= 2,2'-bipyridine (bpy), 1,10-phenanthroline (phen), l,10-phenanthroline-5,6-dione 
(phendione), dipyrido[3,2-a:2',3'-c]phenazine (dppz), and 4b,5,7,7a-tetrahydro-
4b,7a-epiminomethanoimino-6H-imidazo[4,5-fl[l,10]-phenanthrorme-6,13-dione 
(bpg) showing efficient DNA binding and cleavage activity (Figure 13). The 
coordinated bipy, phen, and dione complexes intercalate partially or display groove 
binding interactions with DNA while dppz complexes binds via intercalative 
interaction within DNA helix as revealed by various DNA-binding techniques such 
as absorption titrations, viscosity, thermal melting and fluorescence quenching and 
DNA cleavage studies (gel electrophoretic mobility assays). The cytotoxicity of the 
complexes against HeLa (cervical) cancer cell lines exhibited synergy between the 
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metal and the ligands resulting in significant enhancement in the cell death with IC50 
of-150-270 ^g/mL"'. 
Figure 13. ORTEP diagram of complex [Cu(bpy)(maltol)(NOi)] showing the atom 
numbering scheme. Thermal ellipsoids are drawn at 50%probability. 
Divalent zinc(n) is an integral part of all biological systems and among the trace 
elements; zinc is second, only to iron, in abundance in human organisms. Zinc plays 
an important role in genetic stability and function [107,108]. Mechanistically, zinc 
has significant impact on DNA as a component of chromatin structure, DNA 
replication and transcription and DNA repair [109]. Lewis acidity affinity for hard 
oxygen ligands, substitutional lability together contributes towards the effective 
hydrolytic activity of zinc metal ions. Zinc enzymes efficiently catalyse the 
hydrolysis of nucleic acid under physiological condition in the living system. 
Structural changes induced by zinc(II) on DNA suggest that this cation can bind to 
both the nucleobase and the phosphate group [110]. A novel mononuclear zinc{Il) 
complex bJs(3-methyIpicolinato-K ,^A ,^O)2(l,10-phenanthroline-»c ,^A,A0-
zinc(II)pentahydrate, [Zn(3-Me-pic)2(phen)] prepared by H.-L. Seng et al. [ I l l ] 
(Figure 14) has shown potential DNA-binding effects together with potent 
nucleolytic activity and inhibition of topoisomerase I. These octahedral [Zn(3-Me-
pic)2(phen)] complexes have been found to be able to differentiate different DNA 
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conformations (B-, A-, and Z- forms) to have a binding site selectivity (minor or 
major groove; mismatched nucleobase site) and nucleobase sequence recognition. 
H(51*)' 
Figure 14. Ortep plot of bis(3-methylpyridim-2carboxylato-K^,O,N)(l,10-
phenathroline n?,N,N)zmc(II) pentahydrate (50% probability ellipsoids). Water 
molecules are not shown. 
Several other mononuclear zinc(II) complexes have also been exploited due to their 
potential anti-cancer activity. Recently, D. Kovala-Demertzi et al. [112] described 
the synthesis, crystal structure and spectral characterization of novel zinc(II) 
complexes namely bis(2-acetylpyridine-N4-l -(4-fluorophenyl)-piperazinyl 
thJosemicarbazonato)zinc(lI) and bis(^-acetato(2-acetylpyridme-N4-l-(4-
fluorophenyl)-piperazinyl thiosemicarbazonato)zinc(II). The complexes were 
screened in vitro against four human cell lines namely HeLa (cervix adenocarcinoma 
cell line), K562 (chronic myelogenous leukaemia), MDA-MB-361 and MDA-MB-
453 (breast cancer cell lines) showing potent cytotoxic activity and induction of 
apoptosis in cells resistant to cisplatin. The complex bis(2-acetylpyridine-N4-l-(4-
fluorophenyl)-piperazinyl thiosemicarbazonato)zinc(II) is 305 and 59 times more 
active than cisplatin against MDA-MB-361 and MDA-MB-453 cell lines and 38 and 
111 times more active than cisplatin against K562. Similarly, the cytotoxic activity 
of complex bis(^-acetato(2-acetylpyridine-N4-l-
(4fluorophenyl)piperazinylthiosemicarbazonato)zinc(II) is 406 and 120 times more 
active than cisplatin against MDA-MB-361 and MDA-MB-453 and 60 and 298 
times more active than cisplatin against HeLa and K562 cell lines. The above 
differences in the anti-proliferative activity of the zinc(II) complexes than the 
prevalent benchmark metallodrug cisplatin proves its clinical efficacy in the 
pharmaceutical regime and its significance in new metal based chemotherapeutic 
drug design [113]. 
In addition to transition metals, very important progress in field of medicinal 
organometallic chemistry has taken place during the past few years, allowing the 
design of novel, non-conventional, platinum compounds as well as innovative non-
platinum metal-based antitumor agents. The antitumor potential of tin complexes 
have been established since 1929 [114] and among them organotin(IV) complexes 
were regarded as effective candidates in organometallic oncology due to their novel 
apoptosis inducing property. Promising success of different organotin derivatives 
which has shown acceptable in vitro and in vivo antiproliferative activity were 
developed as new lead chemotherapeutic agents [115,116]. Organotin chelated to 
oxygen/nitrogen donating ligands have been found to be active towards a number of 
tumour cells. During the period of 1980's and later on, M. Gielen [117] published a 
series of papers describing various biologically active organotin complexes which 
exhibited potent in vitro and in vivo cytotoxicities greater than the classical drug, 
cisplatin. In a recent review, P.J. Blower also described thirty interesting inorganic 
pharmaceuticals, four of which were tin complexes [118] which further atteunates 
the importance of these tin complexes. Pettinari et al. [119] developed a large 
number of organotin derivatives of beta-diketones and described their crvstal and 
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molecular structures such as l-(4-trifluoromethylphenyl)-3-methyl-4-R (C"=0)-5-
pyrazolone proligands LH (L' H; R' -CeHjrL^H; R' -CHaiL^ H; R' -CF3) and their 
interaction with R3Sn(IV) acceptors (R-Me, Bu", Ph) (Figure 15). TTiese fluorinated 
ligands reported were proved to be eflFective antitumor agents against several cell 
lines viz; MCF-7, EVSA-T, WiDr, IGROV, M19 MEL, A498. Various other tin(IV) 
complexes namely (4-acylpyrazolo-5-ato-dihalotin) derived from a variety of beta-
diketone ligands were also explored by this group and their in vitro antitumor 
profiles were evaluated against all human melanoma cell lines. 
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Figure 15. Structures of tin complexes of 4-acyl-5-pyrazolone ligands developed by 
Pettinari group. 
Depending on the number of organic moieties, organotins are classified as mono, di. 
and tetraorganotin (RSnXs, R2SnX2, RsSnX, R4Sn), where X is an anionic species 
(halide, oxide, hydroxide, carboxylate, or thiolate). Tin and organotin(IV) 
compounds containing electronegative atoms such as halogen atoms show Lewis 
acid character and the tin atom increases its coordination number from four or five, 
six or seven upon addition of neutral organic donor ligands [120,121]. The 
emergence of new experimental techniques (EXAFS, multinuclear 'H, '^C, "'Sn 
NMR, Sn Mossbauer, etc., spectroscopic techniques) provided useful information 
about the structure and stabilities of the complexes formed. L. Pellerito and L. 
Nagy [122] reviewed the literature on organotin(IV)'^ complexes taking into account 
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the biological aspects of these complexes including the interactions of 
organotin(IV)'^ with biologically active ligands viz. amino acids, peptides, 
carbohydrates, nucleic acids and DNA. 
The binding ability of organotin compounds towards DNA largely depends upon 
both the nature and number of organic groups directly attached to the tin(IV) cation 
[123]. The phosphate group of DNA sugar back bone usually acts as an anchoring 
site. Nitrogen of DNA base binding is extremely effective, stabilizing the tin(IV) 
centre as an octahedral stable species. However, researches indicate that there is 
negligible interaction of tin complexes with nucleotide bases, but rather strong and 
irreversible binding to the vicinal phosphate groups of phosphoribose residues 
(Scheme 1) [124]. The presence of cyclic groups (aromatic or heterocyclic) in the 
tin-containing molecules was found to be important for anticancer activity as well 
[125-131]. 
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Scheme 1. Irreversible binding to the peripheral phosphate groups of phosphoribose 
residues by tin(IV) metal ion. 
To evaluate the potential biomolecular recognition of the organotin(IV) complexes, 
various authors have investigated their interactions with model compounds of DNA 
such as nucleotides. Barbieri et al. [132] have investigated coordination of 
Me2Sn(IV)^ ^ to 5'-GMP, 5'-ATP and 5'-[J(CGCGCG)2] and to their sugar 
constituents (D-ribose and 2-deoxy-D-ribose) in aqueous solution by means of 
potentiometric titration and 'H- and '^P-NMR spectroscopic methods. The results 
indicated that the phosphate groups can provide suitable sites for metal ion 
coordination in acidic medium, while in the higher pH range the hydroxyl groups of 
the studied sugars or the sugar moieties of the two nucleotides play a role in the 
mechanistic process. Li et al. [133] investigated the interaction of Et2SnCl: (phen) 
with 5'-dGMP in aqueous medium, using [rran5-en20s(ri-H2)](CF3S03)2, a \ersatile 
'H -NMR probe. Hadjiliadis et al. [134] have studied the interactions of purine 
nucleotides 5'-IMP and 5'-GMP with Et2SnCl2 using various techniques, including 
'H-, '^C and ^'P-ID-NMR and Mossbauer spectroscopy. Other researchers studied 
the interactions of Me2Sn(lV)^ ^ with 5'-AMP, D-ribose-5-phosphate, D-glucose-6-
phosphate and D-glucose-1-phosphate [135]. All these authors concluded that at low 
pH values (pH < 4) the organotin(IV) cations interact with pyrophosphate {O}. At 
intermediate pH values (pH = 4-9.5) no interaction takes place (depending on the 
concentration of metal ion and the ligand to metal ratio a precipitate is formed). 
while at pH > 9.5 the sugar 0'-2 and 0'-3 atoms are the preferred coordination sites. 
Additionally two oligomeric complexes were obtained, containing tin(IV) centers in 
trigonal-bipyramidal or octahedral geometry. From these investigations, it was 
concluded that the mechanism of antitumor action of organotin(IV) complexes (if the 
target is DNA) differs substantially from cisplatin as it forms stable adducts with the 
N7 of guanine residue of DNA whereas the activity of these organotin(IV) 
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complexes seems to come from their preferred binding to the phosphate bacicbone of 
DNA double helix. 
The current synthetic trend in the pharmaceutical regime includes the development 
of multinuclear metal assemblies that provide better recognition for the drug target. 
Keeping with this trend, the novel heterobimetallic complexes of copper-tin scaffold 
were developed by our group [136]. Previous studies of copper(ll) and copper(ll)-
tin(IV) complexes have shown interesting results against various cancerous ceil 
lines (HeLa cells, T47D, HT29) [137,47]. These heterobimetallic complexes of 
copper(II)-tin(IV) ions enhance the chemotherapeutic action many-fold as they 
provide a dual mode of binding at the molecular target and also exhibit novelty due 
to preferential selectivity inside the cell (the tin(IV) ions interact with the phosphate 
backbone of DNA while the copper(II) ion show selectivity towards the N7 position 
of guanine nucleobase). The molecular design of novel chiral complex [CuLzSn^Cls] 
was very unique as it provided distinct recognition properties for biopol>mer 
structure. The complex possesses two metal centers, a copper(H) and tin(IV) metal 
ion, which act in accord with each other to distort the DNA structure. Thus, the 
mechanism of antitumor action of tin(IV) complexes substantially differs from 
classical anticancer drugs (cisplatin) and modulatory activity of transition metal ions 
in presence of tin is a unique way to address resistance of the anticancer drugs. 
Preliminary DNA binding profile of the complexes exhibit an electrostatic mode of 
binding of the complex with DNA as revealed by the apparent hyperchromism in the 
absorption spectra of the complex (Figure 16b). 
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Figure 16. (a) Chemical structure of heteronuclear tin(IV) modulated copper(IIj 
trinuclear complexes, (h) Absorption spectral traces of complex [CuL2Sn2Cl5j Jin 
Tris-HCl buffer upon addition ofDNA. Inset: Plots of [DNAJ / Sa-s/vs [DNAJ for 
the titration of CT-DNA with complexes m, experimental data points: full lines, 
linear fitting of the data. [Complex]=0.16 xl 0'* M, [DNA]=0-0.40 xlO'M. 
It has been demonstrated that these complexes induce apoptosis via, mitochondrial 
pathway. In vitro antitumor activity of [CuL2Sn2Cl5] further justifies its potent 
antitumor effect, which is capable of inhibiting the growth of SY5Y by 60% at 8 |iM 
and of PC-12 by 70% at 2 |xM. In the case of the SY5Y neuroblastoma ceil line, the 
complex exhibited significant antiproliferative activity indicative of apoptosis. The 
immunoblot analysis demonstrated that mitochondrion play a key role in governing 
the induction of apoptosis by [CuL2Sn2Cl5]. 
The combined interest to improve the DNA cleavage specificity of Cu(3-clip-Phen) 
complexes together with their ability to perform double strand breaks (DSB) and to 
circumvent drug resistance owing to the use of cisplatin has inspired Reedijk et al. 
[138] to synthesize heterodinuclear bifunctional molecules containing both active 
entities namely copper unit and platinum component from cisplatin (Figure 17). The 
inherently specific DNA binding characteristics of two seperate active metallic 
centers contribute towards a higher affinity of the complexes CuPt[N*l*{6-[3-Clip-
Phen]-hexyl}-ethane-l,2-diamine]Cl4 and CuPt[N*l*{10-[3-Clip-Phen]-decyl}-
ethane-I,2-diamine]Cl4 with DNA, binding selectively to their respective target sites. 
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Figure 17. Strategy adopted for the synthesis of heterodinuclear minor / major 
groove interacting complexes. 
Depending on their mutual degree of freedom, both molecule will or will not reach 
their preferential site of interaction (the nitrogen atom N7 of guanine in the major 
groove for the platinum component and and the minor groove for the copper unit) 
simultaneously. 
Heterodinuclear complexes also exhibit cleavage activities and were able to perform 
direct double strand cuts in contrast to monometallic Cu(3-clip-Phen) alone which 
was capable of carrying out successive single strand cuts (Figure 18). 
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Figure 18. Comparison of the oxidative cleavage of 0X174 plasmid DNA performed 
by CuPt[N* 1*-{6-[3-aip-Phen]-hexyl}-ethane-l,2-diamine]Cl4 (13), CuPt[N*l*-
{10-[3-Clip-Phen]-decyl}-ethane-l,2-diamine]Cl4 (14) and Cu(3-Clip-Phen) in the 
presence of 5 mM MPA. Lane 1: control DNA. Lane 2: 250 nM 13 without MP A. 
Lane 3: 100 nM 13. Lane 4: 150 nM 13. Lane 5: 250 nM 13. Lane 6: 250 nM 14 
without MPA. Lane 7: 100 nM 14. Lane 8: 150 nM 14, Lane 9: 250 nM 14, Lane 10: 
250 nM Cu(3-Clip-Phen) without MPA. Lane 11: 100 nM Cu(3-Clip-Phen). Lane 
12: 150 nM Cu(3-Clip-Phen). Lane 13: 250 nM Cu(3-Clip-Phen). 
27 
With the objective of lowering the systemic toxicity of metal-based drugs, successful 
modular synthesis of heterotrinuclear complexes has been carried out that combines 
the class of compounds with paltinum(II) centre, resembling cisplatin and two 
ruthenium (III) centres that resemble NAMI by bridging dinitrogen ligands [139]. 
Such design has been done to achieve both efficacy and selectivity of the drugs and 
studies pertaining to these complexes have demonstrated that these complexes are 
potent against both neoplastic tumors and metastatic cancer. 
DNA biopolymer comprises of a polymorphic structure with a polyanionic 
nucleotide chains and sugar phosphate backbone [140]. It exists predominantly in a 
right handed B-form helical conformation although other conformations of DNA (A-
form and Z-DNA) are also known (Figure 19). It plays an important role in the life 
processes since it contains all the genetic information necessary for cellular function. 
Figure 19. Different conformational variations of DNA (a) B-DNA (b) Z-DNA 
(c)A-DNA. 
The DNA molecules are much susceptible to damage by interacting with metal 
complexes under various physiological conditions. This damage may lead to various 
pathological changes in living organisms. Thus, the interaction of metal complexes 
with DNA was regarded deciding factor to ascertain the chemotherapeutic potential 
of these metal complexes. Based on these considerations, binding modes of 
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metallomolecules can be classified broadly into covalent binding and non-covalent 
interactions. Covalent binding involve the replacement of the labile ligand by 
nitrogenous base of DNA such as N7 of guanine. On the other hand, non-covalent 
interactions include intercalative, electrostatic and groove (surface) binding of the 
cationic metal complexes along the outside of the DNA helix (Figure 20). 
Intercalative interaction involves stacking of the planar fused aromatic cations in 
between the adjacent base pairs of DNA helix. 
Figure 20. Various interaction modes of small molecules with DNA (a) electrostatic 
(b) groove binding (c) intercalation. 
The other non-covalent interactions include the electrostatic and groove binding 
interactions. Molecules that bind in the minor grooves comprise arc shaped aromatic 
architectures with terminal base functions while the electrostatic mode of binding is 
governed by charge of the molecule, ligand hydrophobicity and total size of the ions. 
In the electrostatic mode of binding, complexes exhibit an effective binding with the 
phosphate backbone of DNA double helix. Apart from the damage of the secondary 
structure of DNA by these electrostatic interactions, the other consequences 
associated with the external binding of the cations to the DNA backbone is that 
separate DNA duplexes associate together to form aggregates or condensed 
structures. 
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The DMA-binding compounds such as B B R 3 4 6 4 (Figure 21) is covalent , but a 
significant non covalent componen t arises from the presence of the central platinum 
(tetramine) unit which interacts with D N A only through electrostatic and hydrogen 
bonding effects [141] . 
Ck NHj HjN. NHj(CH2p,N. .NHj *^  
Pt Pt ?( 
HjN NHjiCHiPzN NHj HjN CI 
Figure 21. Structure ofBBR3464(l,0,l/t,t,t). 
The highly charged compound induces B—>A and B ^ Z conformation changes in the 
canonical sequences of DNA. Non covalent concept is extended in this complex by 
use of dangling amines which increase the charge and charge dispersion along these 
linear cations, surprisingly results in significantly enhanced cellular accumulation, 
with a higher charge (8+) has about 5 times greater cellular uptake enhanced 
cytotoxity is observed across a panel of ovarian tumor cell lines despite the 
reversible nature of DNA binding. The ultimate goal of these approaches is to 
disrupt the vital cellular processes at the molecular level to trigger downstream 
events ultimately leading to cancer cell death. 
The specific binding mode of metal complexes as well as consequent DNA structural 
changes can be analysed employing biophysical techniques such as UV-visible. 
fluorescence, NMR ( ' H and ^'P NMR), circular dichroism, viscosity, gel 
electrophoresis. Each of these techniques has proven to be reliable for discerning the 
exact nature of DNA-metallomolecule interactions. The cooperative conformational 
and structural transitions induced by metal complexes were assessed primarily by 
UV-visible spectrometry revealed by absorption spectral perturbations of the 
30 
complexes upon addition of DNA. Recent report by U. Cliaveerach et al. [142] 
described the synthesis and characterization of copper(II) complexes [Cu(L''^ )2]Cl2 
(L"" = amidino-0-methylurea) and [Cu(L '^^ )2]Cl2 (L^™ = N-methylphenyl-amidino-
0-methylurea) and their DNA binding studies. Upon addition of CT-DNA to the 
complexes [Cu(L''^ )2]Cl2 and [Cu(L '^")2]Cl2, increase in the absorption intensity 
(hyperchromism) was obtained indicative of a partial or non-intercalative binding 
mode possibly by (i) hydrogen bonds of the amine group with the nucleobases of 
DNA (ii) electrostatic interactions among [CU(L''^^'^)2]^^ cationic species and the 
negatively charged phosphate groups on the DNA backbone (iii) in case of complex 
[Cu{L""')2]Cl2, an intercalative interactions by the aromatic species. The intrinsic 
binding constants (Kb) of complexes [Cu(L''^ )2]Cl2and [Cu(L''")2]Cl2 were found out 
to be 5.67x10'* M"' and 1.16x10^ M"' respectively, lower than that of classical 
intercalator ethidium bromide (1.40x10'' M'') suggesting a weak electrostatic 
association of these complexes with DNA (Figure 22a,b). 
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Figure 22. Absorption titration spectra of complexes (a) [Cu(L'"')2]Cl2 and (hj 
[Cu(L '")2]Cl2 in the absence ('') and presence (~) of increasing amounts of DNA 
from 0 to 35 fiM. [complex] = 25 p.M. Arrows show the absorbance change with 
increasing DNA concentrations. 
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Viscosity measurements were carried out on DNA by varying the concentration of 
copper(Il) complexes in the [Complex]/[DNA] ratio (r) of 0.00-0.50 (Figure 23). The 
relative viscosity change of a classical intercalators ethidium bromide was compared 
with the synthesized complexes [Cu(L'"')2]Cl2 and [Cu(L '^^ )2]Cl2. Both the 
complexes exhibit considerable decrease in the relative viscosity (r=0.00-0.25) of 
DNA reducing its effective length by producing bends and kinks in the DNA strand. 
Secondly, when the value of r was increased from 0.25-0.40, a rapid increase in the 
DNA viscosity was observed attributed to an intercalative binding mode. FinalK, the 
relative viscosity of DNA remains unchanged from 0.40-0.50 due to electrostatic 
interactions and saturation of the binding site. These results reveal that the complex 
[Cu(L'^ '")2]Cl2 exhibits greater binding propensity as compared to [Cu(L''")2]Cl2. 
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Figure 23. Effect of increasing amount of ethidium bromide (k) complex 
Im 2m [Cu(L"")2]Cl2 (u) and complex [Cu(L^"')2]Cl2 (•) on the relative viscosity of CT 
DNA vs. the [complex]/[DNA] (r) ratio with [DNA]= 50 nM. 
In addition to the above spectral studies carried out with CT-DNA, gel 
electrophoresis experiments using pBR322, plasm id DNA were also performed 
under physiological conditions to investigate the ability of the complexes to serve as 
metallonucleases. The naturally occurring supercoiled form (Form I), when nicked, 
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gives rise to an open circular relaxed form (Form 11) and further cleaves to a linear 
form (Form III). When subjected to gel electrophoresis, Form 1 shows the fastest 
migration compared to Forms II and III. Form II migrates very slowly prior to its 
relaxed structure whereas Form III migrates somewhere between the positions of 
Form I and Form II. From the results, it was verified that at millimolar 
concentrations cleavage of plasmid DNA. (Figure 24a,b) (Lanes 2-6) represents the 
cleavage pattern observed for complexes [Cu(L'"')2]Cl2 and [Cu(L '^")2]Cl2 with 
increasing concentrations of the complex ranging from 50, 100, 200, 300, 400 f^ M. 
The results reveal that an increasing amount of the complex [Cu(L '")2]Cl2 led to a 
gradual diminish of Form I with a subsequent increase in Form 111 by 16.55%. 
Figure 24. Gel electrophoresis diagrams showing the cleavage of supercoiled 
pBR322 DNA (0.25 ng) by complexes (a) [Cu(L"")2jCl2 and (b) [Cu(L^"')2]Cl2 in 5 
mM Tris~HCl/50 mMNaCl buffer atpH 7.0 and 37 °C with an incubation time of 24 
h: Lane 1, DNA control; Lanes 2-^, DNA + [complex] (50, 100, 200, 300 and 400 
/.{M, respectively). Forms /, / / and III are supercoiled. nicked circular and linear 
DNA, respectively. 
While the complex [Cu(L '^")2]Cl2 also shows a similar result with a disappearance of 
Form I and gradual increase in the Form III by 17.75% suggestive of a stronger 
DNA cleavage activity for complex [Cu(L '^")2]Cl2 compared to complex 
[Cu(L ™)2]Cl2 which corroborates well with their DNA binding capabilities. 
On incubation of complexes [Cu(L'"')2]Cl2 and [Cu(L '^^ )2]Cl2 (400 nM) with 
pBR322 DNA in the presence of hydrogen peroxide, the amount of Form 111 
obtained was considerably greater than in the presence of complexes alone (Lanes 
6,7 Figure 25a,b) showing that DNA degradation induced by the copper(II) 
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complexes via oxidative pathway was enhanced in the presence of hydrogen 
peroxide. 
Kttrm II 
Vorm 111 
K.irm I 
Figure 25. Gel electrophoresis diagrams showing the cleavage of supercoiled 
Im, pBR322 DNA (0.25 ^g) by complexes (400 nM): (a) [Cu(L""j2jCl2 and (b) 
[Cu(L^'")2jCl2, with addition of H2O2 (100 IAM) with/without scavengers including 
DMSO (4 IL), t-BuOH (100 IM) and NaNj (100 IM) in 5 niM Tris-HCl/50 mM NaCl 
buffer at pH 7.0 and 37 "C with an incubation time of 24 h. Lane f DNA control; 
Lane 2, DNA + H2O2: Lanes 3-5, DNA + scavengers (DMSO, t-BuOH and NaN}. 
respectively): Lane 6, DNA + complex; Lane 7, DNA + complex + H2O2; Lanes 8-
10, DNA + complex + H2O2 + scavenger (DMSO, t-BuOH and NaNs, respectively). 
In order to gain further insight of the DNA cleavage by these copper(n) complexes 
hydroxyl radical scavengers (DMSO and t-BuOH) and a singlet oxygen scavenger 
(NaNs) were added into the samples under similar conditions (Lanes 8-10. Figure 
25a,b). The results revealed that both the hydroxyl radical (Lane 8,9) and more 
dominant singlet oxygen species (Lane 10) were involved in the oxidative cleavage 
pathway. 
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Present Work 
The development of metal-based chemotherapeutic drugs has gained much emphasis 
owing to their superior binding ability and specific recognition to the molecular 
target DNA. Heterobimetallic architecture utilizes a unique building block strategy 
which involves combination of two or more active metal centers exhibiting 
differential behaviour towards the cellular target DNA. Furthermore, the metal 
properties are fine-tuned by introducing appropriate ligands which are themselves 
active pharmacophores. Such combination agents behave as a single chemical entity 
capable to modulate muhiple targets simultaneously acting in accord, possibly 
delivering superior efficacy against diseases in particular, for treating tumors. 
Literature supports that heterobimetallic complexes exhibit better cleavage activities 
as two or more metal centers involved were found to act synergisticalK in DNA 
cleavage in contrast to monometallic analogues. 
In an attempt to identify new metal-based antitumor agents that show promise to 
overcome inherent resistance and exhibit fewer side effects, new heterobimetallic 
complexes [C6H24N406CuSn2Cl4]Cl2 and [C6H24N406ZnSn2Cl4]Cl2 derived from 
their monometallic analogues [C6H2oN402Cu]Cl2, [C6H2oN402Zn]Cl2, were designed 
and synthesized. These complexes were thoroughly characterized by spectroscopic 
(IR, 'H , '^C, "^Sn NMR, EPR, UV-vis, ESI-MS) and analytical methods. Electronic 
absorption fitrafions, fluorescence and cyclic voltammetric studies in free complexes 
and in the presence of DNA supported that both the complexes bind to DNA by 
electrostatic interaction via phosphate backbone of the helix pertaining to the 
presence of Lewis acid metal binding sites- copper and tin centers. Cleaving activity 
of the complexes employing agarose gel electrophoresis with pBR322 plasm id DNA 
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was also carried out to examine their scission activity. These studies revealed that 
both the heterobimetallic complexes were efficient cleaving agents of pBR322 
plasmid DNA. 
Among the various factors governing the binding mode of complexes molecular 
shape, size and stereo chemical orientation of the molecule are regarded as most 
significant. Those complexes that best fit against the helical structure of DNA 
display the highest binding affinity for DNA. Thus, chirality plays a profound role in 
the different pharmacological effects exhibited by enantiomeric drug molecules 
revealing a preferential binding of one conformation over another, which is termed 
as enantioselectivity. The chiral discrimination of DNA has been crucial for the 
determination of the binding mode of the complexes with DNA. Keeping this in 
mind new chiral complexes(S)/(R)-[C,5H2iN02Sn] and (S)/(R)-[C,oH|6NOSnCI] 
were designed and synthesized with the aim to develop new chiral chemotherapeutic 
antitumor agents. The conformational difference arising due to the binding of S- and 
R-enantiomer of the organotin Schiff base complexes (S)/(R)-[C]5H2iN02Sn] and 
(S)/(R)-[CioHi6NOSnCl]was ascertained by comparative DNA-binding studies of 
both forms of the complexes and ligands. Electronic absorption, fluorescence 
titrations and circular dichoric studies in the presence of CT-DNA supported that 
both the enantiomers bind to DNA by non-covalent mode of binding viz. 
electrostatic interaction via phosphate backbone of the helix, nevertheless, S-
enantiomer is more potent and exhibits enhanced binding propensity for DNA as 
compared to R-enantiomer. Significantly promising in vitro cytotoxic activity of S-
enantiomer of complexes demonstrates their high antitumor potential. 
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The ligand framework plays significant role in metal-based pharmaceuticals via, 
alteration in the biological properties by modifying reactivity or substitution 
inertness. Besides this, the introduction of chirality enhances the pharmacological 
behaviour of the metal complexes by adopting specific conformation and target 
selective binding with DNA. The organotin(IV) complexes [Ci8Hi9N402SnCl], 
[C28H23N402SnCl] and [C52H42N402Sn2] of biologically significant benzimidazole 
tridentate chiral ligand via, l,2-Bis(lH-benzimidazole-2yl)-ethane-l,2-diol. were 
synthesized and their DNA-binding properties were elucidated by various 
biophysical techniques. The results of these techniques revealed a pronounced 
multifaceted binding for complex [C2gH23N402SnCl] owing to its different structural 
constraints in comparison to [Ci8Hi9N402SnCl] and [C52H42N402Sn2] complexes. 
The varying DNA recognition of the complexes [CigH|9N402SnCl]. 
[C2gH23N402SnCl] and [C52H42N402Sn2] was also elucidated on the basis of circular 
dichroism studies. Furthermore, specific mode of binding exhibited by the 
complexes as ascertained by nucleotide recognition of these complexes with 5'-GMP 
and 5'-TMP using electronic absorption and NMR techniques ( 'H and ^'P NMR). 
Another class of Schiff base ligand derived from condensation reaction of natural 
chromone derivative 2-amino-3-formylchromone and 2-amino-2-phenylethanol was 
synthesized and thoroughly characterized. The complexation of ligand 2-amino-3-
((2-hydroxy-l-phenylethylimino)methyl)-4H-chromen-4-one with Cu(N03)2. 3H2O 
and Zn(N03)2.6H20 was carried out to obtain desired complexes 
[C36H34N407Cu](N03)2 and [C36H32N406Zn](N03)2 in moderate yields. In vitro 
DNA binding and cleavage studies of both the complexes [C36H34N407Cu](N03)2 
and [C36H32N406Zn](N03)2 were investigated to evaluate their comparative binding 
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extent with CT-DNA. The DNA binding studies reveal a clear preference of binding 
exhibited by copper(II) complex [C36H34N407Cu](N03)2 with DNA in comparison to 
its [C36H32N406Zn](N03)2 analogue. DNA cleavage studies with pBR322 plasmid 
DNA was carried out for [C36H34N407Cu](N03)2Complex owing to its high binding 
potential. The complex revealed an excellent DNA cleavage activity both in absence 
and presence of any external reducing or activating agents. The results of DNA 
binding and cleavage activity cumulatively show a groove binding pattern of 
complexes with CT-DNA. 
CHAPTER II 
Experimental 
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CHAPTER II 
EXPERIMENTAL METHODS 
The following techniques were employed 
1. Materials 
2. Characterization techniques 
2.1 Infrared spectroscopy 
2.2 Ultra-violet and visible spectroscopy 
2.3 Nuclear magnetic resonance spectroscopy 
2.4 Electron paramagnetic resonance spectroscopy 
2.5 Mass spectroscopy 
2.6 Molar conductance measurements 
2.7 Polarimetry 
3. DNA binding studies 
3.1 Absorption spectral studies 
3.2 Fluorescence spectral studies 
3.3 Circular dichroic spectral studies 
3.4 Cyclic voltammetry 
3.5 Viscometry studies 
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4. In vitro antitumor studies 
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1.Materials 
CUCI2.2H2O, Cu(N03)2.3H20, Zn(N03)2.6H20, acetylacetone and L-(+)-tartaric acid 
(E.Merck), l,3-diamino-2-propanol, 2-amino-3-fomiylchromone (Aldrich). ZnCb 
(anhydrous) (Rankem), SnCl4.5H20 (Lancaster), (S)/(R)-2-amino-2-phenylethanol, 
dimethyltin(IV)dichloride, diphenyltin(IV)dichloride, triphenyltin(IV)chloride, 
Tris(hydroxymethyl)aminomethane or Tris-buffer (Sigma), 1,2-diamino benzene 
(Loba Chemie) were used as received. Disodium salt of calf thymus DNA (CT-
DNA), guanosine 5'-monophosphate disodium sak (5'-GMP), thymine 5-
monophosphate disodium sah (5'-TMP), cytidine 5'-monophosphate, adenosine 5'-
monophosphate (Sigma) and was stored at 4 "C. 6X loading dye (Fermental Life 
Science), agarose gel, ascorbic acid, sodium azide (NaN3), DMSO, superoxide 
dismutase (SOD), methyl green, DAPI, mercaptopropionic acid (MPA) (Sigma-
Aldrich) and Super coiled pBR322 DNA (Genei) were utilized as received. All 
reagent grade compounds were used without flirther purification. 
2. Characterization techniques 
Carbon, hydrogen and nitrogen contents were determined using Carlo Erba analyzer 
model 1108. Melting points were determined by electrothermal apparatus. LLC was 
performed on commercial aluminium sheets precoated with 0.20 mm layers of silica 
gel. The visualization of spots on TLC plates was effected by exposure to iodine. 
2.1 Infrared spectroscopy 
Fourier transform infrared spectra were recorded on Interspec 2020 ITIR 
spectrometer in KBr pellets from 4000-400 cm"'. The infrared spectroscopy is a 
useful technique to characterize a compound. It results from transition between 
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vibrational and rotational energy levels. IR region of the electromagnetic spectrum 
covers a wide range of wavelength from 200-4000 cm"'. It has been found that in 
IR absorption, some of the vibrational frequencies are associated with specific 
groups of atoms and remain same irrespective of the molecules in which the group is 
present. These are called characteristic frequencies and their constancy results from 
the constancy of bond force constants from molecule to molecule. The important 
observation that the IR spectrum of a complex molecule consists of characteristic 
group frequencies makes IR spectroscopy, unique and powerful tool in structural 
analysis. 
2.2 Ultra-violet and visible spectroscopy 
The electronic spectral studies of metal complexes provide useful information about 
the stereochemistry, oxidation state of the metal ion and in suitable circumstances, 
the nature of metal-ligand bond. Electronic spectra were recorded on a UV-1700 
PharmaSpec UV-visible spectrophotometer in methanol and DMSO and methanol as 
solvent. 
2.3 Nuclear magnetic resonance spectroscopy 
The nuclei of certain isotopes possess a mechanical spin or angular momentum. The 
NMR spectroscopy is concerned with nuclei having nuclear spin quantum number 1 
= 1/2, example of which include 'H , '^C, ^ 'P, "''Sn and ' ' 'F. 
For a nucleus with I = 1/2, there are two values for the nuclear spin angular 
momentum quantum number mi = ±1/2 which are degenerate in the absence of a 
magnetic field. However, in presence of the magnetic field, this degeneracy is 
destroyed such that the positive value of mj corresponds to the lower energy state 
and negative value to higher energy state separated by AE. 
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In an NMR experiment, one applies strong homogeneous magnetic field causing the 
nuclei to presses. Radiation of energy comparable to AE is then imposed with radio 
frequency transmitter equal to precision or Larmor frequency and the two are said to 
be in resonance. The energy can be transferred from the source to the sample. The 
NMR signal is obtained when a nucleus is excited from low energy to high energy 
state. 
'H, '^C and "'Sn NMR spectra were obtained on a Bruker Avance DRX-400 
spectrometer at 400 and 500 MHz, respectively operating at room temprature. 
2.4 Electron paramagnetic resonance spectroscopy 
Electron paramagnetic resonance (EPR) spectra of the Cu(II) complexes were 
obtained on a Varian E 112 EPR spectrometer using tetracyanoethylene (TCNB) as 
field marker. The spectra were recorded for solid and solutions of the complexes in 
appropriate solvents at room temperature (RT) as well as at liquid nitrogen 
temperature (LNT). 
2.5 Mass spectroscopy 
Mass spectrometry is one of the most accurate microanalytical technique which 
requires only a few nanomoles of the sample to obtain characteristic information 
regarding the molecular mass and to detect within a molecule the places at which it 
prefers to fragment from which the presence of recognizable group within the 
molecule can be deduced. Mass spectrometry is complementary to FT IR, NMR, 
UV-vis and EPR spectral techniques for structural identification of compounds. 
Electrospray mass spectra were recorded on Micromass Quattro II triple quadrupol 
mass spectrometer. 
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2.6 Molar conductance measurements 
The conductivity measurement is one of the simplest and easily available techniques 
used to study the nature of the complexes. It gives direct information regarding 
whether a given compound is ionic or covalent. For this purpose, the measurement 
of molar conductance (Am), which is related to the conductance value in the 
following manner is made. 
cell constant x conductance 
Am = 
concentration of solute expressed in mol cm"^  
Conventionally, solutions of 1.0x10"^  M strength are used for the conductance 
measurements. Molar conductance values of different types of electrolytes in a few 
solvents are given as, 1:1 electrolyte has a value of 80-115 ohm' cm" mol"' in 
methanol, 65-90 Q"' cm^ mol"' in DMF, 78-80, 50-70 D"' cm^ mol"' DMSO and 35-
45 fl"' cm^ mol"' in ethanol [143]. Similarly a solution of 2:1 electrolyte has a value 
of 160-220 Q"' cm^ mol"' in methanol, 130-170 Q"' cm^ mol"' in DMF and 70-90 Q"' 
cm^ mol"' in ethanol. 
Molar conductance was measured at room temperature on a Digisun electronic 
conductivity bridge. 
2.7 Polarimetry 
Optical isomerism manifests itself by the rotation that certain molecules impart to 
the plane of polarized light when in gaseous, liquid or molten state or in solution 
(Figure 29). This rotation is observed and measured by a rather simple instrument. 
known as polarimeter. The specific rotation [a] of a dissolved substance is given by 
the expression 
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[a] 
1 xc 
where a is the observed rotation in degrees 
1 is the path length of the sample in decimeters 
c is the concentration in grams per milliliter 
The dependence on wavelength and temperature is indicated by subscripts and 
superscripts respectively. Thus [a]D^^  means the specific rotation at 25 °C measured 
at the wavelength of the sodium D line. 
Optical rotation is generally measured using light from a sodium-vapour lamp, 
which gives essentially monochromatic radiation (the yellow sodium D line is a 
doublet at 5890 and 5896 A°). 
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Figure 29. Rotation of plane of polarized light by optically active compounds. 
A beam of light is polarized by passage through nicol prism (the polarizer),which 
consists of two calcite prisms cemented together so that only one of the two rays 
formed by double refraction is transmitted. The beam of polarized light passes 
through the solution and then through a second nicol prism. When no optically active 
material is placed between the prisms (0" rotation), the prisms are positioned at right 
angles so that no light is transmitted. When an optically active material is placed 
between the prisms, the analyzer must be turned in order to maintain the darkness in 
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the field of view. The optical rotation is the angle by which the analyzer is turned in 
order to reach darkness. It is very difficult to determine by eye the setting for 
complete darkness, because positions near the completely dark position are very 
dark. Therefore, many instruments are constructed such that the field of view is 
divided into two equal parts, and the analyzer is adjusted so as to equalize the light 
intensity in each half of the field. 
Opfical rotations of chiral ligands and complexes were determined on a Polarimeter 
Rudolf Autopol III. 
3. DNA binding studies 
All the experiments involving interaction of the complexes with CT-DNA were 
conducted in Tris buffer containing HCl (0.01 M) adjusted to pH 7.2 with 
hydrochloric acid. The CT-DNA was dissolved in Tris-HCl buffer and was dialyzed 
against the same buffer overnight. Solutions of CT-DNA gave ratios of UV 
absorbance at 260 and 280 nm above 1.8, indicating that the DNA was sufficiently 
free of protein [144]. DNA concentration per nucleotide was determined by 
absorption spectroscopy using the molar absorption coefficient 6600 dm^ mof' cm"' 
at 260 nm [145]. The stock solution was stored at 4 °C. 
3.1 Absorption spectral studies 
The intrinsic binding constant Kb of the complex to CT-DNA was determined from 
equation (1), through a plot of [DNA]/Sa-Ef vs [DNA], where [DNA] represents the 
concentration of DNA, and e^, er, and 8b the apparent extinction coefficient (Aobs 
/[M]), the extinction coefficient for free metal complex (M), and the extinction 
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coefficient for the free metal complex (M) in the fully bound form, respectively. In 
plots of [DNA]/|Ea-ef] vs [DNA], Kb is given by the ratio of slope to intercept [146]. 
[DNA] / |8a-8f] = [DNA] / |8a-£f] + 1/Kb K-Sf | (1) 
Absorption spectral titration experiments were performed by maintaining a constant 
concentration of the complex and varying the nucleic acid/nucleotide concentration. 
This was achieved by diluting an appropriate amount of the metal complex solutions 
and DNA/5'-GMP and 5'-TMP stock solutions while maintaining the total volume 
constant. This results in a series of solutions with varying concentrations of DNA/5'-
GMP and 5'-TMP but a constant concentration of the complex. The absorbance (A) 
was recorded after successive additions of DNA or 5'-GMP or 5'-TMP. While 
measuring the absorption spectra an equal amount of either CT-DNA or S'-GMP or 
5'-TMP was added to both the compound solution and the reference solution to 
eliminate the absorbance of the either CT-DNA or 5'-GMP or 5'-TMP itself 
3.2 Fluorescence spectral studies 
The emission spectrum is obtained by setting the excitation monochromator at the 
maximum excitation wavelength and scanning with emission monochromator. Often 
an excitation spectrum is first made in order to confirm the identity of the substance 
and to select the optimum excitation wavelength. Further experiments were carried 
out to gain support for the mode of binding of complexes with CT DNA. Non-
fluorescent or weakly fluorescent compounds can often be reacted with strong 
fluorophores enabling them to be determined quantitatively. On this basis molecular 
fluorophore EthBr was used which emits fluorescence in presence of CT DNA due 
to its strong intercalation. Quenching of the fluorescence of EthBr bound to DNA 
were measured with increasing amount of metal complexes as a second molecule 
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and Stem-Volmer quenching constant K was obtained from the following equation 2 
[147]. 
I o / I = l + K r (2) 
where r is the ratio of total concentration of complex to that of DNA and Ip and 1 are 
the fluorescence intensities of EthBr in the absence and presence of complex. 
Binding constant K of the metal complexes was also determined from equations 3 
and 4 (Scatchard equations) by emission titration [148]. 
CF = C T ( I / I O - P ) ( 1 - P ) (3) 
r/CF = K(n-r) (4) 
Where CF is the free probe concentration, CT is the total concentration of the probe 
added, I and loare fluorescence intensities in presence and absence of CT DNA, 
respectively and P is the ratio of the observed fluorescence quantum yield of the 
bound probe to that of the free probe. The value P was obtained as the intercept by 
extrapolating from a plot of I/Io vs 1/ [DNA], r denotes ratio of CB (=CT-C!) to the 
DNA concentration i.e., the bound probe concentration to the DNA concentration, K 
is the binding constant and CF, is the free metal complex concentration and "n" is the 
binding site number. Emission intensity measurements were carried out using 
Hitachi F-2500 spectrofluorometer at room temperature. 
3.3 Circular dichroic spectral studies 
Circularly polarized light represents a wave in which the electrical component spirals 
around the direction of propagation of the ray, either clockwise or counterclockwise. 
Within the absorption band, the molar absorptivity for right and left handed 
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circularly polarized light is different, that is (sd-ei) i- 0. This effect changes linearly 
polarized light into elliptically polarized light and is known as circular dichroism. 
The amplitude of d component will be greater than the 1 component when 1 
component of the substance absorbs left circularly polarized light, more strongly 
than d component which absorb the right circularly polarized light i.e. r.| > Sd 
Furthermore, if Ed > si then the d component will be retarded more than the 1 
component (Figure 30). 
The ellipticity, that is the angle whose tangent is ratio of minor axis of the ellipse OB 
to the major axis OA, is denoted by 0. The molecular ellipticity [6] can be shown by 
the relationship [149]. 
[6] = 3305 (si - Ed) 
Circular dichroism graphs are plots of [0] against wavelength. Circular dichoric 
spectra were obtained on JASCO J-715/J-710 CD spectropolarimeter at 25 "C. 
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Figure 30. Elliptically polarized light produced when r]j>rii andEi>8d 
3.4 Cyclic voltammetry 
Cyclic voltammetry involves the measurement of current-voltage curves under 
diffusion controlled, mass transfer conditions at a stationary electrode, utilizing 
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symmetrical triangular scan rates ranging from a few millivolts per second to 
hundred volts per second. The triangle returns at the same speed and permits the 
display of a complete polarogram with cathodic (reduction) and anodic (oxidation) 
waveforms one above the other. Two seconds or less is required to record a complete 
polarogram [150]. 
Consider the reaction 
O + ne" • R (i) 
Assuming semi-infinite linear diffusion and a solution containing initially only 
species O. With the electron held at a potential Ei where no electrode reaction 
occurs. The potential is swept linearly at v v/sec so that the potential at any time is 
E(t) = Ei-vt 
or Epeak = E°-0.0285 
The rate of electron transfer is so rapid at the electrode surface that species O and R 
immediately adjust to the ratio according to the Nemst equation, which is as follows, 
Co (0,t) = Co* - [nFA(7rDo)''']-' j l(7t)(t-x)-"' dt (ii) 
I = nFACo*(nDoa)"^ X (a t) (iii) 
Redox (electron-transfer) reactions of metal complexes can be investigated bj cyclic 
voltammetry. An electrode is immersed in a solution of the complex and voltage is 
swept while current flow is monitored. No current flows until oxidation or reduction 
occurs. After the voltage is swept over a set range in one direction, the direction is 
reversed and swept back to the original potential. The cycle may be repeated as often 
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as desired. Figure 31(a-b). shows the cyclic voltammograms (CV) for a reversible 
one-electron redox reaction such as, 
CpFe(CO)LMe • CpFe(CO)LMe^ + e" 
Sweeping the potential in an increasing direction oxidize the complex as the anodic 
current la flows; reversible reduction of CpFe(CO)LMe* generates cathodic current 
Ic on the reverse sweep. The magnitude of the current is proportional to the 
concentration of the species being oxidized or reduced. 
The measured parameters of interest on these cyclic voltammograms are Ipa/lpc the 
ratio of peak currents, Epa - Epc the separation of peak potentials and the formal 
electrode potential E°. For a Nemstian wave with stable product, the ratio Ipa/lpc = 1 
regardless of scan rate, E^  and diffijsion coefficient, when Ipa is measured from the 
decaying current as a base line. The difference between Epa and Epc (AEp) is a useful 
diagnostic test of a Nemstian reaction. Although AEp is slightly a fiinction of E". it is 
always close to 2.3RT/ nF. 
0 Switching time, X 
(«) 
. 
' 
:" —"["T* 
—-•^ \ 
1 1 1 1 1 , ,,. 1 
Figure 31. (a) Cyclic potential sweep 
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(b) Resulting cyclic voltammogram 
The technique yields information about reaction reversibilities and also offers a rapid 
means of analysis for suitable systems. The method is particularly valuable to study 
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interaction of metal ions to DNA as it provides a useful compliment to other 
methods of investigation, such as UV/vis spectroscopy. Cyclic voltammetric studies 
were accomplished on a CH Instrument Electrochemical analyzer using a three-
electrode configuration comprised of a Pt wire as the auxiliary electrode, a platinum 
micro-cylinder as the working electrode and Ag/AgCl as the reference electrode. 
Supporting electrolyte for the experiments was 0.4 KNO3. Electrochemical 
measurements were made under nitrogen atmosphere. All electrochemical data were 
collected at 298 K and are uncorrected for junction potentials. 
Cyclic voltammetric measurements were carried out on a CH instrument 
electrochemical analyzer. 
3.5 Viscometric studies 
The hydrodynamic changes are the consequence of the change in length of the 
molecule, the diminished bending between layers and the diminished length-specific 
mass. Viscosity measurements were carried out using Ostwald's viscometer at 
29±0.01 °C. Flow time was measured with a digital stopwatch. Each sample was 
measured three times and an average flow time was calculated. Data were presented 
as (TJ/TIO) versus binding ratio ([M]/[DNA]), [151] where T) is a viscosity of DNA in 
the presence of complex and r|o is the viscosity of DNA alone. Viscosity values were 
calculated from the observed flow time of DNA containing solution (t >100s) 
corrected for the flow time of buffer alone (to), q = t- to 
Viscosity measurements were carried out using Ostwald capillary viscometer 
maintained at 29±0.01 °C. Several time readings were obtained at each titration 
point. DNA binding and cleavage experiments were performed at 25 °C. 
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3.6 Gel electrophoresis 
Gel electrophoresis is a technique widely used for separation and analysis of charged 
biomolecules like nucleic acids [152]. Any charged biomolecule migrates when 
placed in an electric field. The ratio of migration of a molecule depends on its net 
charge, size, shape and the applied current. This can be represented as follows 
V = E.q/f 
Where V = velocity of migration of the molecule, E = electric field in volts/cm, q = 
net charge on the molecule, f = frictional coefficient which is function of mass and 
shape of molecule. The movement of a charged molecule in an electric field is often 
expressed in terms of electrophoretic mobility (n), which is defined as the velocity 
per unit of electric field. 
H = V/E = E. q/f E 
For molecules with similar conformation, ' f varies with size but not with shape. 
Thus electrophoretic mobility (^) of a molecule is directly proportional to the charge 
density (charge/mass ratio). Molecules with different charge/mass ratio migrate 
under the electric field at different rates and hence get separated. This is the basic 
principal for all the electrophoretic techniques. Depending upon the nature of 
support medium, electrophoresis is of different types such as paper, starch. 
polyacrylamide and agarose gel electrophoresis. We have opted agarose gel 
electrophoresis, because agarose gels are more porous as compared to 
polyacrylamide gels and are, therefore, used to fractionate large macromolecules 
such as DNA that cannot be readily penetrate into and move through other types of 
supporting materials. Agarose is a linear polymer of D-galactose and 3,6-anhydro-L-
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galactose. When an electric field is applied across agarose gel, DNA molecules that 
are negatively charged at neutral pH, migrate towards oppositely charged electrode 
at rates determined by their molecular size and conformation. DNA molecules of the 
same size but with different conformation travel at different rates. The order of 
migration velocity in the increasing order of various forms of DNA is : supercoiled 
DNA> linearized DNA > open circular DNA. 
4. In vitro antitumor studies 
The cell lines used for in vitro antitumor screening activity were Hop62 (human 
lung), DWD (Human oral), K562 (Human leukemia), DU145 (Human prostrate) and 
MCF-7 (Human breast). These human malignant cell lines were procured and grown 
in RPMI-1640 medium supplemented with 10% Fetal Bovine Serum (PBS) and 
antibiotics to study growth pattern of these cells. The proliferation of the cells upon 
treatment with chemotherapy was determined using the Sulphorhodamine-B (SRB) 
semi automated assay [153]. Cells were seeded in 96 well plates at an appropriate 
cell density to give optical density in the linear range (from 0.5 to 1.8) and were 
incubated at 37 °C in CO2 incubator for 24 h. Stock solutions of the complexes were 
prepared as lOOmg/ml in DMSO and four dilutions i.e. lO^L, 20|.iL, 40|JL, SO^L, in 
triplicates were tested, each well receiving 90p.L of cell suspension and 10 nL of the 
drug solution. Appropriate positive control (Adriamycin) and vehicle controls were 
also run. The plates with cells were incubated in CO2 incubator with 5% CO2 for 
24 h followed by drug addition. The plates were incubated further for 48 h. 
Termination of experiment was done by gently layering the cells with SO^ iL of 
chilled 30% TCA (in case of adherent cells) and 50 % TCA (in case of suspension 
cell lines) for cell fixation and kept at 4 °C for 1 h. Plates were stained with 50nL of 
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0.4% SRB for 20 min. The bound SRB was eluted by adding 100 nL 10 mM Tris 
(pH 10.5) to each of the wells. The absorbance was read at 540 nm with 690 nm as 
reference wave length. All experiments were repeated 3 times. 
CHAPTER III 
Comparative DNA binding studies of monometallic 
and heterobimetallic complexes possessing Cu-
Sn2/Zn-Sn2 metallic cores: DNA cleavage activity of 
heterobimetallic complexes. 
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Synthesis of monometallic complexes 
Synthesis of [C6H2oN402Cu]Cl2 
This complex [C6H2oN402Cu]Cl2 was synthesized by adopting slight modification to 
the previously reported procedure [154]. To a methanolic solution of l,3-diamino-2-
propanol (1.80g, 20mmol), CUCI2.2H2O (1.70g, lOmmol) in methanol (20 ml) was 
added dropwise in (2:1) molar ratio. The resulting blue solution thus obtained, was 
stirred for 12 h to obtain a dark blue crystalline solid product which was washed 
thoroughly with hexane and dried in vacuo (Scheme 2). 
Yield 65%, m.p.= 276 ± 2 °C. Anal. (%) Calc. for [C6H2oN402Cu]Cl2: C, 22.90; H. 
6.41; N, 17.80. Found: C, 22.92; H, 6.43; N, 17.80. IR (v(cm"')): 3334 (0-H), 3292 
(NH2), 1400 (C-N), 1272 (C-0), 830 (H2O), 537 (Cu-N), 462 (Cu-0) Molar 
conductance, AM (1X10'^ M, Methanol): 179 O'cm^mof' (1:2 electrolyte). UV-vis. 
in Methanol [X^ ax / nm]: 229, 308, 670. 
Synthesis of [C6H2oN402Zn]Cl2 
The complex [C6H2oN402Zn]Cl2 was synthesized with ZnCh (anhydrous) (1.36g, 
lOmmol) by a similar procedure as described for C6H2oN402ZnCl2. 
Yield 60%, m. p. = 60 ± 2 °C. Anal. (%) Calc. for [C6H2oN402Zn]Cl2: C, 22.77; H, 
6.37; N, 17.70. Found: C, 22.73; H, 6.38; N, 17.71. IR (v(cm-')): 3332 (0-H), 3233 
(NH2) ,1315 (C-N), 1170 (C-0), 849 (H2O), 525 (Zn-N), 467 (Zn-O). Molar 
conductance, AM (1x10'^  M, Methanol): 194 D"'cm^ mof' (1:2 electrolyte). UV-vis 
in Methanol [A^ ax / nm]: 223, 245, 308. 
'H NMR (DMSO-d6, ppm): 8.1 (OH), 5.2 (NH2), 3.8 (CH), 3.5-2.0 (CH2). ''C 
NMR (DMS0-d6, ppm): 66 (C-0), 45 (C-N). 
Synthesis of heterobimetallic complexes 
Synthesis of [C6H24N406CuSn2Cl4]Cl2 
To a methanolic solution of the complex [C6H2oN402Cu]Cl2 (1.57g, 5mmol), SnCl4 
(8ml in CCU, lOmmol) was added in (1:2) molar ratio. The blue coloured solution 
turned green which was further stirred for 1 h and allowed to stand at room 
temperature overnight. A yellow crystalline solid product was obtained, washed 
thoroughly with n-hexane and dried in vacuo (Scheme 3). 
Yield 70%, m.p. = 220 ± 2 °C. Anal. (%) Calc. for [C6H24N406CuSn2Cl4]Cb: C, 
9.46; H, 3.17; N, 7.35. Found: C, 9.46; H, 3.18; N, 7.36. IR (v(cm"')): 3337 (O-H). 
3135 (N-H), 1592 5(N-H), 1391 (C-M), 1275 (C-O), 842 (H2O), 549 (Cu-N), 454 
(Cu-O), 440 (Sn-N), 245 (Sn-Cl). Molar conductance, AM (1x10"^  M, Methanol): 
173 Q'cm^mor' (1:2 electrolyte). UV-vis. in Methanol [A.max / nm]: 224, 270, 840. 
Synthesis of [C6H24N406ZnSn2Cl4]Cl2 
To a methanolic solution of complex [C6H2oN402Zn]Cl2 (1.58g, 4mmol), SnCU (8 
mL in CCI4, lOmmol) was added in (1:2) molar ratio. The white solid product thus, 
obtained on stirring, was filtered, washed with n-hexane and dried in vacuo. 
Yield 65%, m.p.= 222 ± 2 °C Anal. (%) Calc. for [C6H24N406ZnSn2Cl4]Cl2: C. 
9.43; H, 3.17; N, 7.34. Found: C, 9.44; H, 3.16; N, 7.33. IR (v(cm')): 3337 (O-H). 
3190 (N-H), 1535 5(N-H), 1300 (C-N), 1146 (C-O), 851 (H2O), 556 (Zn -N), 480 
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(Zn-0), 443 (Sn-N), 235 (Sn-Cl). Molar conductance, AM (1X10'^ M, Methanol): 180 
D'cm^mol"' (1:2 electrolyte). UV-vis in Methanol [>.max / nm]: 224, 255. 
'H NMR (DMS0-d6, ppm): 8.1 (-OH), 5.9 (-NH), 4.0 (CH), 3.5-2.8 (CH2). ' T 
NMR ( DMS0-d6, ppm): 68 (C-O), 45 (C-N). "''Sn NMR (DMSO-ds, ppm): -625, 
-668. 
Results and discussion 
Synthesis and characterization 
Preparation of heterobimetallic complexes [C6H24N406CuSn2Cl4]Cl2 and 
[C6H24N406ZnSn2Cl4]Cl2 were carried out by the reaction of [C6H2oN402Cu]Ci2 and 
[C6H2oN402Zn]Cl2 with SnCU in 1:2 metal-to-ligand stoichiometric ratio (Scheme 
3). The complexes are highly hygroscopic and soluble in methanol and DMSO. 
Molar conductance values of complexes in methanol (173 and 180 Q'' cm^ mol') at 
25 °C suggest their 1:2 electrolytic nature. The complexes [C6H2oN402Cu]Ci2 
[C6H2oN402Zn]Cl2, [C6H24N406CuSn2Cl4]Cl2, [C6H24N406ZnSn2Cl4]Cl2 reveal 
octahedral coordination geometry for the central metal ions copper(lI)/zinc(ll) as 
well as the tin(IV) ions (in case of complexes [C6H24N406CuSn2Cl4]Cl2 and 
[C6H24N406ZnSn2Cl4]Cl2) as proposed by various spectroscopic studies. DNA 
binding studies were carried out with the complexes [C6H20N4O2CUJCI2 
[C6H2oN402Zn]Cl2, [C6H24N406CuSn2Cl4]Cl2 and [C6H24N406ZnSn2Cl4]Cl2. The 
interaction studies of these complexes reveal that complex [C6H24N406ZnSn2Ci4|Cl2 
binds to CT-DNA with highest affinity. 
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Scheme 3. Synthesis of heterobimetallic complexes [C6H24N406CuSn2Cl4]Cl2 and 
[C6H24N40^nSn2Cl4]Cl2 
Figure 29. Cylindrical bonded three dimensional model of complexes (a) 
[C6H24N406CuSn2Cl4]Cl2 and (b) [C6H24N40^nSn2Cl4]Cl2. Colour scheme: 
Copper(II) and Zinc(II) dark gray; Tin(IV) light green; Chloride fluorescent green; 
N dark blue; O red; C gray. Chloride ion and other H atoms and are omitted for 
clarity. 
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IR spectral studies 
The complexes [C6H2oN402Cu]Cl2 and [C6H2oN402Zn]Cl2 exhibit characteristic 
broad envelope at 3292 cm"' attributed to v(NH2) coordinated to the 
copper(ll)/zinc(Il) centers [155]. The complexes [C6H24N406CuSn2Cl4]Cl; and 
[C6H24N406ZnSn2Cl4]Cl2, exhibit bands in 3135-3190 cm"' region and the 1592 cm ' 
region attributed to v(N-H) and 5(N-H), respectively suggesting that NH2 groups of 
l,3-diamino-2-propanol are coordinated to central metals copper(ll)/zinc(Il) and 
simultaneously to tin(IV) ion by the elimination of HCl molecules [156,155]. The 
v(O-H) band of the free ligand at 3360 cm"' [43] was shifted to lower wave numbers 
ca. 3334 cm"' indicative of coordinated -OH group. Other medium intensity bands 
observed at 1300-1391 cm"' and 1275-1146 cm"' were assigned to v(C-N) and v(C-
O) stretching vibration in the complexes[ 157,43]. The coordination of water 
molecules to the tin(IV) metal ion was supported by the appearance of non-iigand 
band in the region 845-858 cm"' attributed to the rocking mode of water [158]. In far 
IR region, medium intensity Cu/Zn-N, Cu/Zn-O, Sn-N and Sn-Cl bands around 
~525, ~ 480, ~ 441 and -250 cm"', respectively revealing the complex formation 
[159-161] as proposed in Scheme 2. 
Electronic spectra 
The UV-visible absorption spectra of the monometallic complexes 
[C6H2oN402Cu]Cl2 and [C6H2oN402Zn]Cl2 in methanol were characterized by strong 
IL absorption bands centered at -225-308 nm, respectively and a band in the visible 
region at 670 nm for complex [C6H2oN402Cu]Cl2 [162,163]. The heterobimetallic 
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complexes [C6H24N406CuSn2Cl4]Cl2 and [C6H24N406ZnSn2Cl4]Cl2 display sharp 
absorption maxima in the UV region at -224-270 nm while complex 
[C6H24N406CuSn2Cl4]Cl2 exhibited a broad and intense d-d absorption maximum at 
840 nm in the visible region. This spectral feature is typical of copper(ll) complexes 
in an octahedral coordination environment [164]. 
ilex was 
EPR spectrum 
The solid state X-band EPR spectrum of the polycrystalline copper(II) compk 
recorded in DMSO at LNT (25 "C) with a magnetic field strength of 3000 G. The 
EPR spectrum of [C6H24N406CuSn2Cl4]Cl2 revealed a set of four well resolved 
peaks both in low field and high field region with an axial symmetry with 
g||»gj>2.0023 pattern indicating that the unpaired electron is localized in d(x"-y") 
orbital (spectroscopic state ^Big) of a copper(II) center [165,166] with g)| = 2.36, gx 
= 2.09 [167] (Fi 
g|| =2.36 
g± =2.09 
Figure 30. X-band EPR spectrum of complex [C6H24N406CuSn2Cl4]Cl2 at LNT with 
g|| =2.36 and g± =2.09. 
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These values were consistent with an octahedral geometry of copper with d (Cu ") 
configuration i.e. (eg)" (aig)^ (b2g)^  (b,g)' [168], occupied by an unpaired electron. 
The exchange interaction parameter G = 4.07, suggesting absence of exchange 
coupling between the copper centers. 
NMR spectra 
The monometallic and heterobimetallic complexes [C6H2oN402Zn]Cl2 and 
[C6H24N406ZnSn2Cl4]Cl2 were characterized by 'H, '^C and "''Sn NMR spectra 
recorded in DMSO-de solution. The complex [C6H2oN402Zn]Cl2 exhibited the 
characteristic signal of NH2 group of bis-[l,3-diamino-2-propanol] at -5.2 ppm 
[155]. The free -OH group of bis-[l,3-diamino-2-propanol] also appeared in the 
same region while the coordinated -OH group to the zinc(II) center appears at 8.1 
ppm, therefore it becomes quite amenable that the -OH group of bis-[l,3-diamino-2-
propanol] is coordinated to the zinc(II) center in complex [C6H2oN402Zn]Cl2 [169]. 
The 'H NMR spectrum of complex [C6H24N406ZnSn2Cl4]Cl2 reveals a sharp 
resonance at -5.9 ppm attributed to -NH proton of bis-[l,3-diamino-2-propanol] 
coordinated simultaneously to the zinc(II) ion and to tin(IV) metal ion through 
deprotonation. Other resonances of the complex [C6H24N406ZnSn2Cl4]Cl: appeared 
at 2.8-3.5 ppm and 4.0 ppm for methylene proton and -CH proton adjacent to the OH 
group, respectively [170,155]. 
The '^ C NMR spectrum of complexes [C6H2oN402Zn]C"l2 and 
[C6H24N406ZnSn2Cl4]Cl2 recorded two signals at -68 ppm and -45 ppm attributed 
to -CHOH and -CH2N carbon atom, respectively [171,172]. 
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"^Sn NMR spectra of complex [C6H24N406ZnSn2Cl4]Cl2 displayed two signals at 
625 and -668 ppm, due to the presence of two tin(lV) metal centers (Figure 31) 
^n•i^^.l•JX«in•^|•1•1ri'••^'1'^ " '" * '••••'>-''w*'«>w»V^*^'**»«'>*i^^»^*''*^^^^ 
Figure 31. Sn NMR spectrum of complex [C6H24N406ZnSn2Cl4]Cl2 
These chemical shift values are consistent with those reported for complexes with 
the hexacoordinated tin(IV) metal atom [173]. 
DNA binding studies 
UV-visible absorption studies 
The interaction of complexes [C6H2oN402Cu]Cl2, [C6H2oN402Zn]Cl2. 
[C6H24N406CuSn2Cl4]Cl2, [C6H24N406ZnSn2Cl4]Cl2 with DNA were investigated by 
UV absorption titrations. Fixed amount of the complexes [C6H2oN402Cu]Cl2 
[C6H2oN402Zn]Cl2, [C6H24N406CuSn2Cl4]Cl2 and [C6H24N406ZnSn2Cl4lCl2 were 
titrated with increasing amount of CT-DNA (0-0.33x10"^ M) resulting in an overall 
hyperchromism at the intraligand absorption bands at 224-308 nm of the complexes 
(Figure 32a,b). Hyperchromicity and hypochromicity is the spectral feature of DNA 
concerning its double helix structure [174]. "Hyperchromic effect" reflects the 
corresponding changes of DNA in its conformation and structure after the complexes 
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are bound to CT-DNA. Hypochromism results from contraction of DNA in the helix 
axis while hyperchromism results from the damage of DNA double helix structure. 
A strong "hyperchromic effect" [175] with a moderate red shift of 1-4 nm was 
observed for heterobimetallic complexes [C6H24N406CuSn2Cl4]Cl2 and 
[C6H24N406ZnSn2Cl4]Cl2 in comparison to monometallic complexes, implying their 
higher DNA binding propensity. The propensity for DNA binding enhances in 
[C6H24N406CuSn2Cl4]Cl2 and [C6H24N406ZnSn2Cl4]Cl2 by the introduction of 
tin(IV) cations in the monometallic core; tin ions have a hard Lewis acid nature and 
thus, neutralize the dinegative charge of the phosphate sugar backbone of the DNA 
double helix [176]. In the complexes [C6H24N406CuSn2Cl4]Cl: and 
[C6H24N406ZnSn2Cl4]Cl2, heterobimetallic core possesses two tin(lV) ions and one 
copper(II)/zinc(II) ions; tin(IV) ions are accessible at two ends to a pair of DNA 
double helix in end-to-end fashion as illustrated by Mc Millan et al [177| to fomi a 
bridge-like structure which minimizes the Coulombic repulsions between the 
negatively charged duplexes (Figure 33). Such trinuclear complexes exhibit 
electrostatic binding, involving inner sphere complex formation via, negative charge 
of the phosphate oxygen with the positive charge of complex [178]. Furthermore, no 
significant changes were observed at ligand field bands of complexes monometallic 
and heterobimetallic complexes as the coordination environment around the 
transition metal ion is coordinatively saturated (octahedral); however, we cannot rule 
out the possibility of covalent binding of the transition metal ions {copper(ll) and 
zinc(II)} via, N7 and N3 atom of nucleobase of DNA helix which is their inherent 
characteristic trait [27]. 
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Figure 32. Absorption spectra of (a) complex [C6H24N406CuSn2Cl4]Cl2 (h) complex 
and [C6H24N406ZnSn2Cl4]Cl2 in Tris-HCl buffer (pH= 7.2) in the absence and 
presence of increasing amount ofCT-DNA. Inset: Plots of [DNA]/(Sa-£f) vs [DNA] 
for the titration of CT-DNA with complexes. Arrow indicate the increase in the 
absorbance upon increasing CT-DNA concentration. Plots of [CT-DNA]/ fsa - £f) vs. 
[CT-DNA]. 
The spectral "hyperchromic effect" arises mainly due to the presence of enhanced 
positive charge of cations copper(II)/zinc(II) and tin(lV) which bind to DNA via, 
non-covalent interaction presumably through strong electrostatic attraction to the 
phosphate group of the DNA backbone and thereby causing a contraction and overall 
damage to the secondary structure of CT-DNA [179]. 
To evaluate the binding affinity of the mono and heterobimetallic complexes with 
DNA, the intrinsic binding constant were determined by observing the changes of 
absorbance with varying concentration of CT-DNA. To quantify the extent of DNA 
binding the intrinsic binding constant Kb of complexes were determined (Table 2) 
which follows the order [C6H24N406ZnSn2Cl4]Cl2>[C6H24N406CuSn2Cl4]Cl2 
>[C6H20N4O2Zn]Cl2 > [C6H2oN402Cu]Cl2. 
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Figure 33. A schematic representation of a pair ofB-form DNA duplexes bridged by 
Cu-Sn2 complex [C6H24N40^uSn2Cl4]Cl2at the sugar phosphate backbone. 
Thus, we can deduce from the intrinsic binding value that the complex 
[C6H24N406ZnSn2Cl4]Cl2 bind more avidly to CT-DNA in comparison to complex 
[C6H24N406CuSn2Cl4]Cl2 as the divalent zinc(n) complexes are known to 
distinctively recognize the thymine base in double stranded DNA by cleavage of the 
A-T base pairs and making the DNA exposed at the A-T region for nuclease activity, 
thereby altering the local structure of the A-T regions of DNA duplex [180]. 
Table 2. The binding constant (K/,) values of complexes with the CT-DNA. 
Complexes Kb(M") Monitored at %Hyperchrom ism Red shift 
(nm) (nm) 
1.42±0.02xl0'' 308 
,4 
[C6H20N4O2Cu]Cl2 
[C6H2oN402Zn]Cl2 1.67±0.02xl0'* 308 
[C6H24N406CuSn2Cl4]Cl2 4.75±0.01xl0'* 225 
[C6H24N406ZnSn2Cl4]Cl2 2.0l±0.02xl0^ 254 
20 
39 
20 
42 
02 
03 
04 
04 
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Interaction with 5'-GMP and 5'-TMP 
The principles that govern the site-selective recognition of nucleic acid fragments 
such as 5'-GMP and 5'-TMP by the complexes [C6H24N406CuSn2Cl4]Cl2 and 
[C6H24N406ZnSn2Cl4]Cl2 include inherent specificity of binding of the copper(ll) 
and zinc(II) ions towards N7 of guanine as well as N3 of thymine base, respectively. 
In order to elucidate this preferential selectivity, the interaction of complexes with 
low molecular building blocks of large DNA molecules viz; guanosine 5'-
monophosphate (5'-GMP) and thymidine 5'-monophosphate and (5'-TMP) were 
investigated using electronic absorption spectroscopy. Addition of 5'-GMP to the 
complexes [C6H24N406CuSn2Cl4]Cl2 and [C6H24N406ZnSn2Cl4]Cl2 results in sharp 
increase in absorbance, 'hyperchromism' of the intraligand transitions with a red 
shift of 2-3 nm (Figure 34a,b). This observation provides an authentic proof for 
binding of complex to 5'-GMP through electrostatic interaction via, phosphate 
backbone of the DNA helix. It was observed copper(II) complex displays higher 
binding for 5'-GMP as compared to 5'-TMP validated by a larger Kb values of 
heterobimetallic copper(II) complex with 5'-GMP in contrast to its zinc(ll) analogue 
suggestive of strong binding preference of the complex with 5'-GMP. The intrinsic 
binding constant Kb values for [C6H24N406CuSn2Cl4]Cl2 and 
[C6H24N406ZnSn2Cl4]Cl2 were compared to quantify the extent of binding of 
copper(II) and zinc(n) complexes which were found out to be 6.66x10"*, 1.75 xlO"*. 
respectively indicative of higher preference of copper complex to the 5'-GMP in 
comparison to zinc complex [C6H24N406ZnSn2Cl4]Cl2. This observation is in accord 
66 
with the literature revealing that the copper(II) ions exhibit substantially large 
selectivity for N7 of guanine residue [27,181]. 
(a) _ t », (b) 
238.19 JOO.OO 
W a v e l e i l g t l i ( i i m ) 
241.27 300.00 
WavetengtlKiini) 
Figure 34. Absorption spectral traces of (a) Complex [C6H24N406CuSn2Cl4jCl: and 
(b) Complex [C6H24N406ZnSn2Cl4]Cl2 in DMSO upon addition of 5'-GMP. Inset: 
Plots of [5'-GMP]/(sa-s^ vs [5'-GMP] for the titration of 5'-GMP with complexes. 
[Complex]=1.0xl(r^M, [5'-GMPJ=0-0.33xJO'"M. 
Furthermore, interaction studies of [C6H24N406CuSn2Cl4]Cl2 and 
[C6H24N406ZnSn2Cl4]Cl2 with 5'-TMP were carried under similar conditions (Figure 
35a,b). The Kb binding constant follows the order [C6H24N406ZnSn2Cl4lCl2> 
[C6H24N406CuSn2Cl4]Cl2 . 
t 
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Figure 35. Absorption spectral traces of (a) Complex lC(fi24N406CuSn2Cl4]Cl2 and 
(b) Complex [C6H24N40^nSn2Cl4]Cl2 in DMSO upon addition of 5'-TMP. Inset: 
Plots of [5'-TMP]/(Ea-e^ vs [5'-TMP] for the titration of 5'-TMP with complexes. 
[Complex]=1.Ox 10'*M, [5'-TMP]=0-0.33xlO"M. 
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The zinc(II) complex [C6H24N406ZnSn2Cl4]Cl2 displays a much higher Kb value for 
5'-TMP compared to copper(ll) complex exhibiting preference of zinc for thymine in 
contrast to guanine [180]. The oxo groups at the C2 and C3 position of the thymine 
lowers the energy of the lone pair orbital at N3 of thymine base resulting in stronger 
molecular orbital interaction of complex with thymine in comparison to guanine. 
Table 3. The binding constant (Kb) values of complexes [C6H24N40(,CuSn2Cl4]Cli 
and[C6H24N40^nSn2Cl4]Cl2 with the 5'-GMP and5'-TMP 
Complex 5'-GMP 5'-TMP 
(xlO^) (xlO'') 
[C6H24N406CuSn2Cl4]Cl2 6.66 3.74 
[C6H24N406ZnSn2Cl4]Cl2 1.75 6.21 
Monitored at 
(nm) 
256 
259 
% Hyper- Red Shift 
-chromism (nm) 
22 02 
38 03 
Fluorescence studies 
In the absence of CT-DNA, complexes [C6H24N406CuSn2Cl4lCl2 and 
[C6H24N406ZnSn2Cl4]Cl2 emit weak luminescence in Tris-HCl buffer at room 
temperature, with a fluorescence maximum appearing at 520 nm and 524 nm, 
respectively, when excited at 260 nm. Upon addition of increasing concentration of 
CT-DNA over a range 0-0.16x10"^ M, to the fixed amount of complex (1.0x10"' M) 
the emission intensity of [C6H24N406CuSn2Cl4]Cl2 and [C6H24N406ZnSn2Cl4|Cl2 
increases appreciably as illustrated in the Figure 36(a-b), respectively. The 
enhancement of the emission intensity is largely due to the change in the 
environment of the metal complex and related to the extent to which the complex 
gets into a hydrophobic environment inside the CT-DNA. Since, it is found that 
complexes with increased ligand hydrophobicities show greater increase in emission 
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intensities upon binding to polyelectrolytes via, DNA, therefore, such an increase in 
emission intensities is attributed to electrostatic association. Thus, we infer that the 
complexes are less deeply accommodated inside the hydrophobic pockets inside the 
DNA which is indicative of electrostatic mode of binding of the complex to the CT-
DNA. The relative fluorescence intensity plotted as a function of DNA concentration 
(in terms of ([DNA]/[M])), (Figure 36a,b) shows larger increase in the emission 
intensity of complex [C6H24N406ZnSn2Cl4]Cl2 than the complex 
[C6H24N406CuSn2Cl4]Cl2. This implies that complex [C6H24N406ZnSn2Gl4]Cl2 is 
bound to the DNA more strongly by means of surface binding with the duplex 
(Table 4). 
Table 4. Emission properties of complexes [C6H24N406CuSn2Cl4]Cl2 and 
[C6H24N406ZnSn2Cl4]Cl2 hound to CTDNA. 
Complex Emission Excitation Monitored At K(M ) 
[C6H24N406CuSn2Cl4]Cl2 220 
[C6H24N406ZnSn2Cl4]Cl2 220 
260 
262 
520 
524 
6.00x10-
8.50x10^ 
(a) 
450 m 5S0 
> I I * ' r" I >"} I 
4st m iH m 
Figure 36. Emission spectra of (a) complex [C6H24N406CuSn2Cl4]Cl2 (b)complex 
[C6H24N40^nSn2Cl4]Cl2 in Tris-HCl buffer (pH 7.2) in the absence and presence of 
CT-DNA. Arrow indicates the change in the intensity upon increasing DNA 
concentration. 
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To demonstrate the interaction strength of the complexes [C6H24N406CuSn2Cl4]Cl2 
and [C6H24N406ZnSn2Cl4]Cl2 with CT-DNA, steady state emission quenching 
experiments using [Fe(CN)6]'*' as quencher were also performed [182,183], The 
propensity to CT-DNA for the complexes follows the order: 
[C6H24N406ZnSn2Cl4]Cl2 > [C6H24N406CuSn2Cl4]Cl2 as evidenced by the binding 
constant Ksv values given in the Table 5. 
(a) (b) 
Q.i 
PFe(CN>s]-'ilO-*M-i 
0.00 0.05 0.10 0.15 
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Figure 37. Emission quenching curves of (a) complex [C6H24N406CuSn2Cl4]Cl2 in 
the absence of CT-DNA (u) and in the presence of CT-DNA (•) and fb) complex 
[C6H24N40eZnSn2Cl4]Cl2 in the in the absence of CT-DNA (m) and in the presence 
ofCT-DNA(»).[M] = 1.0x10-^ M. 
In the absence of CT-DNA, emission intensity of complex [C6H24N406CuSn2Cl4jCl2 
and [C6H24N406ZnSn2Cl4]Cl2 were efficiently quenched by [Fe(CN)6]'*" as shown in 
Figure 37(a,b). The greater decrease of the Ksv value for [C6H24N406ZnSn2Cl4]Cl2 as 
compared to [C6H24N406CuSn2Cl4]Cl2 indicates higher DNA binding ability of 
[C6H24N406ZnSn2CU]Cl2. These results are consistent with the electronic absorption 
titration (Table 5). 
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Table 5. Emission quenching of CT-DNA bound [Fe(CN)6] ' by 
fC6H24N406CuSn2Cl4]Cl2 and [C6H24N406ZnSn2Cl4]Cl2. 
Complex Emission Excitation Monitored at Ksvi 
(xlO') 
[C6H24N406CuSn2Cl4]Cl2 462 260 432 10.66 
[C6H24N406ZnSn2Cl4]Cl2 460 262 440 15.00 
complexes 
Ksv^ 
(xlO"*) 
2.60 
4.00 
Effect of ionic strength 
Monitoring the changes of ionic strength is an efficient method for distinguishing the 
binding modes between small molecules and DNA. Due to a competition for 
phosphate anion, the addition of cation weakens the surface binding interactions viz; 
the electrostatic and hydrogen binding between the DNA and molecules [184,185). 
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Figure 38. Effect of different concentration ofNaCl on the fluorescence spectra of 
(a) complex [C6H24N406CuSn2Cl4]Cl2 (b) complex [C6H24N40^nSn2Cl4]a2 (1.0 
xlO'^ M) with CT-DNA (1.0x10"' M). Arrow indicate the gradual decrease of 
emission intensity as a function ofNaCl concentration. 
The effect of ionic strength on complex-DNA binding of [C6H24N406CuSn2C UJCb 
and [C6H24N406ZnSn2Cl4]Cl2 was studied and spectral changes were presented in 
Figure 38(a,b), which reveals a strong dependence of fluorescence intensity on ionic 
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strength. The fluorescence of zinc(II) complex-CT-DNA system displayed a distinct 
quenching with the increasing concentration of NaCl from 0.06-0.40x10'^  M. 
However, moderate fluorescence quenching was observed for copper(Il) complex-
DNA system. The results indicate that the interaction between complexes and CT-
DNA is predominantly electrostatic via; DNA phosphate backbone. Furthermore. 
zinc(II) complex displays stronger electrostatic interaction in comparison to the 
copper(II) complex. This is concomitant with our other DNA binding assays. 
Cyclic voltammetric studies 
Cyclic voltammetry is a useful technique for studying the interaction of metal 
complexes with DNA and understanding the nature of DNA binding [186], The 
cyclic voltammetric responses of complex [C6H24N406CuSn2Cl4]Cl2 in absence and 
presence of CT-DNA are shown in Figure 39. 
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Figure 39. Cyclic voltammogram (95:5 MeOH/H20) of complex 
[C6H24N406CuSn2Cl4]Cl2 in the (a) absence and (b) presence of CT-DNA fMJ= 1 0 
xlO-^M, [DNA] =1.0x10-" M. 
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The redox properties of complex [C6H24N406CuSn2Cl4]Cl2 were explored by cyclic 
voltammetry in MeOH/H20 95:5 at 0.2 Vsec' in presence and in the absence of CT-
DNA over a potential range of 0.5-(-0.6 V). The complex [C6H24N406CuSn2Cl4]Ci2 
contains a bimetallic core of copper(II) and tin(IV) ions. While the copper(Il) ions 
are redox active, tin(IV) metal ions are inaccessible to the surface of the electrode. In 
the absence of DNA, complex [C6H24N406CuSn2Cl4]Cl2 displays a one electron 
quasi-reversible electrochemical wave for Cu(II)/Cu(I) couple at a cathodic peak 
potential Epc= -0.429 V and the corresponding anodic wave Epa = -0.359 V. The 
formal electrode potential E1/2 taken as an average of Epa and Epc was found to be 
-0.388V. On addition of CT-DNA to the complex [C6H24N406CuSn2Cl4]Cl2. 
significant reduction in the cathodic (Epc= -0.410 V) and anodic (Epa= -0.348 V) 
peak currents were observed due to slow diffusion of an equilibrium mixture of the 
free and DNA bound complexes to the electrode surface [187]. 
In addition, the E1/2 potential shifts to a slightly more negative value £1/2= -0.394 V 
upon addition of CT-DNA to the complex suggesting that the complex binds 
strongly by electrostatic association to CT-DNA [188] which corroborates well with 
the results of absorption titration studies with CT-DNA. To elucidate the binding 
mechanism involving the copper(II) or copper(I) forms of complex to DNA, the net 
shift in E//2 can be used to estimate the ratio of equilibrium constants by the 
following equation (Scheme 4). 
EV-E°f = 0.059 log (/:/+//:2+) 
The ratio of binding constants of+1 and +2 species was (1.01) suggesting that both 
Cu(II) and Cu(I) forms interact with CT-DNA to the same extent. 
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CuLi+e — CuL2 E°f' 
CuLi^+DNA+e:^ liCuLi^+DNA E%' 
Scheme 4. Cyclic voltammetric behaviour of heterobimetallic copper(JI)-tin(IVj 
complex [C6H24N406CuSn2Cl4]Cl2 bound to CT-DNA. 
Viscosity studies 
The interaction of the metal complexes [C6H24N406CuSn2Cl4]Cl2 and 
[C6H24N406ZnSn2Cl4]Cl2 with CT-DNA was further explored by the relative 
specific viscosity of DNA after the addition of varying concentration of complexes 
[C6H24N406CuSn2Cl4]Cl2 and [C6H24N406ZnSn2Cl4]Cl2 (Figure 40). In the absence 
of crystallographic structural data, viscosity measurements are regarded as most 
critical test of a DNA binding model in solution [58]. 
Figure 40. Effect of increasing amount of complex (a) [C6H24N406CuSn2Cl4]Cl2 (•) 
and (b)[C6H24N406ZnSn2Cl4jCl2 (m) on the relative viscosities (t]/i]oJ of CT-DNA in 
tris-HCl buffer (pH 7.2). 
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A classical intercalation tends to increase the length of the DNA helix, due to the 
accommodation of the ligand in between the base pairs of CT-DNA resulting in an 
increase in the CT-DNA viscosity [189]. Partial or non-classical intercalation 
reduces the effective CT-DNA length as they produce kinks in the DNA helix, which 
results a decrease in viscosity [190]. Figure 40 shows the relative changes in the 
viscosity upon addition of complexes [C6H24N406CuSn2Cl4]Cl2 and 
[C6H24N406ZnSn2Cl4]Cl2. The relative specific viscosity decreases suggesting that 
the complexes could bend and kink the DNA helix, reducing its effective length and 
consequently its viscosity. The decrease for complex [C6H24N406ZnSn2Cl4]Cl2 is 
much greater than the complex [C6H24N406CuSn2Cl4]Cl2 which imply that complex 
[C6H24N406ZnSn2Cl4]Cl2 binds to CT- DNA strongly by simple electrostatic 
binding. 
DNA cleavage activity 
The DNA cleavage activity of the complex [C6H24N406CuSn2CL4]Cl2 and 
[C6H24N406ZnSn2Cl4]Cl2 was assessed by agarose gel electrophoresis with 
supercoiled (SC) pBR322 DNA as substrate. A concentration dependant DNA 
cleavage was observed as shown in Figure 41(a,b). The activity of complexes 
[C6H24N406CuSn2Cl4]Cl2 and [C6H24N406ZnSn2Cl4]Cl2 was assessed by the 
conversion of DNA from Form I to Form II and Form III. When pBR322 plasmid 
DNA undergoes electrophoresis, there is fast migration to the supercoiled (Form I). 
If one strand is cleaved, the supercoiled form will relax to produce slower-moving 
nicked circular (Form II). If both strands are cleaved, a linear form (Form III) will be 
75 
generated which migrates in between [191]. With increase in concentration of the 
complexes more intense Form II was observed (shown in Lane 2-6, Figure 41) with 
the simultaneous reduction of Form I, whereas no conversion to Form III was 
observed. The reduction in the intensity of Fom^ I and appearance of more intense 
Form II of pBR322 DNA on the gel shows that both the complexes 
[C6H24N406CuSn2Cl4]Cl2 and [C6H24N406ZnSn2Cl4]Cl2 are involved in an efficient 
double strand DNA cleavage pathway. 
Figure 41. Agarose gel electrophoresis patterns for the cleavage of pBR322 plasmid 
DNA as a function of increasing concentration of (a) complex 
[C6H24N406CuSn2Cl4]Cl2; Lane 1: DNA control, Lane 2: DNA + SOfiM of 
[C6H24N406CuSn2Cl4]Cl2, Lane 3: DNA + JOOfjM of [C6H24N406CuSn2Cl4ja2, 
Lane 4: DNA + 150^M of [C6H24N406CuSn2Cl4]Cl2, Lane 5: DNA + 200juM of 
[C6H24N406CuSn2Cl4jCl2 Lane 6: DNA + 250/JM of [C6H24N406CuSn2Cl4]Cl2. (h) 
complex [C6H24N406ZnSn2Cl4jCl2; Lane 1: DNA control, Lane 2: DNA + 50juM of 
[C6H24N406ZnSn2Cl4]Ch Lane 3: DNA + lOO^M of [C6H24N406ZnSn2Cl4]Cl2 Lane 
4: DNA + 150nM of [C6H24N406ZnSn2Cl4]Cl2, Lane 5: DNA + 200fiM of 
[C6H24N40eZnSn2Cl4jCl2, Lane 6: DNA+250^MoffC6H24N4O6CuSn2Cl4jCl2. 
The nuclease activity of complex [C6H24N406ZnSn2Cl4]Cl2 markedly depends on 
different activators [192,193]. Thus, activators such as ascorbate (Asc), 3-
mercaptopropionic acid (MPA), and glutathione (GSH) (Lanes 2-4, Figure 42) were 
also used to investigate the DNA cleavage activity of complex 
[C6H24N406ZnSn2Cl4]Cl2 at a concentration of IOOJAM. The activity followed the 
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order MPA > Asc > GSH, therefore, it appears that nuclease activity is significantly 
enhanced in presence of MPA. 
Minor groove binding agent DAPI [194], and major groove binding agent methyl 
green [195] (Lane 5 and 6, Figure 42) were used to examine the potential interacting 
site of complex [C6H24N406ZnSn2Cl4]Cl2 with supercoiled plasmid DNA. The 
cleavage patterns, demonstrated that in presence of both DAPI and methyl green 
DNA cleavage activity is not affected significantly, suggesting that neither major nor 
minor groove are involved in the complex-DNA interactions. 
Figure 42. Gel electrophoresis of pBR322 by complex [C6H24N406ZnSn2Cl4]Cl2 
(100 nM) in the presence of different activators Lane 1: DNA contol, Lane 2: DNA + 
complex [C6H24N40eZnSn2Cl4]Cl2 (100 fiMj + Ascorbic acid, Lane 3: DNA + 
complex [C6H24N406ZnSn2Cl4]Cl2 (100 nM) + GSH, Lane 4: DNA + complex 
[C6H24N406ZnSn2Cl4]Cl2 (lOO^M) + MPA, Lane 5: DNA + complex 
[C6H24N406ZnSn2Cl4]Cl2 (100 fiM) + DAPI, Lane 6: DNA+ complex 
[C6H24N406ZnSn2Cl4]Cl2 (100 ^iM) + methyl green. 
In these circumstances, complexes may interact directly with the exterior phosphate 
of DNA through electrostatic attraction. Such interactions would enhance the local 
concentrations of complexes around DNA [91] and consequently enhance DNA 
cleavage activity. The pattern of cleavage is in accord with the proposed electrostatic 
binding mode of complexes [C6H24N406CuSn2Cl4]Cl2 and [C6H24N406ZnSn2Cl4]Cl2 
to CT-DNA. 
Conclusions 
In this work, we have described the synthesis and characterization of 
heterobimetallic complexes [C6H2oN402Cu]Cl2, [C6H2oN402Zn]Cl2 
[C6H24N406CuSn2Cl4]Cl2 and [C6H24N406ZnSn2Cl4]Cl2 which can be explored as 
potential cancer chemotherapeutic agents. In vitro DNA binding studies of these 
complexes [C6H2oN402Cu]Cl2, [C6H2oN402Zn]Cl2, [C6H24N406CuSn2Cl4]Cl; and 
[C6H24N406ZnSn2Cl4]Cl2 were carried out by using various biophysical and 
spectroscopic techniques. These complexes are unique as they possess two different 
metal ions (transition and non-transition, copper(II)/zinc(II) and tin(IV) respectively) 
which act synergistically at molecular level but with a different binding mode. The 
interaction studies revealed that the complexes bind to the phosphate sugar backbone 
of the DNA double helix via, electrostatic interaction, in addition to the coordinate 
covalent binding favored by the transition metal ions to N7 or N3 site of the 
nucleobases which was elucidated by the absorption titration of the complexes with 
nucleotides 5'-GMP and 5'-TMP. The results revealed that the complex 
[C6H24N406ZnSn2Cl4]Cl2 exhibits highest propensity for DNA which is attributed to 
the presence of the hydrolytically active zinc metal ion together with tin(lV) metal 
ion as compared to complex [C6H24N406CuSn2Cl4]Cl2. Both the complexes 
[C6H24N406CuSn2Cl4]Cl2 and [C6H24N406ZnSn2Cl4]Cl2 exhibited an effective DNA 
cleavage activity at physiologically relevant conditions. 
CHAPTER IV 
In vitro DNA binding studies of chiral [4-(2-hydroxy-l-
phenylethylimino)pent-2-ol]diniethyltin(IV) and 2-
(chlorodimethylstannyloxy)-l-phenylethanamine: 
Antitumor activity of their S-enantiomer against human 
tumor cell lines. 
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Synthesis of Ligand 
Synthesis of (S) and (R)-[C,3Hi7N02] 
The Schiff base ligand was prepared by adopting the reported procedure [ 196]. To a 
methanolic solution (20 mL) of acetylacetone (1.03 ml) was added a stirred solution 
of (S)-2-amino-2-phenylethanol (1.37g, lOmmol) in 1:1 molar ratio. The reaction 
mixture was refluxed for 4-8 h with continuous stirring during which the color ot the 
solution tuned to yellow-orange. The completion of the reaction was monitored b\ 
TLC. After the completion of the reaction, it was cooled on an ice bath affording a 
solid product. The ligand thus, obtained was washed with hexane and dried in vacuo 
(Scheme 5). 
The corresponding Schiff base ligand (R)-[Ci3Hi7N02] was synthesized according to 
the above procedure described for (S)-[Ci3Hi7N02] by using (R)-2-amino-2-
phenylethanol. 
(S-enantiomer): Yield 65%, m.p.= 110 ± 2 °C Anal. (%) Calc. for [CnHnNO:]: C. 
71.21; H, 7.81; N, 6.39: Found: C, 71.24; H, 7.80; N, 6.38. [af^o = +37. ESI-MS 
(m/z) 220 [C,3H,7N02+H]. 
(R-enantiomer): Yield 60%. m.p. 115 ± 2 "C. Anal. (%) Calc. for [C13H17NO2I: C. 
71.21; H, 7.81; N, 6.39: Found: C, 71.22; H, 7.79; N, 6.38. [af^o = -39. ESl-MS 
(m/z)219[Ci3Hi7N02f. 
Both enantiomers exhibited identical IR, UV-vis spectra 
Selected IR data in KBr (v/cm"'): 3204-3028 (OH); 2837 (CH2); 1551 (C-N); 797 
(Ar). UV-vis in Methanol [J^^ax/nm]: 228, 266, 315. 
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(S)-[C,3H,7N02], ' H N M R (DMS0-d6, ppm): 2.3 (-0H, Aliphatic); 3.6 (-CH:): 3.7 
(Chiral CH); 1.9 (N=C-CH3); 3.9 (-CH2); 4.9 (=CH); 7.1-7.3 (Aromatic-H). ' \ : 
NMR (DMS0-d6, ppm): 193.6 (C=N); 19.0 (-C^C-CHj); 28.8 (-C=N-C H3); 95.5 
(=C-), 162.7 (0-C=); 126.0-128.0 (Ar-C); 68.0 (-CH2OH); 65.7 (Chiral C). 
(R)-lC,3Hj7N02], ' H NMR (DMSO-de, ppm): 2.5 (-0H, Aliphatic); 3.5 (-CH:): 3.7 
(Chiral CH); 1.5 (N=C-CH3); 4.0 (-CH2); 4.5 (=CH); 7.3-7.7 (Aromatic-H). "C 
NMR (DMSO-d6, ppm): 196.6 (C=N); 17.0-19.0 (-C=C-CH3); 24.8 (-C=N-CH3): 
97.4 (=C-), 163.7 (0-C=); 128.0-133.0 (Ar-C); 69.5 (-CH2OH); 64.9 (Chiral C). 
Synthesis of Complexes 
Synthesis of (S) and (R)-[Ci5H2iN02Sn] 
To a methanolic solution (20 ml) of the Schiff base ligand (S)-[Ci3Hi7N02] (1.07g. 
4.90mmol), two drops of triethylamine was added and the resulting yellow solution 
was allowed to stir for 3-4 h. To this solution, 20 ml methanolic solution of 
dimethyltin(IV)dichloride (1.07g, 4.90mmol) was added dropwise in equivalent 
molar ratio. The final product obtained was washed with n-hexane and dried in 
vacuo. 
The corresponding (R)-[Ci5H2iN02Sn] complex was synthesized in accordance with 
the procedure described for (S)-[Ci5H2iN02Sn] by using ligand (R)- [Ci^HnNO^J 
(Scheme 6). 
(S-enantiomer): Yield 57%. m.p. 138 ± 2 "C. Anal. (%) Calc. for [Ci5H2iN()2Sn]: C. 
49.22; H, 5.78; N, 3.83. Found: C, 49.23; H, 5.75; N, 3.80. [af^o = +12. ESI-MS 
(m/z): 367 [dsHaiNOjSn+Hf. "^Sn NMR (DMSO-de, ppm): -179. 
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(R-enantiomer): Yield 55%. m.p. 139 ± 2 "C. Anal. (%) Calc. for [CsHjiNOsSn]: C. 
49.22; H, 5.78; N, 3.83. Found: C, 49.24; H, 5.75; N, 3.82. [afu = -M. ESI-MS 
(m/z): 368 [CisH2iN02Sn+2H]^ "^Sn NMR (DMSO-d6, ppm): -200. 
Both enantiomeric metal complexes exhibited identical molar conductance, IR, UV-
vis spectra. 
Molar conductance, AM (1.0X10'^ M , Methanol): 29 fi'cm^ moP' (non-electroh'te). 
Selected IR data (v/cm"'): 2568 (-CH2); 1525 (-C=N); 771 (Ar); 569 (Sn-O); 424 
(Sn-N); 549 (Sn-C). UV-vis in Methanol [)wnax/nm]: 211, 258, 299. 
(S)-[C,5H2iN02Sn], ' H NMR (DMSO-dg, ppm): 0.6-1.0 (Sn-CHs); 3.6 (-CH2); 3.7 
(Chiral CH); 1.8 (N=C-CH3); 4.9 (=CH); 7.3-7.1 (Aromatic-H). '^C NMR (DMSO-
d6, ppm): 193.5 (C=N); 19.0 (C=C-CH3); 28.8 (C=N-CH3); 95.5 (=C-), 162.7 (-0-
C=); 126.0-128.0 (Ar-C); 65.6 (-CH2OH); 63.3 (Chiral C); 10.0-14.0 (Sn-CHs). 
(R)-[C,5H2iN02Sn], ' H NMR (DMSO-de, ppm): 0.9-1.0 (Sn-CHj); 3.2 (-CH2); 3.8 
(Chiral CH); 1.3 (N=C-CH3); 4.9 (=CH); 7.3-7.4 (Aromatic-H). '^C NMR (DMSO-
de, ppm): 196.2 (C=N); 20.0 (C=C-CH3); 25.8 (C=N-CH3); 97.3 (=C-), 162.7 (-0-
C=); 126.0-127.9 (Ar-C); 67.6 (-CH2OH); 63.2 (Chiral C); 11.2-13.0 (Sn-CH3). 
Synthesis of (S) and (R)-[CioHi6NOSnCl] 
To a stirring solution of (S)-2 -amino-2-phenylethanol (1.37g, lO.OOmmol) in 
methanol, the solution of dimethyltin(IV)dichloride (2.19g, lO.OOmmol) was added 
in 1:1 molar ratio. After 3-4 h a white amorphous compound was isolated, which 
was washed with n-hexane and dried in vacuo (Scheme 7) 
The corresponding (R)-[CioHi6NOSnCl] complex was also synthesized according to 
the above procedure by using (R)-2-amino-2-phenylethanol. 
(S-enantiomer): Yield 72%. m.p. 240 ± 2 T. Anal. (%) Calc. for [C,oH,6NOSnCl]: 
C, 37.49; H, 5.03; N, 4.37. Found: C, 37.47; H, 5.01; N, 4.39. [af^D = +23. ESI-MS 
(m/z): 336 [C,oH,6NOSn+0.5CH30Hr. "^Sn NMR (DMSO-dg, ppm): -161. 
(R-enantiomer): Yield 78%. m.p. 231 ± 2 °C. Anal. (%) Calc. for [C,oHi6NOSnCl]; 
C, 37.49; H, 5.03; N, 4.37. Found: C, 37.46; H, 5.02; N, 4.35. [af^u = -20. ESI-MS 
(m/z): 336 [CoHisNOSnCl+O.SCHsOH], "''Sn NMR (DMSO-de, ppm): -166. 
Both enantiomeric metal complexes exhibited identical molar conductance, IR, UV-
vis spectra. 
Molar Conductance, AM (1.0x10"' M, Methanol): 87 n'cm^mol' (non-electrolyte). 
Selected IR data (v/cm"'): 3007 (NH2); 2362 (CH2); 704 (Ar); 575 (Sn-C); 549 
(Sn-0); 466 (Sn-N); 279 (Sn-CI). UV-vis in Methanol [^ max/nm]: 222, 252. 
(S)-[CioH,6NOSnCl], 'H NMR of (DMSO-d6, ppm): 0.6-1.1 (Sn-CHj); 3.6 (-CH.); 
4.1 (Chiral CH); 7.3-7.4 (Aromatic-H). '^ C NMR (DMSO-dg, ppm): 127.0-132.0 
(Ar-C); 66.0 (-CH2OH); 64.1 (Chiral C); 10.0-14.0 (Sn-CHj). 
(R)-tCioHi6NOSnCi], 'H NMR of (DMSO-de, ppm): 0.8-1.2 (Sn-CHj); 3.8 (-CH2); 
4.2 (Chiral CH); 7.3-7.7 (Aromatic-H). " c NMR (DMSO-ds, ppm): 128.0-135.0 
(Ar-C); 68.0 (-CH2OH); 65.0 (Chiral C); 10.0-13.2 (Sn-CHj). 
Results and Discussion 
Synthesis and characterization 
The in situ condensation reaction of chiral 2-amino-2-phenylethanol and acetyl 
acetone in 1:1 molar ratio resulted in a light yellow Schiff base ligands 
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Scheme 5. Synthesis ofchiral ligands (S)/(R)-[Ci3H,7N02]. 
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Scheme 6. Synthesis of dimethyhin(IV) complexes derived from ligands (S)/(R)-
CsHnNO^. ^ ^ 
+ R j S n C b st i r r ing 
3-4 h HjN, \ , 0 
HiN 
^ „ „ R = C H j . , 
OH Sn 
H3C I CH3 
l-amino-l-phenylethanol dimethyltin(IV)dichloride Complex (S)/(R)-[C,eH,«NOSnCI| 
Scheme 7. Synthesis ofdimethyltin(IV) complexes of(S)/(R)-C,oHi6NOSnCl. 
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Figure 43. Cylindrical bonded three dimensional model of complexes (a) (S)/(R)-
C,sH2,N02Sn and (b) (S)/(R)-C,oH,6NOSnCl Color scheme: Tin(IV) light green; 
Chloride, fluorescent green; N dark blue; O red; C gray. The H atoms and are 
omitted for clarity. 
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(S)-[Ci3Hi7N02] and (R)-[Ci3Hi7N02] respectively, by the slight modification of 
above mentioned procedure (Scheme 5). The ligands on complexation with 
dimethyltin(rV)dichloride behave as a dibasic tridentate O N O donor iigand 
corresponding to end tautomer of acetyl acetone [197]. Since the Iigand exist in enol 
tautomeric form, an electron shift from the -OH group enhances the negative charge 
on the azomethine nitrogen atom so the transamination reaction of the carbonyl 
group is prohibited which would prevent the formation of the ligands in 1:2 
stoichiometric ratio. The complexes (S)-[CioHi6NOSnCl] and (R)-[CioHi6NOSnCll 
were prepared by mixing equimolar ratio of both enantiomeric form of 2-amino-2-
phenylethanol with dimethyltin dichloride, (Scheme 7). These complexes were 
characterized by spectral studies using IR, 'H NMR, '^C NMR, "'^ Sn NMR. ESI-MS 
and elemental analysis. 
IR spectral studies 
The formation of the complexes (S)-[Ci5H2iN02Sn], (R)-[Ci5H2iN02Sn], (S)-
[CioHieNOSnCl] and (R)-[CioHi6NOSnCl] has been ascertained by the comparison 
of the IR spectra of the ligands with complexes. The spectra of the Iigand (S)/(R)-
[C13H17NO2] revealed a broad envelope at 3028-3204 cm' region assigned to 
intramolecular hydrogen bonded -OH group which was found absent in complexes 
(S)/(R)-[Ci5H2iN02Sn] indicating the deprotonation of the hydroxyl group upon 
coordination to the metal ions. The bands corresponding to azomethine group 
u(-C=N) at 1551-1568 cm"', in the spectra of the free Iigand (S)- and (R)-
[C13H17NO2] respectively [198] has been considerably shifted to lower frequencies 
-1518 cm' and 1525 cm' in the complexes (S)/(R)-[Ci5H2iN02Sn] indicating the 
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involvement of azomethine nitrogen in the coordination with tin(IV) metal ion which 
is further supported by the appearance of new bands in their spectra at 424-432 cm ' 
assigned to \)(Sn-N) stretching vibrations [60]. The absence of ketonic group 
vibrations u(C=0) at 1700 cm"' in the IR spectra of ligands reveal that the ligands 
exist predominantly in enolic form rather than ketonic form. Further evidence for the 
complexation is provided by the appearance of bands at 549-557 cm"' and 565-593 
cm"' for u(Sn-O) and u(Sn-C) stretching frequencies for (S)/(R)-[Ci5H:iN02Sn]. 
respectively [199,200]. 
On the other hand, ligand 2-amino-2-phenylethanoI reveals a band at 3335-3276 
cm"' region assigned to ^(OH) and 1)0^ 112) stretching vibrations. A considerable 
lowering observed in the NH2 frequency at 3007-3002 cm" together with a 
subsequent disappearance of -OH frequency is indicative of the coordination 
through -NH2 and -OH groups for the formation of (S)/(R)-[CioHi6NOSnCl]. The 
coordination of dimethyltin(IV)dichloride with the ligand to yield (S)/(R)-
[CioHieNOSnCl] was revealed by the presence of medium intensity bands u(Sn-C). 
u(Sn-N), \)(Sn-0) and u(Sn-Cl) bands 569-575 cm"', 461-466 cm"' and 549-550 cm"' 
and 279-295 cm"', respectively in the IR region [60, 201,202] 
Electronic spectra 
The ligands (S)/(R)-[CnHi7N02] display broad bands around 312-315 nm range 
attributed to n^ ^Tt* transition of the azomethine group and band appearing at 228-
230 nm with a shoulder at 266-269 nm assigned to intraligand n-^n* transition 
[203]. In the spectra of the complexes (S)/(R)-[C,5H2iN02Sn], the bands of the 
azomethine chromophore were shifted to lower frequencies (299 nm) indicating the 
coordination of imine nitrogen atom to the tin(lV) metal ion. Other bands associated 
with complexes (S)/(R)-[Ci5H2iN02Sn] at 258 and 211 nm were attributed to 
intraligand transitions. 
The complexes (S)/(R)-[CioH,6NOSnCl] reveal a band in 210-258 nm region 
attributed to IL transitions. 
NMR spectra 
The ligands (S)/(R)-[Ci3Hi7N02] and complexes (S)/(R)-[C|5H2iN02Sn] show 
approximately same peaks except that in the 'H NMR spectra of the complex 
additional signals due to methyl protons attached to the tin metal ion were observed 
at 0.6-0.9 ppm, respectively [204]. The other characteristic signatures for (S)-
[CioHieNOSnCl] corresponding to ArH, CH-N and CH2-OH protons appear at 7.3-
7.4, 4.7-3.7, 3.1-3.6 ppm, respectively, as compared to ligand [205]. 
The position of the azomethine carbon at 193.6-196.6 ppm of the ligands (S)/(R)-
[C13H17NO2] [205], respectively, is slightly shifted downfield in complexes (S)/(R)-
[Ci5H2iN02Sn] indicating the coordination of azomethine nitrogen with the tin metal 
ion. Additional resonances observed in the C NMR spectra of the complexes (S)-
[Ci5H2iN02Sn] at 126-128, 162, 95, 28, 19 ppm were attributed to ArC, 0-C=, -C=. 
CH3-C=0, CH3-C=N carbons, respectively [206]. The '^ C NMR spectra of complex 
(S)-[CioHi6NOSnCl] reveals various other resonances attributed to -CH2-O, CH-N, 
ArC and CH3-Sn carbons at 66, 38-40, 128 and 10-14 ppm, respectivel>, of the 
coordinated 2-amino-2-phenylethanol [207]. 
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The "^Sn NMR spectra displays peaks in the range of-179 ppm for complex (S)-
[Ci5H2iN02Sn] and in range -161 ppm for complex (S)-[CioH|6NOSnCl], 
respectively (Figure 44a,b). 
(a) (b) 
Figure 44. "^Sn NMR spectra of complexes (a) (S)-C,sH2iN02Sn and (b) (S)-
CioHioNOSnCl. 
These chemical shift values obtained are typical of a five coordinated environment 
around tin metal ion [208]. 
DNA binding studies 
UV-visible absorption studies 
The comparative DNA binding ability of chiral ligands (S)/(R)-[Ci3Hi7N02], 
complexes (S)/(R)-[Ci5H2iN02Sn], (S)/(R)-[CioH,6NOSnCl] and cisplatin drug were 
evaluated using metal complex-DNA interactions. Figure 45(a-f) illustrates the 
respective absorption spectral changes of the (S)-[Ci3Hi7N02] and its complexes in 
absence and the presence of CT-DNA. Upon addition of incremental amount of CT-
DNA (0-0.40x10'* M) to a fixed concentration of complex/ligand (0.06x10* M) an 
increase in the absorbance of the intraligand bands was observed. This increase in 
the absorbance is attributed to the "hyperchromic effect". Cations can cause the 
hypochromism of DNA by predominant binding to the phosphate group of CT-DNA 
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backbone and make contraction in the helix axis of CT-DNA while destruction or 
complete structural damage of the DNA double helix is caused b) the 
hyperchromism [209,174]. In the complexes (S)/(R)-[Ci5H2iN02Sn] and (S)/(R)-
[CioHieNOSnCl] and ligands (S)/(R)-[Ci3H,7N02], hyperchromism was followed by 
concomitant red shift of 2-4 nm which arises due to the preferential binding of the 
predissociated tin(IV) to nucleotides via; phosphate group of DNA. This preferential 
binding of tin(IV) arises as the tin(IV) cations in the complexes, in an unsaturated 
geometry (TBP), exhibit tendency to expand their coordination number by the 
addition of solvent molecules or further by the coordination to the nucleotides, the 
geometry changes to octahedral [210]. Moreover, the affinity of tin(IV) with 
dinegative phosphate group is very strong because of its hard Lewis acidic property 
which is also evidenced by the intrinsic binding constant Kb values. 
Ligands (S)/(R)-[Ci3Hi7N02] also differ significantly in their DNA binding ability 
which is attributed to the enantiomeric selectivity of CT-DNA. The Kb \ alues of 
ligand (S)-[Ci3Hi7N02] (S-enantiomer) reveal multifold higher preferential binding 
to the DNA in comparison to (R)-[Ci3Hi7N02] (R-enantiomer). The complexes (S)-
[Ci5H2iN02Sn] and (S)-[CiiHi9NOSnCI] show greater propensity for DNA as 
compared to free ligands due to the presence of tin(IV) metal center which is 
attributed to its strong tendency for phosphate binding as observed from Table 6. 
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Table 6. The binding constant (Kb) values of ligand (S)/(R)-ICuHnSOjJ and 
complexes (Sj/iRHCisHiiNOjSn] and (S)/(R)-[C,oH,6NOSnCl] with CT-DNA (mean 
standard deviation ± 0.15) 
Complex 
(S)-[C,3H,7N02] 
(R)-[C,3H,7N02] 
(S)-[C,5H2iN02Sn] 
(R)-[C,5H2,N02Sn] 
(S)-[C,oH,6NOSnCl] 
(R)-[C,oH|6NOSnCl] 
Cisplatin 
Kb(M-') 
1.27x10^ 
1.10x10^ 
4.20x10^ 
1.42x10^ 
3.96x10^ 
1.27x10'* 
3.20x10'* 
Monitored at 
(nm) 
220 
220 
226 
226 
224 
224 
248 
% Hyperchromism 
25 
17 
42 
35 
46 
21 
17 
Red Shift 
(nm) 
02 
02 
04 
03 
04 
02 
02 
Furthermore, it has also been observed that, S-enantiomer of both [Ci5H2iN02Sn] 
and [CioHieNOSnCl] complexes exhibits pronounced propensity for DNA binding in 
comparison to R-enantiomer. As DNA itself is a chiral molecule, the fact that optical 
isomers of the complexes differ in their biological effects is a priori not surprising. 
DNA-complex interactions are usually dependent on chirality and conformation of 
the isomers involving two pole complimentary recognition hypotheses to right 
handed domain of B-form of DNA. Complexes (S)/(R)-[Ci5H2iN02Sn] and (S)/(R)-
[CioHieNOSnCl] show structural dissimilarity due to the presence of Schiff base 
ligand in (S)/(R)-[Ci5H2iN02Sn] which actually mutes the toxicity as well as tunes 
the metal to enforce stereoselective binding to the DNA leading to a spectacular 
propensity for DNA binding for the complex (S)-[Ci5H2iN02Sn]. These Kb values 
were compared to the cisplatin which revealed that the Kb value of cisplatin 
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(3.20x10'* ±0.15 M"') was slightly lower in comparison to Kb values of the 
complexes (S)-[Ci5H2iN02Sn] and (S)-[C,oHi6NOSnCl]. 
(a) 
•J 9Ji UA 
WavrlraElk inn.) W"aveleDgfh(Boi) 
Cisplatin (Figure 45a) and classical metal based cisplatin drug show covalent 
binding with DNA via; 1,2-intrastrand crosslinks between adjacent N7 atoms of 
guanine nucleobase (GpG) and adenine (ApG) and secondary interaction with 
phosphate backbone [211]. 
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Figure 43. Absorption spectra of (a) cisplatin (b) (S)-C/jHj7N02 (c) fSj-
C,sH2iN02Sn (d) (R)-CisH2,N02Sn (e) (S)-CioH,6NOSnCl (f) (R)-C/oH,6A'OSnCl in 
Tris-HCl buffer (pH= 7.2) in the absence and presence of increasing amount ofCT-
DNA. Inset: Plots of [DNAJ/fsa-ej) vs [DNA] for the titration of CT-DNA with 
complexes. Arrow indicate the increase in the intensity upon increasing DNA 
concentration. [Complex] ^1.0x1 a" M, [DNA]=1.0x10'" M 
On the contrary, organotin prefer phosphate binding to the oxygen atom of sugar 
phosphate backbone and the nitrogen involved in the CT-DNA base binding is 
extremely effective, often resulting in the stabilization of the tin(lV) center as a 
stable octahedral species [212]. Therefore, the above resuhs indicate that all the 
studied complexes bind predominantly to the phosphate group, neutralizing the 
negative charge of the CT-DNA and causing contraction and conibrmational 
changes in the DNA by an electrostatic interaction. 
Interaction with 5'-GMP by absorption spectroscopy 
In order to elucidate the mechanism of binding phenomenon with CT-DNA at the 
molecular level, interaction of the complexes with nucleotides is notabl> important. 
We have undertaken the UV-visible absorption titrations of complex (S)-
[CisHsiNOjSn] and (S)-[C,oHi6NOSnCl] with 5'-GMP owing to the fact that (S) 
enantiomer of complexes (S)-[Ci5H2iN02Sn] and (S)-[C,oHi6NOSnCl] exhibited 
greater Kb value in comparison to other complexes studied (Figure 46a,b). 
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Figure 46. Absorption spectra of (a) (S)-[CisH2iN02SnJ in Tris-HCl buffer (pH= 
7.2) in the absence and presence of increasing amount of 5'-GMP. Inset: Plots of 
[5'-GMPJ/(£a-£j) vs [5'-GMP] for the titration of 5'-GMP with complexes. Arrow 
indicate the increase in the intensity upon increasing DNA concentration. 
On addition of increasing amount of 5'-GMP to the (S)-[Ci5H2iN02Sn] and (S)-
[CioHieNOSnCl], a sharp increase in the absorption intensity "hyperchromism" with 
slight shift of 2-3 nm was observed in the spectra of both the complexes indicative of 
electrostatic binding involving damage to the secondary structure of (T-DNA 
through phosphate backbone interaction. However, the higher intrinsic Kb value of 
for the complex (S)-[Ci5H2iN02Sn] accounts for its higher binding with CT-DNA in 
comparison to the other complex (S)-[CioHi6NOSnCl] (Table 7). 
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Table 7. The comparative binding constant (Kb) values of complexes (Sj-
[Ci5H2iN02Sn] and (Sj-fCjoHj^NOSnCl] with the 5'-GMP (mean standard deviation 
of± 0.025). 
Complex 5'-GMP Monitored at % Hyperchromism Red Shift 
(xlO'*) (nm) (nm) 
(S)-[Ci5H2iN02Sn] 1.40 247 36 02 
(S)-[C,oH,6NOSnCl] 1.02 246 38 03 
' H and '^P NMR interaction with 5'-GMP 
The more conclusive evidence for the interaction of (S)-[Ci5H2iN02Sn] with 5'-
GMP was fiirther obtained by 'H and ^'P NMR spectroscopy, being the most 
sensitive and reliable technique. The 'H NMR of 5'-GMP in D2O solvent records the 
proton resonance of guanine H8 at 8.1 ppm and ribose Hl'-HS' at 3.8-5.8 ppm. 
respectively [213]. The resonance of 2-NH2 was obscured due to the exchange of 
proton with deuterium solvent. On interaction of (S)-[Ci5H2iN02Sn] with 5'-GMP. 
G-H8 signal did not display significant shift (8.1 ppm in free 5'-GMP to 7.96 ppm in 
5'-GMP bound complex) which shows non-involvement of N7 position of guanine in 
coordination (Figure 47a,b). However, the resonances of ribose were perturbed to a 
substantial extent revealing their binding to the tin(IV) complex through O2 and O3' 
atoms of the sugar moiety of 5'-GMP. This type of binding behaviour is suggestive 
of electrostatic binding mode of the complexes while covalent coordination is ruled 
out as evidenced also by the UV-vis. titration of complexes with 5'-GMP and CT-
DNA itself. 
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Figure 47. HNMR spectra of (a) 5'-GMP alone and (b) the reaction of complex 
(S)-[C,6H24N02Sn] (2.5 mmol) with 5'-GMP (5 mmol) at 25 °C. 
31 P NMR spectrum of 5'-GMP records a signal at 3.73 ppm which undergoes a large 
upfield shift to 1.20 ppm (Figure 48). Such large upfield chemical shift in ^ 'P signal 
provides a strong evidence for the selective binding of complex to the phosphate 
oxygen of 5'-GMP and validates the electrostatic interaction [214]. 
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Figure 48. ^'P NMR spectra of (a) 5'-GMP and (b) the reaction of complex (Sj-
[C,5H2iN02Sn] (2.5 mmol) with 5'-GMP (5 mmol) at 25 "C. 
Fluorescence studies 
To further elucidate the mode of binding of optically active complexes (S)/(R)-
[C,5H2iN02Sn] and (S)/(R)-[CioH,6NOSnCl] with CT-DNA, fluorescence spectral 
methods were employed by following the changes in the emission intensity of the 
complexes. In absence of CT-DNA, complexes (S)/(R)-[Ci5H2iN02Sn] and (S)/(R)-
[CioHieNOSnCl] emit luminescence around 260-500 nm in Tris-HCl buffer pH 7.2 
when excited at 260 nm. Fixed volumes (l.OxlO"^ M) of the studied complexes were 
titrated, respectively with increasing concentration of DNA in the range from 
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(0-0.40x10"* M). As seen from the Figure 49(a,b), the intensity of emission increases 
appreciably in the presence of DNA. 
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Figure 49. Emission spectra of (a) (S)-[Ci5H2iN02SnJ (b) (S)-[CioH,6NOSnCl] in 
Tris-HCl buffer (pH 7.2) in the absence and presence of CT-DNA. Arrow indicate 
the change in the intensity upon increasing DNA concentration. 
The observed enhancement could be due to relatively non-polar environment of the 
bound metal complex in the presence of DNA, such that the complexes were less 
deeply inserted inside the hydrophobic pockets or grooves of CT-DNA [2I5J. 
Cationic complexes usually bind to DNA non-covalently as the cationic core of the 
complexes exerts a strong electrostatic attraction to the anionic phosphate backbone 
of DNA thus precluding substantial overlap with the base pairs leading to higher 
emission intensity indicative of electrostatic binding of the probe to the DNA, The 
binding constant K of the complexes follows the order: (S)-[Ci5H2iNO:>Sn] > (S)-
[C,oH,6NOSnCl] > (R)-[C,5H2,N02Sn] > (R)-[CioH,6NOSnCl] as given in Table 8. 
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Table 8. Emission properties of complexes (S)/(R)-[Ci5H2iN02Sn] and (Sj/{R)-
[CioHi^OSnCl] bound to CTDNA (mean standard deviation ±0.09). 
Complex 
(S)-[C,5H2,N02Sn] 
(R)-[C,5H2,N02Sn] 
(S)-[C,oH,6NOSnCl] 
(R)-[C,oH,6NOSnCl] 
Emission 
(nm) 
230 
230 
235 
235 
Excitation 
(nm) 
450 
450 
520 
520 
Monitored at 
(nm) 
315 
315 
430 
430 
K(M"') 
2.90x10' 
1.10x10' 
1.83x10' 
6.70x10' 
A variety of molecular interactions can result in quenching phenomena including 
excited state reactions, molecular rearrangement, energy transfer, ground state 
complex formation, and collisional quenching. Quenching normally refers to non-
radiative energy transfer from the excited species to the other molecules. 
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Figure 50. Emission quenching curves of (a) {S)-[CjsH2jN02SnJ (h) (Sj-
[CjoHjeNOSnClJ in absence of CT-DNA (m) and in the presence of CT-DNA (•). 
[Complex] = 1.0x10'^ M. 
The fluorescence quenching studies using K4[Fe(CN)6] as an anionic quencher were 
performed to further probe the binding characteristic of both chiral complexes 
(S)/(R)-[C,5H2,N02Sn] and (S)/(R)-[C,oH,6NOSnCl]. Figure 50(a,b) shows a typical 
Stem-Volmer plot of FQ/F versus [Fe(CN)6]'*" for the complexes (S)-[Ci5H2iN02Sn] 
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and (S)-[CioHi6NOSnCl]. In the absence of DNA, the positively charged complexes 
(S)-[Ci5H2iN02Sn] and (S)-[CioHi6NOSnCl] were efficiently quenched by 
[Fe(CN)6]''" ion resulting in linear Stem-Volmer plot with a slope of 10.71x10" and 
8.57x10'* M'', respectively. In presence of DNA, the slope was remarkably decreased 
to S.SOxlO'' and 6.42x10" M'', respectively. Similarly, the slope of linear Stem-
Volmer plot for the complexes (R)-[Ci5H2iN02Sn] and (R)-[CioHi6NOSnCl] were 
also quenched from 7.14x10'* and 4.85x10* M"' in the absence of DNA to 5.0x10* 
and 3.71x10'' M'' in presence of CT-DNA, respectively (Table 9). 
Table 9. Emission quenching of CT-DNA bound [Fe(CN)6p' by complexes (S)/(R)-
[Ci5H2iN02Sn] and (S)/(R)-[CioHi6NOSnCl] 
Complex Emission Excitation Monitored at Ksvi Ksv2 
(nm) (nm) (nm) (xIO") (xlO") 
(S)-[C,5H2,N02Sn] 
(R)-[C,5H2,N02Sn] 
(S)-[C,oH,6NOSnCl] 
(R)-[C,oH,6NOSnCl] 
462 
462 
460 
460 
260 
240 
260 
262 
432 
430 
440 
440 
10.71 
7.14 
8.57 
4.85 
3.50 
5.00 
6.42 
3.71 
A greater decrease in the Ksv value for complexes (S)-[Ci5H2iN02Sn] and (S)-
[CioHieNOSnCl] than (R)-[C,5H2iN02Sn] and (R)-[CioH,6NOSnCl] corresponds to 
a stronger binding of these complexes with DNA double helix [216]. Therefore, the 
above results are consistent with our UV-visible titration observations that both the 
S-enantiomeric forms of the complexes [C]5H2iN02Sn] and [CioHi6NOSnCl] bind to 
the DNA more avidly as compared to R-enantiomeric form. Such type of quenching 
behavior is regarded as non-competitive quenching pertaining to electrostatic 
binding of the complexes with DNA. 
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Effect of ionic strength 
In order to ascertain the probable binding mode between the molecule and DNA, 
fluorescence titrations were carried out under the conditions of increasing ionic 
strength (0-0.40x10'" M) through added amounts of NaCl. It was observed that the 
fluorescence intensity of the studied (S)- as well as (R)- enantiomer of complexes 
was appreciably quenched with increasing ionic strength. However, the (S)-
enantiomer of complexes shows a higher change in emission intensity upon 
increasing concentration of NaCl. A cation such as Na^ can bind to phosphate group 
of the DNA by electrostatic forces to form a cation atmosphere around DNA. This 
cationic atmosphere shields the DNA and inhibits the binding of the positively 
charged molecules to the DNA phosphate backbone. This invokes a competitive 
interaction for the phosphate anions and subsequent addition of the cations weakens 
the surface binding interactions and hydrogen bonding between DNA and molecule, 
(a) I (b) , 
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Figure 51. Effect of different concentration of NaCl on the fluorescence spectra of 
complex (a) (S)-[C,sH2,N02Sn] (b) (S)-[C,oH,6NOSnCl]. [Complex]=1.0 xlO' M. 
[DNA]=1.0x10''' M. Arrow indicate the gradual decrease of emission intensity as a 
function of NaCl concentration. 
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Therefore, the results implicate that the complexes (S)/(R)-[Ci5H2iN()2Sn] and 
(S)/(R)-[CioHi6NOSnC]] preferably bind to the DNA phosphate backbone by 
electrostatic interactions [184,185]. In addition, it could be seen from Figure 51(a,b). 
that the effect of salt concentration on the fluorescence intensity of (S)-
[Ci5H2iN02Sn]-DNA system was far greater than the other complex (S)-
[CioHieNOSnCl] so the complex (S)-[Ci5H2iN02Sn] has a greater propensity for 
DNA binding. 
Effect of phosphate group 
As a means of further exploring the selective binding site of complexes (S)/(R)-
[C,5H2iN02Sn] and (S)/(R)-[C,oH,6NOSnCl] with DNA, fluorescence titrations 
were performed in presence of increasing amount of K2HPO4 (Figure 50a,b). It was 
observed from the Figure 52(a,b) that fluorescence intensity of the complexes 
increases when K2HPO4 is added to the system. These results demonstrate a 
competitive binding behavior between the phosphate group of K2HPO4 and DNA for 
complexes studied. 
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Figure 52. Effect of increasing concentration of K2HPO4 on the fluorescence 
intensity of complex (a) (S)-[C,5H2iN02Sn] (b) (S)-[C,oH,6NOSnClj. 
[Complex]=1.0x10'^ M, DNA=1.0xJ0''' M. 
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Thus, the phosphate group of K2HPO4 weakens the interaction between the 
complexes and CT-DNA, this observation provides supportive evidence for 
electrostatic interaction of the complexes (S)/(R)-[Ci5H2iN02Sn] and (S)/(R)-
[CioHieNOSnCl] which bind selectively to the phosphate group of DNA double 
helix [217]. Furthermore, there is a strong evidence in literature for tin(lV)-
phosphate binding which was validated by binding studies of tin(lV) complexes with 
nucleotide employing 'H and ^'P NMR techniques as illustrated above [174]. It was 
observed that the complex (S)-[Ci5H2)N02Sn] binds with relatively higher affinity 
towards CT-DNA in contrast to (R)-[Ci5H2,N02Sn] and (S)/(R)-[C,oH,6NOSnCI] 
complexes due to the effect of phosphate group. 
Circular dichroic studies 
Circular dichroic spectral studies have been performed to diagnose the changes in 
DNA morphology during complex-DNA interactions. The CT-DNA exhibits two 
consecutive bands, a positive band at 275 nm due to base stacking and a negative 
band at 245 nm due to helicity in the UV region [218]. The changes in CD signals of 
DNA observed on interaction of both enantiomers (R)/(S)-[CisH2iN02Sn] and 
(S)/(R)-[CioHi6NOSnCl] complexes are depicted in Figure 53(a-d). On addition of 
complex (S)-[Ci5H2iN02Sn] to CT-DNA there is a pronounced red shift in both the 
positive and negative bands attributed to the helicity and base stacking of DNA and 
the absorbtion intensities show decrease in intensity in both the enantiomers to the 
extent there is inversion in the base stacking CD signal at 275 nm. 
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Figure 53. CD spectra ofCT-DNA in the absence (a) and presence (b) of complexes 
(1 nM) in plot, (a) DNA in the presence of (R)-[C,5H2iN02Sn] (b) DMA in the 
presence of (S)-[C,5H2iN02Sn] (c) DNA in the presence of (R)-[CioH,6NOSnCl] (d) 
DNA in the presence of(S)-[C,oH,6NOSnClJ. 
However, in case of (S)- enantiomeric form there is more predominant perturbations 
in comparison to (R)-enantiomeric form indicative of preferential enantiomeric 
binding of the complexes. These observations have been ascribed to conformational 
changes [219] induced by B—vA transition of DNA. Furthermore, both the 
enantiomers of (R)/(S)-[CioHi6NOSnCI] reveal identical CD changes of equal 
magnitude but opposite signs resulting from structural perturbations. (S)-
enantiomeric form of complex [Ci5H2iN02Sn] displays a greater affinity than both 
the enantiomers (R)/(S)- of complex [CloHieNOSnCI]. 
Viscosity studies 
To clarify further the mode of interaction between the complexes (S)/(R)-
[CisHsiNOsSn] and (S)/(R)-[CioHi6NOSnCl] and DNA, viscosity measurements 
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were performed and the results were presented as ir\/r]o) versus binding ratio, where 
r\ is the viscosity of DNA in the presence of complex and tio is the viscosity of DNA 
alone. 
1/R 
Figure 52. Effect of increasing amount of (a) (R)-fC,oHt6NOSnClJ(red) (b) (R)-
[CsHiiNOiSn] (black) (c) (S)-fCioHi6NOSnClJ(green) (d) (S)-[C,sH2,N02Sn] 
(blue)on the relative viscosities (rj/rjoj ofCT-DNA in Tris-HCl buffer (pH 7.2). 
Figure 52 shows the relative viscosity of DNA (0.06x10^ M) in the presence of 
increasing concentration of complexes (S)/(R)-[Ci5H2iN02Sn] and (S)/(R)-
[CioHiftNOSnCl] from (0-0.40x10-^ M). In case of complex (S)/(R)-[C,5H2iN02Sn], 
the relative viscosity decreases steadily upon addition of varying concentration of 
complexes. A similar behaviour was also observed for complex (S)/(R)-
[CioHi^NOSnCI], The decrease in the viscosity of the two complexes reveal an 
electrostatic non classical mode of binding of complexes witii DNA [190]. However, 
decrease observed for complex (S)-[Ci5H2iN02Sn] and (S)-[CioHi6NOSnCI] is more 
pronounced than complex (R)-[C,5H2]N02Sn] and (RHC,oH,6NOSnCl] which 
supports a more strong electrostatic binding of complexes (S)-[Ci5H2iN02Sn] and 
(S)-[CioHi6NOSnCl] with CT-DNA compared to complexes (R>-[Ci5H2iN02Sn] and 
(R)-[C,oH,6NOSnCI]. 
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DNA cleavage activity 
Gel electrophoretic pattern of complexes (S)-[Ci5H2iN02Sn] and (S)-
[CioHieNOSnCl] were obtained due to their high binding ability with DNA as 
evidenced by UV, fluorescence and viscosity studies. Initially in the untreated 
pBR322 plasmid DNA (Lane 1) two bands corresponding to Form 1 and Form 11 
were observed. When the supercoiled pBR322 plasmid DNA were treated with both 
the complexes (S)-[Ci5H2iN02Sn] and (S)-[CioH,6NOSnCl] supercoiled (Form I) 
was cleaved to nicked circular DNA (Form II) (Lane 2 and 4, Figure 55). 
respectively. With increasing concentration of the complex from 50-200 ixM 
apparently very little transformation of the plasmid DNA from Form I to Form II 
was observed (Lanes 3 and 5, Figure 55). 
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Figure 55. Agarose gel electrophoresis patterns for the cleavage ofpBR322 plasmid 
DNA as a function of increasing concentration of (a) complex (S)-[Ci5H2iN02Sn] 
(b) complex (S)-[CioH,6NOSnCl]. (a) DNA control (Lane 1); DNA + 50^M (S)-
[C,5H2iN02Sn] (Lane 2); DNA + ]00/uM (S)-[C,sH2iN02Sn]. (Lane 3); DNA + 
150nM(S)-[C,5H2,NO2Sn] (Lane 4; DNA + 200fiM (S)-fC,sH2iN02SnJ (Lane 5).fb) 
DNA control (Lane I); DNA + 50^M (SJ-fCioHieNOSnClJ. (Lane 2); DNA + lOOpiM 
(S)-[C,nHi6NOSnCl] (Lane 3); DNA + ISOuM (S)-[CioH,6NOSnCl] (Lane 4): DNA 
+ 200fiM (S)-[CioHi6NOSnClJ (Lane 5). 
These small changes in the intensity of Form I and Form II with an increase in the 
concentration of the complexes is due to the unwinding of the supercoiled Form I to 
Form II owing to cleavage of DNA phosphodiester backbone. Thus, the complex 
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(S)-[Ci5H2iN02Sn] and (S)-[CioHi6NOSnCl] does not cleave the plasmid DNA 
efficiently [220]. These results are consistent with the observations of other 
spectroscopic studies. Thus, we can conclude that the activity of these complexes 
against various tumor cell lines seems not to come from the complete destruction of 
DNA caused by the complexes but from the high affinity of these complexes 
towards DNA. 
In vitro antitumor activity 
In vitro antitumor activity of complexes (S)-[Ci5H2iN02Sn] and (S)-
[CioHieNOSnCl] has been evaluated in terms of GI50, TGI and LC50 values against 
five different human carcinoma cell lines of different histological origin; Hop62 
(Human lung), DWD (Human oral), K562 (Human leukemia), DU145 (Human 
prostrate) and MCF-7 (Human breast). The in vitro antitumor screening of these 
complexes (S)-[Ci5H2iN02Sn] and (S)-[CioH,6NOSnCl] was evaluated as a 
consequence of their high binding affinity towards CT-DNA by applying 
microculture sulforhodamine B test (SRB) [153]. The initial cytotoxic screening data 
(Table 10) shows that the complex (S)-[Ci5H2iN02Sn] act as a potential selective 
anticancer agent with a pronounced GI50 values <10 ^g/mL specifically towards 
Hop62, K562 and DWD tumor cell lines while complex (S)-[C,oHi6NOSnCi] 
exhibited efficient in vitro activity towards Hop62, DWD, MCF-7 and DU145 tumor 
cell lines. 
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Table 10. Cytotoxicity against different tumor cells in terms ofGUo value. 
Where GIso = Growth inhibition of 50 % (GIso) calculated from [(Ti-Tz)/ (C-Tz) x 
100 = 50, drug concentration resulting in a 50% reduction in the net protein 
increase. 
Complexes 
(S)-[C,5H2,N02Sn] 
(S)-[C,oH,6NOSnCI] 
Hop62 
<10 
<10 
DU145 
30.8 
15.0 
DWD 
15.5 
<10 
MCF7 
23.3 
<10 
K562 
<I0 
>80 
Gl5o< 10 is considered to demonstrate activity. 
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Conclusions 
The newly synthesized modulated organotin complexes derived from (R)- and (S)-
enantiomers of [4-(2-hydroxy-l-phenylethylimino)pent-2-ol] and 2-amino-2-
phenylethanol [Ci5H2iN02Sn] and [CioHieNOSnCl], respectively were synthesized 
with the aim to examine the effect of chirality on the DNA binding ability of two 
enantiomeric forms (enantiomeric selectivity). Many properties of metal complexes 
such as size, charge, shape, and chirality could influence the binding mode and 
modification extent to DNA. In vitro complex-DNA interaction studies (UV-vis.. 
fluorescence, ' H and ^'P NMR, circular dichroism, viscosity measurements and gel 
electrophoresis) reveal that complexes (S)/(R)-[Ci5H2!N02Sn] and (S)/(R)-
[CioHieNOSnCl] bind to DNA via, electrostatic interaction mode preferentially 
involving phosphodiester backbone. However, (S)-enantiomers bind more strongly 
in comparison to (R)-enantiomeric analogues. (S)-[Ci5H2iN02Sn] and (S)-
[CioHieNOSnCI] exhibit higher Kb values for DNA binding as compared to cisplatin 
drug as well which is used for clinical treatment in cancer chemotherapy.. Higher 
binding propensity of (S)-Ci5H2iN02Sn could be attributed to (i) Availability of 
coordination sites at tin, tin(rV) is five-coordinate with trigonal bipyramidai 
geometry, (ii) Tin(IV) being a strong Lewis acid exhibits strong affinity 
preferentially towards the anionic phosphate backbone of DNA helix. 
(S)-enantiomer of [Ci5H2iN02Sn] possess good cytotoxic activity against Hop62 
(human lung), K562 (human leukemia), DWD (human oral) with pronounced G150 
values <10 (Ag/mL and warrants further vigorous in vivo investigations. 
CHAPTER V 
In vitro binding studies of organotin(IV) complexes of 1,2-
bis-(2-lH-benzimidazol-2-yl)-l,2-ethanediol with CT-DNA 
and nucleotides (5'-GMP and 5'-TMP): Effect of the 
ancillary ligand on the binding propensity. 
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Synthesis of ligand 
[Ci6H,4N402] 
Ligand was prepared were prepared by reaction of 1,2-diamino benzene (4.6g, 
40mmol) and L-tartaric acid (3.0g, 20mmol), following the method described earlier 
[68]. 
1,2-diaminobenzene (4.32g, 40mmol) and L (+)-tartaric acid (3.00g, 20mmol) were 
dissolved in 50 ml of 4M hydrochloric acid. The solution was refluxed for 24 h. 
After cooling a brown compound (the chloride salt of the protonated ligand) 
crystallized from the dark brown solution. The crystals were filtered and re-dissolved 
in 150 ml water and 150 ml ethanol. After adding active carbon, the solution was 
heated to reflux for 2 h. The colorless solution was neutralized with concentrated 
ammonia and white precipitate was filtered. 
Yield 65%. m.p. 270 ± 2 °C. Anal. (%) Calc. for [C|6H,4N402]: C, 65.30; H. 4.79: N. 
19.04: Found: C, 65.32; H, 4.81; N, 19.01. [af^o = +110. ESl-MS (m/z) 295 
[C,6H,4N402]. 
Selected IR data on KBr pellet (v/cm"'): 3322 (OH); 1623 (C=N); 1227 (C-O); 740 
(Ar). UV-vis in Methanol [kmJnm]: 206, 247, 278. 'H N M R (DMSO-de, ppm): 
5.49-5.67 (-CH); 6.41(-OH); 7.10-7.52 (Aromatic-H). '^ C NMR (DMSO-dg, ppm): 
155 (C=N); 115-121 (Ar-C); 71 (C-O). 
Synthesis of complexes 
[Ci8H,9N402SnCI] 
To a stirring solution of dimethyltin(IV)dichloride (1.07g, 5mmol) in methanol (20 
mL) was added to the ligand [C16H14N4O2] (1.47g, 5mmol). The reaction mixture 
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was refluxed at 80 "C with constant stirring on the rotamantle for 4 h and then 
allowed to stand at room temperature overnight (25 "C). Slow evaporation of the 
resulting mixture afforded white amorphous complex. The above complex was 
washed with hexane and dried in vacuo over anhydrous CaCb (Scheme 8). 
Yield 56%. m.p. 210 ± 2 °C. Anal. (%) Calc. for [C,8Hi9N402SnCl]: C, 45.27; H. 
4.01; N, 11.73: Found: C, 45.30; H, 4.1; N, 11.76. [af\ = +193. ESl-MS (m/z) 478 
[Ci8Hi9N402Sn]. Molar Conductance, AM (1 x 10'^  M, Methanol): 59 Q'cm^ mol' 
(non-electrolyte). 
Selected IR data (v/cm'): 3220 (OH); 3042 (NH); 1625 (C=N); 1222 (C-O); 759 
(Ar); 557 (Sn-C); 470 (Sn-N); 435 (Sn-0); 256 (Sn-Cl). UV-vis in Methanol 
[X^ax/nm]: 210, 245, 275. ' H N M R (DMSO-de, ppm): 5.9 (-CH); 6.4 (-OH); 7.1-7.8 
(Aromatic-H). '^C NMR (DMSO-dg, ppm): 154 (C=N); 114-128 (Ar-C); 70 (C-O): 
10-12 (-CH3).' '^Sn NMR (DMSO-de, ppm): -189. 
[C28H23N402SnCI] 
The complex [C28H23N402SnCl] was prepared with diphenyltin(lV)dichloride 
(1.71g, 5mmol) and ligand [C16H14N4O2] (1.47g, 5mmol) according to the procedure 
described above for complex [Ci8Hi9N402SnCl]. 
Yield 64%. m.p. 215 ± 2 "C. Anal. (%) Calc. for [C28H23N402SnCl]: C, 55.89; H, 
3.85; N, 9.31: Found: C, 55.85; H, 3.86; N, 9.34. [af^u = +120. ESI-MS (m/z) 604 
[C28H23N402SnCl+2H]. Molar Conductance, AM (1 x IQ-^  M, Methanol): 34 Q"'cm' 
mol"' (non-electrolyte). 
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Selected IR data (v/cm"'): 3208 (OH); 3046 (NH); 1625 (C=N); 1226 (C-O); 747 
(Ar); 588 (Sn-C); 472 (Sn-N); 435 (Sn-0); 263 (Sn-Cl). UV-vis in Methanol 
[X^ax/nm]: 207, 244, 274. ' H N M R (DMS0-d6, ppm): 5.5-5.4 (-CH); 6.6 (-0H); 7.1-
7.9 (Aromatic-H). '^C NMR (DMSO-de, ppm): 154 (C=N); 114-136 (Ar-C); 69 
(C-O). "^Sn NMR (DMSO-de, ppm): -586. 
IC52H42N402Sn2l 
The complex [C52H42N402Sn2] was prepared with triphenyltin(IV)chloride (1.92g. 5 
mmol) and ligand [C16H14N4O2] (1.47g, 5mmol) according to the procedure 
described above for complex [Ci8Hi9N402SnCl]. 
Yield 69%. m.p. < 300 "C (decompose). Anal. (%) Calc. for [C52H42N402Sn2]: C. 
62.94; H, 4.27; N, 5.65: Found: C, 62.86; H, 4.22; N, 5.66. [af^o = +90. ESl-MS 
(m/z) 1009 [C52H42N4O2Sn2+0.5CH3OH]. Molar Conductance, AM (1 x 10'^  M. 
Methanol): 37 fi'cm^mol"' (non-electrolyte). 
Selected IR data (v/cm"'): 1621 (C=N); 3062 (NH); 1222 (C-O); 735 (Ar); 561 (Sn-
C); 452 (Sn-N); 446 (Sn-O). UV-vis in Methanol [>vn,ax/nm]: 207, 245, 275. 'H NMR 
(DMS0-d6, ppm): 5.5-5.8 (-CH); 7.1-7.9 (Aromatic-H). '^C NMR (DMSO-de. ppm): 
155 (C=N); 114-136 (Ar-C); 70 (C-O). "^Sn NMR (DMSO-dg, ppm): -222. 
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Scheme 8. Schematic representation of the formation of complexes 
[CisHi9N402SnCl], [C28H2iN402SnCl] and [ C52H42N402Sn2l 
Figure 56. Cylindrical bonded three dimensional model of complexes (a) 
[CisHigNiOiSnCl] (b) [C28H23N402SnCl] (c) [C52H42N402Sn2]. Color scheme: 
Tin(IV) light green; Chloride, fluorescent green; N dark blue; O red; C gray. The H 
atoms and are omitted for clarity 
Results and Discussion 
Synthesis and characterization 
The synthesis of the ligand was a straightforward Phillips condensation reaction and 
the new organotin(IV) complexes [CisHi9N402SnCI], [C28H23N402SnCl] and 
[C52H42N402Sn2] were prepared by the coordination of ligands to the central metal 
ion via nitrogen and oxygen donor atom. Nitrogen atoms participate through the 
coordinate linkages, while oxygen atom is involved in coordination under release of 
HCl in 1:1 stoichiometric ratio (Scheme 8). These complexes were stable at room 
temperature and soluble in various organic solvents such as methanol, ethanol and 
DMSO. Molar conductance values of complexes in methanol were recorded as 59. 
34 and 37 n ' cm^ mof' for the complexes [CigHi9N402SnCl], [C28H23N402SnCl] 
and [C52H42N402Sn2] suggesting their non-electrolytic nature. The geometry of the 
around the tin metal ion was ascertained by "^Sn NMR spectra which revealed a 
pentacoordinated geometry for [CigHi9N402SnCl], [C52H42N402Sn2] and 
hexacoordinated environment for [C28H23N402SnCl] complexes, respectively. 
IR spectral studies 
The IR spectra of the ligands undergo several modifications upon coordination to the 
metal atoms. In the IR spectra of the ligands the -OH and NH frequencies are present 
as a broad envelope in the region from 3450-3199 cm"' due to intermolecular 
hydrogen bonding NH and OH groups [221,75] which display minor changes on 
complexation. However, a medium or relatively weak band at 1623 cm"' with a small 
shoulder at 1536 cm' corresponding to v(C=N) in the IR spectra of the ligands [222] 
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were considerably shifted by 2-3 cm"' and becoming larger and sharper indicating 
the involvement of the nitrogen atom in complexation with tin(IV) metal ion in all 
the complexes [C,8Hi9N402SnCl], [C2gH23N402SnCl] and [C52H42N402Sn2]. Other 
frequencies in complexes corresponding to v(Sn-C), v(Sn-N), v(Sn-O), and v(Sn-Cl) 
appear at 557-588, 435-446, 517-546 and 279-256 cm', respectively [223-225]. 
Electronic spectra 
The absorption spectra of the complexes [Ci8Hi9N402SnCl], [C28H23N402SnCI] and 
[C52H42N402Sn2] were recorded in methanol at room temperature. The spectra of the 
complexes [Ci8Hi9N402SnCI], [C28H23N402SnCl] and [C52H42N402Sn2] reveal 
bands at 207-210, 245, and 275 nm attributed to IL transitions of the ligands. 
NMR spectra 
The conclusions drawn from the 'H NMR spectrum of free ligand were extrapolated 
to the complexes [Ci8Hi9N402SnCl], [C28H23N402SnCI] and [C52H42N402Sn2] owing 
to the data similarity. In complex [Ci8Hi9N402SnCI], the characteristic satellite peak 
of the methyl groups attached to the tin is observed at 0.7-1.9 ppm [226|. While in 
complexes [C2gH23N402SnCl] and [C52H42N402Sn2], the presence of Sn-Ph protons 
at 7.8 and 7.9 ppm [227] shows the formation of the complexes. The 'H NMR 
spectra of all the complexes reveals a resonance for the CH proton attached to the 
hydroxy! group at 5.9-5.8 ppm which is shifted downfield compared to the free 
ligand at 5.4 ppm [68] showing the involvement of adjacent hydrox>l group in 
complexation with tin metal ion. However, the most striking difference in the 'H 
NMR of complex [C52H42N402Sn2] with the other complexes [Ci8Hi9N402SnCl] and 
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[C28H23N402SnCl] is the disappearance of the hydroxyl protons of ligand at 6.4 ppm 
concomitant with the formation of complex in 1:2 stoichiometric ratio [68]. The 
aromatic protons of the ligand appear as a multiplet in the range of 7.1-7.5 ppm. In 
addition, due to rapid exchange between the two nitrogen atoms of imidazole ring 
the NH protons of the ligand were not observed in the NMR spectra. This 
observation was in accordance with the earlier reports [228,229]. 
The '^ C NMR spectra of the ligand exhibit signals corresponding to C=N. C-0 at 
155 and 68-70 ppm, respectively [68] which were shifted in the downfield in the 
complexes. In addition, the complex [Ci8Hi9N402SnCl] displays the methyl carbons 
attached to the tin metal ion (Sn-CHs) at 10-14 ppm; the other complexes 
[C28H23N402SnCl] and [C52H42N402Sn2] exhibit only one set of NMR signals for 
both the phenyl groups (Sn-Ph) and for the ligands from 127-136 ppm, which 
provide evidence for the magnetic equivalence of both the phenyl groups of the 
ligands and the complexes on the NMR time scale [230,231]. 
In order to provide further evidence to establish the structure of the complexes in 
solution [232], we recorded "^Sn NMR spectra (Figure 57a-c). The complexes 
[Ci8Hi9N402SnCl] and [C52H42N402Sn2] displays chemical shifts values of-186 and 
-222 ppm while complex [C28H23N402SnCI] exhibit a signal at -586 ppm which lie 
in the range delimited for five and six coordinated organotin(IV) complexes, 
respectively [233, 234]. 
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(a) (b) (c) 
Figure 57. "^Sn NMR spectra of complexes (a) [CisHigN^OvSnClJ (h) 
C28H23N402SnCl (C) Cs2H42N402Sn2. 
DNA binding studies 
UV-visible absorption studies 
The absorption spectra of complexes in presence and in the absence of CT-DNA are 
shown in Figure 58(a-c). In absence of CT-DNA, all the complexes exhibit similar 
absorption spectra with the peaks centered at 245 and 275 nm corresponding to n-7x* 
and at 207-210 nm for n-n* IL transitions owing to the presence of benzimidazole 
ligand scaffold (Figure 58a-c). In presence of incremental amount of CT-DNA, a 
significant "hyperchromic" effect with a strong bathochromic shift was observed for 
all studied complexes. Complex [C28H23N402SnCI] displays a substantial 
bathochromic shift of ca. 4-5 nm which supports a higher degree of binding for this 
complex towards CT-DNA [235]. Thus, from these spectral changes, we deduce that 
the complexes bind to the CT-DNA by a strong electrostatic interaction mode as a 
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result of a high affinity of cationic tin(IV) to the polyanionic phosphate backbone 
and lack of base specificity in DNA binding. Literature reveals [ 174,209] strong 
Lewis acid tin(IV) ions neutralize the negative charge of the CT-DNA thereby, 
causing contraction and conformational changes in the CT-DNA via, an electrostatic 
interaction with the phosphate backbone of DNA double helix. The spectral features 
reveal that the complex [C2gH23N402SnCl] has much higher affinity towards CT-
DNA among the other complexes which could be attributed to the presence of labile 
groups of varying steric demand and hydrophobicity thereby facilitating multifaceted 
binding modes. The hydrophobic phenyl groups leads to more intimate binding and 
possibly promoting partial insertion of the complex [C28H23N402SnCl] into the DNA 
helix. In addition, hydrolysis of labile chloride atoms in the complex 
[C28H23N402SnCl] [236] and hard Lewis acidic property of tin(lV) together 
contribute to the vicinal electrostatic binding of complex with the polyanionic 
phosphate backbone of CT-DNA [237]. Furthermore, the presence of -OH group in 
the ligand being out of the planar phenyl rings, as validated by the crystal structure 
of the ligand [68] forms hydrogen bonds with DNA. Although complete intercalation 
between a set of adjacent base pairs is sterically prohibited, but some type of partial 
intercalation can be envisioned for complex [C28H23N402SnCl]. Similarly, complex 
[Ci8Hi9N402SnCl] also exhibit an electrostatic binding mode pertaining to presence 
of tin(IV) central metal ion which substantiate preferential binding to the DNA 
phosphate backbone; the discerning binding exhibited by complex 
[CigHi9N402SnCl] compared to complex [C2gH23N402SnCl] is due to the absence of 
phenyl group in the complex. 
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Figure 58. Absorption spectra of complexes (a) [CisHigN402SnCl] (b) 
[C28H23N402SnCl] (c) [C52^42^402Sn2] in the (b-j) presence of increasing amount of 
CT-DNA. Inset: Plots of [DNAJ/(£a-£j) vs [DNA] for the titration of CT-DNA with 
complexes. [Complex]^ 1.3x10''' M, fCT-DNAJ= 1.2x10'''M. 
The complex [C52H42N402Sn2] has steric constraints caused by the bulky phenyl 
groups of the triphenyltin(lV) moiety which accounts for its lower binding 
propensity with DNA. Thus, the comparative binding strength of the complexes with 
CT-DNA were in the order [C28H23N402SnCl]>[C,8H,9N402SnCl]>[C52H42N402Sn2] 
as given in Table 11 below. 
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Table 11. The binding constant (Kb) values of complexes [Ci8HigN402SnCl]. 
[C28H23N402SnClJ and [C52H42N402Sn2] with the CT-DNA 
Complex Kb(M"') % Hyperchromism Red Shift (nm) 
[CigH,9N402SnCl] 2.16x10^ (±0.04) 32 06 
[C28H23N402SnCl] 3.47x10^ (±0.04) 45 05 
[C52H42N402Sn2] 4.60x10^ (±0.04) 20 05 
Interaction with 5'-GMP and 5'-TMP by absorption spectroscopy 
To avoid the macrostructural effects of larger nucleic acid which might obscure the 
fundamental biomolecular selectivity of these complexes, absorption titration with 
small nucleic acid fragments such as mononucleotides (5'-GMP and 5'-TMP) were 
performed under physiological conditions. Nucleotides contain three characteristic 
ligating regions capable of metal binding ie. (a) heterocyclic ring N atoms and 
nucleobase functionalities of purine and pyrimidine (b) phosphate O atoms (c) 
hydroxyl oxygen atoms of ribose sugar moiety. Earlier work of Gellert et al. [238] 
demonstrated X-ray structural studies showing predominant binding of thirty binary 
and ternary mononucleotide-transition metal complexes by first two modes through 
exocyclic nitrogen atom of purine rings (Nl and N7 atom) and N3 of the pyrimidine 
and oxygen atom of the phosphate group present in the nucleotides. Later, extensive 
work on the interaction of organotin(IV) complexes DNA and nucleotides was also 
carried out by Yang et al to elucidate the probable mode of binding of the tin(lV) 
complexes [209,174] 
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Figure 59. Absorption spectral traces of complexes (a) [Ci8HigN402SnCl] fh) 
[C28H23N402SnCl] (c) [C52H42N402Sn2] upon addition of5'-GMP. fComplexJ=!.3 x 
Iff" M, [5'-GMP]=0-0.50x1 ff" M. Inset: Plots of [5'-GMP]/ Sa-Sfvs [S'-GMPJ for 
the titration of 5'-GMP with complexes, [complex] 1.3 x 10'" M, [5'-GMPj=0-
0.33x10" M 
The gradual addition of 5'-GMP/5'-TMP from (0-0.50xlO"V) to the metal 
complexes leads to significant "hyperchromic effect" and strong perturbations in 
absorption peak of complexes (Figure 59,60). 
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Figure 60. Absorption spectral traces of complexes (a) [Ci8Hi9N40:SnClj (b) 
[C28H2iN402SnCl] (c) [C52H42N402Sn2] upon addition ofS'-TMP. [Complex] = 1.3 x 
JO'"M, [5'-TMP]=0-0.33x10". Inset: Plots of [5'-TMP]/\Ea-Sj\ vs [5'-TMPJ for the 
titration ofS'-TMP with complexes. [Complex] 1.3 x 10"'M, [5'-TMP] 0-0.50x10'" M 
As evident from above absorption titration, both the electrostatic binding as well as 
steric effects play an eminent role in the determining the binding potential of these 
analogous complexes with DNA, so the binding of the complexes 
[Ci8H,9N402SnCl], [C28H23N402SnCl] and [C52H42N402Sn2] towards nucleotides is 
also governed by these interactions. The "hyperchromic effect" in the absorption 
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spectra of the complexes indicates an electrostatic outside binding of the complexes 
with nucleotides owing to the presence of tin(IV) moiety which exerts predominate 
phosphate binding of the complexes with nucleotide. 
Moreover, as observed from the binding constant data given in Table 12, the 
interaction of complexes [Ci8Hi9N402SnCl], [C28H23N402SnCI] and 
[C52H42N402Sn2] with 5'-GMP produces more pronounced changes in the absorption 
spectra as compared to 5'-TMP showing a clear preference of binding of the 
complexes with 5'-GMP compared to 5'-TMP (Figure 59,60). 
Table 12. The comparative binding constant (Kb) values of complexes 
[C,8H,9N402SnCl], [C28H23N402SnCl], [C52H42N402Sn2] with the 5'-GMP and 5'-
TMP (mean standard deviation of^ 0.07). 
Complex 
[Ci8H,9N402SnCl] 
[C28H23N402SnCl] 
[C52H42N402Sn2] 
5'-GMP 
(xlO^) 
3.03 
4.80 
0.28 
5'-TMP 
(xlO^) 
0.40 
1.51 
0.16 
Monitored at 
(nm) 
246 
246 
246 
% Hyperchromism 
36 
48 
23 
' H and ^'P NMR interaction with 5'-GMP 
To further understand the selectivity of the complex [C28H23N402SnCl] owing to its 
stronger binding with the CT-DNA and to the strong perturbations induced in the 
absorption spectra when treated with nucleotide 5'-GMP, we have carried out ' H and 
^'P NMR interaction of the complex with 5'-GMP. The ' H NMR spectrum of the 
5'-GMP after addition of the complex [C28H23N402SnCl] shows no significant 
chemical shift differences as depicted in Figure 61. 
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Figure 61. 'H NMR spectra of (a) 5'-GMP alone and (h) the reaction of complex 
[C28H23N402SnCl] (2.5 mmol) with 5'-GMP (5 mmol) at 25 °C. 
The absence of such shift of H8 signal suggests non-involvement of the nucleobase 
in complex binding thus, precluding the base specific interactions with the complex. 
Slight shift of free ribose protons of 5'-GMP after interaction with complex 
[C28H23N402SnCl] from 5.8-3.8 ppm to 5.7-3.9 ppm indicate the binding of the 
tin(IV) complex through O2' and O3' atoms of the sugar moiety owing to its high 
affinity for the backbone binding. Thus, the 'H NMR studies indicates an 
electrostatic binding mode of complex [C28H23N402SnCl] with 5'-GMP. 
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Figure 62. P NMR spectra of (a) 5'-GMP and (b) the reaction of complex 
[C28H23N402SnClJ (2.5 mmol) with 5'-GMP (5 mmol) at 25'^C. 
Additional evidence for the selective and specific binding of tin(IV) complex with 
the phosphate group of 5'-GMP was provided by ^'P NMR (Figure 62). There is 
significant upfield shift of the ^'P signal of free 5'-GMP from 3.73 to 2.10 ppm 
which corresponds to a strong binding exhibited by the complex [C28H23N402SnCI] 
to the phosphate group of the mononucleotide [214]. These observations provide a 
definitive affirmation of phosphate selectivity of complex with biomolecules (C T-
DNA and 5'-GMP). 
Fluorescence studies 
In the absence of DNA, complex [Ci8H|9N402SnCl], [C28H23N402SnCl] and 
[C52H42N402Sn2] emit weak luminescence in Tris-HCI buffer at ambient 
temperature, with a fluorescence maximum centered at 710 nm when excited with a 
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wavelength of 354 nm as depicted in Figure 63. Upon increasing DNA from 0-
0.50x10"^  M, the enhancement in the emission intensity was observed. This observed 
enhancement in the emission intensity results from shielding effect of these 
complexes as a consequence of their unspecific binding to the low affinity outer 
sphere of DNA polyanionic phosphate baclcbone. However, another possibility 
envisioned for such an increase is the effective shielding of these outer sphere 
complexes to the metal complexes intercalated inside the DNA pockets [239]. 
Generally there is interplay between electrostatic and hydrophobic interactions; even 
in systems in which intercalation is evident. The degree to which hydrophobic 
interactions predominate over electrostatic is likely to be dictated by structural, 
geometric, and charge considerations for the binding molecule. Since, the complex 
[C28H23N402SnCl] displays structural variability as compared to [Ci8Hi9N402SnCll 
and [C52H42N402Sn2], the partial-intercalative hydrophobic interaction along with 
electrostatic binding predominates for the complex. The propensity to CT-DNA of 
the complexes follows the order [C28H23N402SnCl] > [C,gH|9N402SnCll > 
[C52H42N402Sn2]. The binding constant K values gave similar trend of the DNA 
binding propensity as observed in case of absorption spectral studies (Table 13). 
Table 13. Emission properties of complexes [Cj8HigN402SnCl], [€23^23^ 402SnCl]. 
[C52H42N4028112] bound to CT-DNA (mean average deviation of± 0.02). 
Complex 
[C,gH,9N402SnCl] 
[C2gH23N402SnCl] 
[C52H42N402Sn2] 
Emission 
(nm) 
442 
446 
442 
Excitation 
(nm) 
354 
354 
354 
Monitored At 
(nm) 
710 
710 
710 
K(M"') 
2.0x10" 
4.3x10" 
1.4x10" 
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Figure 63. Emission spectra of complexes (a) [Ci8HigN402SnCl] (h) 
[C28H2iN402SnCl] (c) [C52H42N402Sn2] in Tris-HCl buffer (pH = 7.2) in the 
absence and presence ofCT-DNA. [Complex] ^1.3x10'" M, [DNAJ = 0-0.50x10'^ M. 
Arrows indicate the change in emission intensity upon increasing the DNA 
concentration. 
Steady-state emission quenching experiments were performed by using anionic 
quencher which has been found to be able to distinguish between the binding modes 
of the complex with DNA [240,241]. Upon addition increasing CT-DNA, the 
quenching of the fluorescence intensity was observed for the complexes 
[Ci8H,9N402SnCl], [C28H23N402SnCl] and [C52H42N402Sn2]. 
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Figure 64. Emission quenching curves of (a) [Ci8HigN402SnClj (bj 
[C28H23N402SnCl] (c) [C52H42N402Sn2] in the absence of CT-DNA (u) and in the 
presence of CT-DNA (•). [Complex] = 1.3x10'" M. 
It is speculated that intercalated chromophores are less accessible to quenching by 
quencher due to electrostatic repulsion between the highly negatively charged DNA 
and anionic quencher [242] whereas compounds which are bound at the DNA 
surface (groove binding or electrostatic binding) are more accessible and therefore, 
the emission from these molecules can be quenched more efficiently. The 
fluorescence-quenching plots of DNA-bound quencher by complexes 
[Ci8H,9N402SnCl], [C28H23N402SnCl] and [C52H42N402Sn2] are shown in Figure 64 
which illustrate that quenching phenomena of DNA bound [Fe(CN)6]'*' by complexes 
[C,8H,9N402SnCl], [C28H23N402SnCl] and [C52H42N402Sn2] are in good agreement 
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with the linear Stem-Volmer equation.However, in presence of DNA the slope of 
the plot of was remarkably decreased as shown in Table 14. These results 
corroborate well with the observations of absorption titrations indicating that the 
complex [C28H23N402SnCl] bind with higher affinity towards DNA as compared to 
other complexes [CigHi9N402SnCl] and [Cs2H42N402Sn2] (Figure 64) predominantly 
via, electrostatic interactions. (Table 14). 
Table 14. Emission quenching of CT-DNA bound [Fe(CN)6j ' by complexes 
[Ci8Hi9N402SnCl], [C28H23N402SnCl] and [C52H42N402Sn2](mean cnerage 
deviation of ±0.02). 
Complex Emission Excitation Monitored at Ksvi Ksv2 
(nm) (nm) (nm) 
2.57x10" 1.28x10' 
1.00x10'' 5.70x10" 
3.14x10" 1.42x10" 
Effect of ionic strength 
In order to validate the probable binding mode between the molecule and DNA, 
fluorescence titrations were carried out under the conditions of increasing ionic 
strength (0-0.50x10"* M) through added amounts of NaCl. As shown in Figure 65, 
the fluorescence intensity of the studied complexes was appreciably quenched with 
increasing ionic strength [184,185]. This change in CT-DNA is in favour of the 
electrostatic binding between complexes [Ci8Hi9N402SnCl], [C2gH23N402SnClj, 
[C52H42N402Sn2] and CT-DNA. As evident from Figure 65(a-c), the effect of salt 
concentration on complex [C28H23N402SnCl]-DNA system was more pronounced in 
case of [C28H23N402SnCl] than the other complexes [CigHi9N402SnCI] and 
[Ci8Hi9N402SnCl] 
[C28H23N402SnCl] 
[C52H42N402Sn2] 
442 
446 
442 
354 
354 
354 
710 
710 
710 
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[C52H42N402Sn2] so, the complex [C28H23N402SnCl] reveals a greater potency for 
DNA binding. 
Wwalmgih 
Figure 65. Effect of different concentration ofNaCl on the fluorescence spectra of 
(a) complexes [C,sH,9N402SnCl] (b) [C28H23N402SnCl] (c) [Cs2H42N402Sn:J where 
[Complex]=1.3x10'" M with [DNA]=1.0xlO^ M. Arrow indicate the gradual 
decrease of emission intensity as a function ofNaCl concentration. 
Effect of phosphate group 
It could be seen from the Figure 66(a-c) that fluorescence intensity of all the 
complexes increases with increase in the K2HPO4 concentration. This observation 
provides supportive evidence for electrostatic interaction of the complexes binding 
preferentially to the phosphate group of DNA double helix. 
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Figure 66. Effect of increasing concentration of K2HPO4 on the fluorescence 
intensity of the complexes (a) [CisHigN402SnCl] (b) [C28H2iN402SnCl] (c) 
[C52H42N402Sn2]. [Complex]=1.0x10'^ M with [CT-DNA]=1.20x10'^ M. Arrow 
indicate the gradual decrease of emission intensity as a function of K2HPO4 
concentration. 
The spectra depicts that the interaction of complex [C2gH23N402SnCl] is relatively 
strong than complexes [Ci8Hi9N402SnCl] and [C52H42N402Sn2] which is consistent 
with the absorption spectral studies. 
Circular dichroic studies 
The circular dichroism pattern observed for CT-DNA provide further and definitive 
confirmation of the probable mode of CT-DNA binding of complexes 
[Ci8H,9N402SnCl], [C28H23N402SnCl] and [C52H42N402Sn2] which is depicted by 
the perturbation induced in the DNA morphology upon the binding of complexes to 
CT-DNA (Figure 67a-c). The two bands of CT-DNA are a net result of exciton 
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coupling interaction of bases which depend on the skewed orientation on the C1 -
DNA backbone [243]. On incubation of the complexes with CT-DNA. moderate 
changes in both the positive and negative bands of CT-DNA were observed as 
shown in Figure 67(a-c). 
(a) . (b) 
(c) 
Figure 67. CD spectra of (a) CT-DNA alone (b) CT-DNA in presence of meial 
complexes [C]sHj9N402SnClJ, [C28H23N402SnCl], [C52H42N402Sn2], respectively, in 
Tris-HCl buffer at 25 "C. [Complex] = LOxia" M, [DNA]=1.20xI0'^M 
The multifaceted binding mode observed for complex [C28H23N402SnCl | promotes 
its higher binding towards the DNA such that effective screening of the negative 
charge on the N7 base site as well as phosphate oxygen, simultaneous!} along the 
phosphate backbone is observed which support a transconformational change [244] 
of the DNA double helical conformation. It has been speculated that the electrostatic 
components of interactions are effective in bringing about such transconformational 
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changes. Further transformation of the DNA structure proceeds by removal of labile 
groups attached in the complexes which removes the water from the base sites and 
grooves of DNA helix resulting in effective binding of the complex to DNA. Ihe 
CD spectrum of DNA shows a significant decrease in intensity of positive band upon 
addition of the complex [C28H23N402SnCl] which reveal a right handed 
conformational change of the DNA double helix possibly due to its partial 
intercalative binding of the complex. In contrast, the complexes [Ci8Hi9N4()2SnCr| 
and [C52H42N402Sn2] {Figure 67(a and c)} exhibit less pronounced CD spectral 
changes in the positive ellipticity band. However, on addition of the complexes, no 
appreciable change in the negative helicity band of CT-DNA was observed for all 
the complexes. The observation is in accordance with the above spectroscopic 
studies revealing avid binding of complex [C28H23N402SnCl] as compared to 
complexes [Ci8Hi9N402SnCI] and [C52H42N402Sn2]. 
Viscosity studies 
The relative viscosity of CT-DNA (1.20x10"* M) in presence of varying amounts of 
complexes [Ci8H,9N402SnCl], [C28H23N402SnCl] and [C52H42N402Sn2] in the 
[complex]/[DNA] (r) ratio of 0.00-0.40 with an interval of 0.1 are shown in Figure 
68(a-c). Complex [C28H23N402SnCl] interacts with the CT-DNA more strongly and 
deeply than other complexes [Ci8Hi9N402SnCl] and [C52H42N402Sn2], leading to the 
greater decrease in viscosity of the DNA with an increasing value of r = 0.00-0.20 
followed by a substantial increase in the viscosity of the CT-DNA from r=0.20-0.40. 
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Figure 68. Effect of increasing amount of complexes (a) lC2sti23N402SnCl] (h) 
[C,8Hi9N402SnCl] (c) [C52H42N402Sn2] on the relative viscosity of CT-DNA 
[DNA]=1.20x10"M, [Complex]=1.0x10"M 
Firstly, the initial decrease in the relative viscosity of CT-DNA indicate non-
intercalative interaction presumably electrostatic interactions of the complexes with 
DNA which would produce bends or kinks in the DNA strand and hence, diminish 
its effective length along with its viscosity. Secondly, when the r ratios were 
increased from 0.20 to 0.40, rapidly increasing viscosity was observed which 
indicates the partial intercalative binding mode of the complexes and supports an 
electrostatic binding mode together with some partial intercalative interactions for 
the complexes [C28H23N402SnCl] and [Ci8H,9N402SnCl] [142]. However, the higher 
reduction at r = 0.00-0.20 and the higher enhancement at r = 0.20-0.40 in the DNA 
viscosity for complex [C28H23N402SnCl] compared to [Ci8Hi9N402SnCl] 
recommends that former complex reveals a greater DNA binding potential than the 
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latter. However, in contrast to this observation, there is a gradual decrease in the 
viscosity of DNA on addition of complex [C52H42N402Sn2] supporting only an 
electrostatic association of the complex towards CT-DNA. These results obtained 
from viscosity studies are consistent with those obtained from above spectroscopic 
studies. 
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Conclusions 
In this report, we have attempted to unravel the binding behaviour of the complexes 
[C,gH,9N402SnCI], [C28H23N402SnCl] and [C52H42N402Sn2] with CT-DNA by 
employing various spectroscopic and biophysical methods. The results suggest a 
multifaceted mode of binding of the complexes [CigHi9N402SnCI]. 
[C28H23N402SnCl] with CT-DNA i.e. electrostatic binding mode in addition to 
partial intercalative interactions owing to the presence of planar architectures within 
the molecule as evidenced by absorption titrations and fluorescence studies. 1 he 
complex [C28H23N402SnCI] (Kb=3.47x10^ ± 0.04 M"') binds to CT-DNA more 
strongly than complexes [C,8Hi9N402SnCl] (Kb=2.16xl0'' ± 0.04 M ' ) and 
[C52H42N402Sn2] (Kb=4.60xl0^ ± 0.04 M"'). Further studies of the complexes 
[Ci8H,9N402SnCI], [C28H23N402SnCl] and [C52H42N402Sn2] with mononucleotides 
5'-GMP and 5'-TMP by employing UV-visible absorption titrations as well as 'FI 
and ^'P NMR lends a strong affirmation of electrostatic interaction of complexes 
with biomolecules. The CD spectra reveal higher perturbations in DNA helical 
conformation for complex [C28H23N402SnCl] as compared to other complexes 
[Ci8Hi9N402SnCl] and [C52H42N402Sn2] suggestive of its higher binding affinity 
with DNA leading to strong conformational changes in the double helical structure 
of CT-DNA. The above DNA binding results were in agreement with viscometric 
studies which supports to two probable mode of association of the complexes 
[Ci8Hi9N402SnCl] and [C28H23N402SnCI] with DNA viz; electrostatic together with 
some partial intercalative interactions. While the complex [C52H42N402Sn2] only 
binds via an electrostatic interaction with DNA. 
CHAPTER VI 
Synthesis of new chiral heterocyclic Schiff base modulated 
Cu(II)/Zn(II) complexes: their comparative binding studies 
with CT-DNA and mononucleotides (5'-GMP, 5'-TMP, 5'-
AMP, 5'-CMP) and cleavage activity. 
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Synthesis of Ligand 
[CisHieNzOa] 
To a methanolic solution of 2-amino-3-formylchromone (1.89g, lOmmol), a solution 
of (R)-2-amino-2-phenylethanol (1.37g, lOmmoi) was added dropwise with 
continuous stirring. After refluxing the above solution for 2 h on rotamantle 
(80 "C), the solution was allowed to stand at room temperature overnight, until a 
yellow precipitate was separated out after the slow evaporation of the solvent. Phe 
precipitate, thus obtained, was then washed thoroughly with hexane and diethyl ether 
and dried in vacuo (Scheme 9). 
Yield 78%. m.p. 142 ± 2 X. Anal. (%) Calc. for [C,8H,6N203]: C, 70.12; H, 5.23: N. 
9.09: Found: C, 70.15; H, 5.22; N, 9.08. [af^o = -HO. ESl-MS (m/z) 30^ 
[C,8H,6N203+Hf. 
Selected IR data on KBr pellet (v/cm"'): 1611 v(C=N); 1654 v(C=0); 757 v(Ar). UV-
vis. in Methanol [X-max/nm]: 206, 247, 267, 310. 'H N M R (DMSO-dfi, ppm): 8.8 
(-CH=N); 2.5(OH); 7.2-7.6 (aromatic-H); 4.3(chiral-CH); 3.3-3.7 (CH.-O). 
'^ C NMR (DMS0-d6, ppm): 174 (C=0), 164 (C=N); 116-132 (Ar-C); 76 (C-0): 67 
(C-N). 
Synthesis of complexes 
[C36H34N407CU](N03)2 
The complex [C36H34N407Cu](N03)2 was prepared in a moderate yield from the 
reaction of Cu(N03)2.3H20 with the prepared ligand in 1:2 molar ratio. The ligand 
[CigHi6N203] (0.61g, 2mmol) dissolved in methanol was added slowlv to a 
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methanolic solution of Cu(N03)2.3H20 (0.24g, Immol) with continuous stirring 
which was followed by change in the colour of solution to intense green. After 
stirring for 24 h at room temperature, a green precipitate obtained was separated out. 
This precipitate was then washed with hexane and dried in vacuo (Scheme 10). 
Yield 69%. m.p. 279 ± 2 °C. Anal. (%) Calc. for [C36H34N60,3Cu]: C, 52.59; H. 
4.13; N, 10.22: Found; C, 52.58; H, 4.12; N, 10.23. [af^o = -110 Molar 
conductance, AM (1 X 10"^  M, Methanol); 210 Q'cm^mof' (1;2 electrolyte). 
Selected IR data on KBr pellet (v/cm"'): 1559 (C=N); 1384 (NO3); 579 (Cu-0); 452 
(Cu-N). UV-vis in Methanol [\r,Jnm]: 246, 302, 419, 564. ESl-MS (m/z) 698 
[C36H32N407CU]^ 
[C36H32N406Zn](N03)2 
The complex [C36H32N406Zn](N03)2 was synthesized by employing same procedure 
as described above for [C36H34N407Cu](N03)2 with ligand [C18H16N2O3J (0.61g, 
2mmol) and Zn(N03)2.6H20 (0.29g, Immol). 
Yield 72%. m.p. < 300 °C (decompose). Anal. (%) Calc. for [C36H32N60i2Zn]; C, 
53.64; H, 4.00; N, 10.43: Found: C, 53.65; H, 4.01; N, 10.46. [af^o = -47. Molar 
conductance, AM (1 X 10"^  M, methanol): 189 Q''cm^mor' (1:2 electrolyte). 
Selected IR data on KBr pellet (v/cm"'): 1579 (C=N); 1388, (NO3); 555 (Zn-O); 420 
(Zn-N). UV-vis in Methanol [>^ ax / nm]: 245, 302, 420. 'H N M R (DMSO-dg. ppm): 
8.29(-CH=N); 2.58(-OH); 7.54-7.81 (aromatic-H); 3.86(chiral-CH); 3.20-3.30(CH:-
O). '^ C NMR (DMS0-d6, Ppm): 175 (C=0), 168 (C=N); 115-133 (Ar-C); 72 (C-0); 
67(C-N). ESI-MS (m/z) 682 [C36H32N406Zn]^ . 
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Figure 69. Cylindrical bonded three dimensional model of complexes 
(a)[C36H34N60i3Cu](N03)2 (b)[C36H32N40i2Zn](N03)2. Color scheme: copper(II) 
dark gray; N dark blue; O red; C gray. The H atoms and are omitted for clarity 
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Results and discussion 
Synthesis and characterization 
The ligands were derived from the condensation reaction of 2-amino-3-
formylchromone with (R)-2-amino-2-phenylethanol in 1:1 stoichiometric ratio. The 
subsequent complexation of the ligand [CigHieNjOs] with metal sahs 
Cu(N03)2.3H20 and Zn(N03)2.6H20 in 2:1 molar ratio achieved the desired 
complex in moderate yields as depicted in Scheme 9. The structural characteristics of 
both ligand [Ci8H)6N203] and complexes [C36H34N607Cu](NO,)2-
[C36H32N406Zn](N03)2 were elucidated by employing elemental analysis, UV-vis.. 
IR, EPR, 'H N M R and '^ C NMR spectra! studies. Both the complexes are air stable 
and readily soluble in common organic solvents such as methanol, ethanol, DMSO. 
DMF, THF. The molar conductivity of the complexes in methanol was in the range 
210-189 D'cm^mof', which is in conformity for 1:2 electrolytic nature. 
IR spectral studies 
The comparative IR spectra of the ligand [C18H16N2O3] and complexes 
[C36H34N407Cu](N03)2 and [C36H32N406Zn](N03)2 give intricate details about the 
binding behaviour of the ligand with metal ions. In free ligand a strong v(C=N) band 
at 1611 cm' gives strong indication of the formation of the Schiff base [245J. 
However, a relative decrease of v(C=N) frequency to 1559-1579 cm"' supports the 
coordination of imine nitrogen atom with metal ion in complexes. Besides, a v(OH) 
band at 3420 cm'' was also observed in copper(II) complex [C36H34N407Cu](N03)2 
owing to the presence of coordinated water molecule [246]. The presence of nitrate 
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group in complexes [C36H34N407Cu](N03)2 and [C36H32N406Zn](N03)2 was 
ascertained by the existence of characteristic v(N03) frequency at 1384-1388 cm 
[247]. Additional support for the formation of the complexes was provided b> the 
existence of medium intensity bands in the region 579-555 cm"' and 452-420 cm ' 
assigned to v(M-O) and v(M-N) ,respectively [248,249]. 
Electronic spectra 
For complexes [C36H34N407Cu](N03)2 and [C36H32N406Zn](N03)2, three absorption 
bands with varied intensity were observed in the high energy UV region at -246 and 
-303 nm corresponding to IL transitions of the ligand. While a band centered at 420 
nm was observed in both the complexes [C36H34N407Cu](M()3)2 and 
[C36H32N406Zn](N03)2 ascribed to ligand to metal charge transfer (LMCT) [250]. 
Besides, a broad band was also observed in case of [C36H34N407Cu](N03)2 complex 
at 564 nm, corresponding to the d-d transition band consistent with a square 
pyramidal geometry of copper(II) ion [251] assigned to dxz, dyz <— d(x^ -y^ ) and d,^ <— 
d(x%'^ ) transitions [252,253] as evidenced further by EPR studies. 
EPR spectrum 
The solid state X-band EPR spectrum of the polycrystalline copper(ll) complex 
[C36H34N407Cu](N03)2 was recorded in DMSO at LNT with a magnetic field 
strength of 3000 G. The EPR spectrum of complex [C36H34N407Cu](NO,)2 revealed 
an isotropic spectrum with a broad signal indicating that the copper ion display a 
distorted square pyramidal geometry with g,so value of -2.08 [254]. Thus, an 
unpaired electron of paramagnetic 3d^ copper(II) ion occupy d(x -^y )^ orbital in (B|g) 
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ground state configuration with an elongated square based pyramidal geometry 
(Figure 70). 
Figure 70. X-bandEPR spectrum of complex [C36H34N607CuJ(N03)2at LNTwiih 
giso =2.08. 
NMR spectra 
The 'H and '^ C NMR spectra of the ligand [C18H16N2O3] and its complex 
[C36H32N406Zn](N03)2 exhibits well resolved signals and exhibit significant 
differences in their chemical shifts. The 'H NMR spectrum of the ligand exhibited 
signal at 8.84 ppm for -CH=N which has been shifted to 8.29 ppm in the /inc(II) 
complex indicating the involvement of azomethine group in complexation [245]. 
The persistence of NH2 protons and OH protons at 9.2 ppm and 2.56 ppm 
respectively, in both the NMR spectra of the ligand and complex suggest the non-
coordination of these groups in the complex [255]. 
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The 13C NMR of the ligand [Ci8H)6N203], display resonance signals at 164 ppm 
corresponding to C=N group [256]. A slight shift observed in C=N resonance 
supports its involvement in complexation with the metal ions. However, due to non-
involvement of other groups in complexation, their resonances remain unaltered 
compared to the free ligand. 
DNA binding studies 
UV-visible absorption studies 
The comparative DNA binding profiles of classical cisplatin drug, ligand 
[CsHieNzOs] and complexes [C36H34N407Cu](N03)2 and [C36H32N406Zn](N03)2 
were elucidated to gain evidence for the probable binding mode of the complexes 
and ligand. The absorption spectra of ligand and complexes, in presence and in the 
absence of CT-DNA are shown in Figure 71(a-d). Upon addition of increasing 
amount of CT-DNA from 0-0.33x10'* M, a significant "hyperchromic" effect in the 
intraligand bands at 246-303 nm was observed accompanied by a moderate red shift 
of 2-3 nm, indicative of stabilization of the DNA helix. These spectral characteristic 
suggest that the complexes and ligand bind either to the external contact 
(electrostatic binding) or to the major and minor grooves of DNA. Moreover, this 
"hyperchromic effect" can be explained on the basis of two phenomena. Firstly, the 
large surface area of the ligand as well as presence of planar aromatic chromophorc 
facilitates a strong binding interaction of the complexes with CT-DNA thereby. 
providing ample opportunity for the complex to bind with the CT-DNA via. partial 
insertion of the aromatic moiety in between the stacking base pair. The binding 
interaction between the cationic complex and CT-DNA leads to diffusion-limited 
14] 
ion-pair formation at higher concentration of the complex such that the complex is 
fitted along the contour of DNA double helix in an induced-fit fashion. Thus, the 
complexes preferably bind to the DNA helix via, groove binding interactions. 
WiVtitBglkiMB) 
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Figure 71. Absorption spectral traces of (a) Ligand [CisHj^NiOi] (b) complex 
[C36H34N407Cu](N03)2 (c) complcx [C36H32N40^n](N03)2 in DMSO upon addition 
ofCT-DNA at 25 "C. Inset: Plots of [DNA]/ Sa-sjvs [DNA] for the titration ofCT-
DNA with complexes. [Complex]=0.10x10'" M, [DNA]=0-0.33 x ] 0'^ M 
This groove binding results in structural reorganization of CT-DNA which entails 
partial unwinding or damage of the double helix at the exterior phosphate backbone 
leading to the formation of a cavity to accommodate the complex. C^onsequentlv, 
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uptake occurs with partial melting of the double helix and generation of an 
appropriate binding pocket [257,258]. 
Secondly, the presence of transition metal ions in complexes also accounts for the 
higher binding extent of the complexes with CT-DNA in comparison to free ligand. 
The complexes could uncoil the helical structure of DNA and expose the embedded 
base pairs to the helix exterior ultimately leading to an effective binding with 
transition metal ions {copper(II) and zinc(II)}. It has been reported earlier that a 
square-planar copper(II) meso-tetra(N-methyl-4-pyridyl)porphyrin, containing four 
positively charged pyridyl rings, binds to DNA via, normal intercalation [259J. 
However, the five-coordinated copper(II) complex, Cu(IDB)Cl2 (IDB = l,5-bis(2-
benzimidazolyl)diethylamine), with the aromatic moiety extending from the metal 
center does not bind to DNA by insertion; instead, the DNA base nitrogen atoms 
substitute for the two CI ions and then coordinate to the cupric ion in the complex 
[260] which reveals the significance of coordination geometry around the metal ion 
in CT-DNA binding. However, the presence of labile water molecule in complex 
[C36H34N407Cu](N03)2 also provide a greater binding extent of this complex to C f-
DNA relative to the [C36H32N406Zn](N03)2 which were efficiently replaced by 
nucleophile on DNA, usually a nitrogenous base such as guanine N7. leading to 
some covalent interactions with DNA [261]. Such covalent interactions were, 
however, prevented due to strong steric hindrance caused by large size of the 
molecule, yet, the partial insertion of the ligand phenyl group can be envisioned. Our 
resuhs illustrate that complexes may bind to DNA primarily via electrostatic 
interactions, preferably groove binding. Further validation of the DNA-binding 
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mode of the complexes was provided by viscosity measurements which was 
concomitant with the above explanation. 
To study quantitatively, the binding ability of complexes with CT-DNA, the intrinsic 
binding constant Kb values determined as given in Table 15. The binding constant Kh 
values follows the order [C36H34N407Cu](N03)2 > [C36H32N406Zn]{N03)2 > 
[Ci8H)6N203] > cisplatin. From the results of the binding constants, it was concluded 
that the studied complexes reveal a higher binding affinity for DNA double heiix 
compared to cisplatin (3.20±0.15xl0'' M"'). This relative difference in the Kb values 
might be the result of different binding mode of the complexes and cisplatin. 
Cisplatin binds to the CT-DNA via, base specific interactions forming 1.2-
intrastrand crosslinks between adjacent N7 atoms of guanine (GpG) and adenine 
nucleobase (ApG) and secondary interaction with phosphate backbone [211] which 
obscure the DNA helix to a much larger extent (Figure 43a). Moreover, the Kh 
values of the complexes were slightly higher than that of classical minor groove 
binder 4',6-diamino-2-phenylindole (DAPI-DNA, 8.90x10^ M'' in 2 mM Tris-0.2 
mM EDTA containing 30 mM NaCl buffer, pH 8) [262]. 
Table 15 . The binding constant (Kb) values of cisplatin, ligand and complexes wilh 
CT-DNA 
Complex Kb(M"') Monitored at X % Hyperchromism Red Shift 
(nm) (nm) 
Cisplatin 3.2(>iO. 15x10^ 248 
[C,8H,6N203] 1.37±0.02xl0' 310 
[C36H34N407Cu](N03)2 3.55±0.02xl0* 264 
[C36H32N406Zn](N03)2 2.33±0.02xl0^ 303 
17 
54 
75 
65 
02 
02 
03 
02 
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Interaction with 5'-GMP, 5'-TMP, 5'-AMP and 5'-CMP by absorption 
spectroscopy 
The site-selective recognition of nucleic acid fragments such as 5'-GMP, 5'-TMP. 5'-
AMP and 5'-CMP by complexes was monitored owing to the base specific 
interaction of the transition metal ions. Nucleotide-metal interactions [263,264] have 
been reported to occur nitrogen atom of the purine and pyrimidine rings as well as 
oxygen atom of the phosphate group present on the nucleotide. These base specific 
interaction of the complexes [C36H34N407Cu](N03)2 and [C36H32N406Zn](N03)2 
include a higher affinity of the copper(II) complexes to bind with N7 of guanine and 
zinc(II) complex with N3 of thymidine. 
(a) (i) 
(iii) 
0 40 
4tXI00 
.!38.76 400.00 
\Vavelength(iini) 
W'a-v-eleDgth(niu) 
Figure 72. Absorption spectral traces of (a) complex [C36H34N407CuJ(NOs): in 
DMSO upon addition of (i) 5'-GMP (ii) 5'-TMP (iii) 5'-CMP (iv) 5'-AMP. 
[Complex]=1.0xlO-^M, [Nucleotide]=0-0.53xlO'^M. 
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On addition of increasing amounts of mononucleotides (5'-GMP, 5'-TMP, 5'-AMP 
and 5'-CMP) to the complexes [C36H34N407Cu](N03)2 and [C36H32N406Zn](N03)2 
there is a sharp increase "hyperchromic" effect in the absorption bands at 246-302 
nm (Figure 72a,b). 
2 4 4 . 5 8 4OO.0O 
Waveleogtb(nin) 
("0 t 
244.25 400.00 
WaveleBgtb(nni) 
235.08 400.00 
W»vclength(nm) 
Figure 72. Absorption spectral traces of (a) Complex [Ci(^i2^406Zn](SOi)2 '^ 
DMSO upon addition of (i) 5'-GMP (ii) 5'-TMP (Hi) 5'-CMP (iv) 5'-AMP. 
[Complex]^1.0xlO-''M, [Nucleotide]=0-0.33xia"M. 
Even though no substantial change in the position of the intraligand band was 
observed by the addition of increasing amount of mononucleotide (0-0.33x10"^ M). 
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marked increase in the absorption intensity of the complexes authenticate binding of 
the complexes to different nucleotides through electrostatic surface binding 
interactions via, phosphate backbone of the DNA double helix. The purine and 
pyrimidine bases of CT-DNA become exposed because of the unwinding of the 
DNA helix promoting an effective binding to these base pairs with the transition 
metal complexes. To compare quantitatively, the affinity of the complexes to 
mononucleotides (5'-GMP, 5'-TMP, 5'-AMP and 5'-CMP), the intrinsic binding 
constants were also determined. The binding constants obtained for the complexes 
[C36H34N407Cu](N03)2 and [C36H32N406Zn](N03)2 have been given in Table 16. 
Table 16 . The comparative binding constant (Kb) values of complexes with the 5'-
GMP and 5'-TMP (mean standard deviation of ± 0.07). 
Complex 5'-GMP 5'-TMP 5'-AMP 5'-CMP 
(xlO*) (xlO') 
[C36H34N407CU](N03)2 22.0 1.20 
[C36H32N406Zn](N03)2 1.41 3.50 
(xlO') (xlO') 
8.50 1.22 
2.55 0.28 
Monitored at Red Shift 
(nm) 
303 
303 
(nm) 
04 
02 
The trend of mononucleotide interaction with [C36H34N407Cu](N03)2 as validated by 
Kb values was 5'-GMP > 5'-TMP > 5'-CMP > 5'-AMP while for 
[C36H32N406Zn](N03)2 complex, 5'-TMP > 5'-GMP > 5'-CMP > 5'-AMP trend was 
observed. The stronger coordination of complex [C36H34N407Cu](N03)2 to 5'-GMP 
compared to the [C36H32N406Zn](N03)2 supports a preferential binding of the 
complex to the N7 nitrogen of 5'-GMP occurring due to thermodynamic and kinetic 
stability of guanine residue [265]. However, the presence of two electron 
withdrawing oxo groups at the C2 and C3 position of the thymine lowers the energy 
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of the lone pair orbital atN3 of thymine base facilitating a stronger molecular orbital 
interaction of complex [C36H32N406Zn](N03)2 with thymine residue compared to 
guanine residue. 
' H and '^P NMR interaction with 5'-GMP and 5'-TMP 
Interaction studies of complex [C36H32N406Zn](N03)2 with nucleotides 5'-GMP and 
5'-TMP provide additional support for the mode of binding of these complexes with 
biomolecules and exhibited preferential selectivity of the zinc(II) complex for 5'-
TMP . Figure 73(a,b), illustrates comparative 'H. NMR spectra for free 5'-GMP and 
after addition of complex [C36H32N406Zn](N03)2. A mixture of complex-5-GMP 
shows insignificant shifts of the all the resonances of the nucleobase compared to the 
free nucleotide, suggestive of an electrostatic association of the complex with 
5'-GMP probably through the phosphate groups along the groove of DNA double 
helix. This observation agrees well with observations of UV-visible studies as 
electrostatic bonding has essentially no effect on the chemical shifts values 1266]. 
The other resonances of the free 5'-GMP undergo a slight shift of sugar hydroxy! 
protons from 5.82-3.87 ppm to 5.78-3.83 ppm revealing binding of the ribose ring 
protons with complex [C36H32N406Zn](N03)2. 
To validate the binding preference of the zinc(II) complex with 5'-TMP. the 
interaction pattern of the complex-5'-TMP with 'H NMR was also studied (Figure 
74a,b). 
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Figure 73. 'HNMR spectra of (a) 5'-GMP alone and (b) the reaction of complex 
[C36H32N406Zn](N03)2 (2.5 mmol) with 5'-GMP (5 mmol) at 25°C 
The ' H N M R spectrum of free 5'-TMP (5 mM in D2O), before the addition of 
complex reveals signals at 7.6, 6.2, 4.2, 1.7 ppm for N3 proton, C6 and C;H, of 
thymine group, respectively. After the addition of complex [C36H32N40AZn](NO,)2 . 
there is chemical slight shift of N3 from 7.65 ppm to 7.68 ppm suggestive of some 
interaction of complex with 5'-TMP. 
The ^'P NMR signal of free of 5'-TMP appeared at 2.39 ppm which was shifted 
upfield to 3.17 ppm in presence of complex [C36H32N406Zn](N03)2 (Figure 75). 
however, in case of 5'-GMP, no such pronounced shift in the ^'P NMR signal was 
observed after the addition of the complex to 5'-GMP ( in free 5'-GMP at 3.73 ppm. 
in complex bound-5'-GMP at 3.76 ppm) (Figure 76). This accounts for the presence 
of higher binding exhibited by the zinc(II) complex for 5'-TMP as compared to 5'-
GMP phosphate group. 
14*) 
(a) 
V V \'^W N\^ 
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Figure 74. HNMR spectra of (a) 5'-TMP alone and (b) the reaction of complex 
[C36H}2N40^n](NOi)2 (2.5 mmol) with 5'-TMP (5 mmol) at 25^C 
These pronounced changes in ^'P chemical shift values arise due to the changes in 
O-P-0 bond angles after its coordination with the complex [C36H32N406Zn](N03):. 
revealing a strong coordination of the complex with phosphate groups of nucleotide. 
The present observation is in agreement with preferential selectivity of the complex 
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[C36H32N406Zn](N03)2 towards 5'-TMP revealing an electrostatic binding mode of 
this complex with the nucleotide. 
(a) 
A_ 
(b) 
k.. 
Figure 75. ^'P NMR spectra of (a) free 5'-GMP (5 mmol) (h) complex 
[C36Hi2N40^n](N03)2 (2.5 mmol) with 5'-GMP at 25 "C 
(a) 
(b) 
1 
3h Figure 76. 'P NMR spectra of (a) free 5'-TMP (5 mmol) (b) complex 
[C36H32N40^n](N03)2 (2.5 mmol) with 5'-TMP at 25 °C. 
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Fluorescence studies 
The emission spectra of the complexes [C36H34N407Cu]CN03)2 and 
[C36H32N406Zn](N03)2 in the absence and presence of increasing amounts of CT-
DNA are depicted in Figure 77(a,b). In the absence of CT-DNA, both the complexes 
emit weak luminescence in Tris-HCI buffer at ambient temperatures with a maxima 
appearing at 480 nm when excited at 260 nm. However, the subsequent addition of 
CT-DNA from 0-0.33x10"^ M causes a gradual enhancement in the fluorescence 
intensity of the complexes with no apparent change in the shape and position of the 
emission bands. This implies that the complexes strongly interact with CT-DNA 
probably due to the inaccessibility of the solvent water molecules to reach the 
hydrophobic environment inside the DNA helix, and the mobility of the complexes 
is restricted at the binding site ultimately leading to decrease in vibrational mode of 
relaxation. However, this enhancement is much less as compared to classical 
intercalators [267,268]. The binding constant K values of the complexes were given 
in Table 17 shows a higher binding propensity of complex [C36H34N407Cu](N03): in 
contrast to complex [C36H32N406Zn](N03)2 concomitant with the absorption 
studies. The extent of DNA binding is evaluated by competitive fluorescence 
displacement assay of DNA-bound ethidium bromide. The studies involve the 
addition of complex with CT-DNA pretreated with EthBr and then the 
measurements of the intensities of EthBr emission. The emission spectra of EB-
DNA in the absence and presence of complexes are presented in Figure 78 Though 
the emission intensity of ethidium bromide in buffer medium is quenched by solvent 
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molecules, it is enhanced by its strong stacking interaction in between the adjacent 
DNA base pairs [185]. 
Table 17. Emission properties of complexes [C36H34N407Cu](NOi)2 and 
fC36Hs2N406ZnJ(N03)2 bound to CT-DNA. 
Complex Emission Excitation Monitored At K(M ) 
(nm) (nm) 
[C36H34N407CU](N03)2 330 
[C36H32N406Zn](N03)2 330 
260 
260 
380 
430 
7.48x10= 
9.83x Hf 
The addition of increasing amount of the complexes [C36H34N407Cu](N03 )2 and 
[C36H32N406Zn](N03)2 to DNA pretreated with ethidium bromide 
([DNA]/[EthBr]=l) resulting in apparent quenching of the emission intensity, 
indicative of the competitive displacement of the bound ethidium bromide from the 
CT-DNA by the complexes. The extent of quenching of the fluorescence of ethidium 
bromide bound to DNA would reflect the extent of DNA bindmg of 
[C36H34N407CU](N03)2 and [C36H32N406Zn](N03)2 
t (a) 10 
i;! 
o 
1 - I 
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Figure 77. Emission spectra of (a) complex [C36H34N407Cu](N03)2 and (h) complex 
[C36H32N40^n](N03)2 in Tris-HCl buffer the absence and presence of CT-DNA. 
Arrow shows the intensity change upon increasing CT-DNA concentration 
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Ethidium bromide, itself is a known intercalator, so a direct as well as an indirect 
displacement could occur. The direct competitive replacement would arise when the 
complex prefers to bind (though not necessarily by intercalation) at the same site as 
fluorescent dye. The dynamic equilibria and the concentration differences between 
the EthBr and complex would effectively exclude the dye from the binding site. It 
appears that the DNA helix simultaneously accommodates both the complex and 
ethidium bromide in the grooves, as validated by viscosity measurements, so an 
indirect displacement could take place, when the complex induces structural 
modifications in DNA from B—+A conformation via, untwisting of DNA base pairs, 
revealed by CD results due to its groove binding statistics thus, affecting the binding 
affinity for ethidium bromide by destabilising the excited state of bound ethidium 
bromide and facilitating an efficient displacement of bound ethidium bromide from 
CT-DNA. 
[DNA] M 
Figure 78. Stern-Volmer plot of fluorescence titration data of DNA-EthBr system 
(Xex=525 nm, Xem=520-680 nm) in presence of increasing concentration of complexes 
(a) [C36H32N40^n](N03)2 (u) (b) complex [C36H3J^407Cu](N03)2 (•) from 0-
0.33x10'" M. Quenching constant Ks^=^ 6.71x10" and 1.89x10" M' 
The fluorescence quenching curves of EB-DNA by the complexes is given in Figure 
73. The quenching plots obey a linear Stern-Volmer equation with Ksv value of 
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6.71x10^ and 1.89x10'* M ' for complexes [C36H34N407Cu](N03)2 and 
[C36H32N406Zn](N03)2, respectively. 
Table 18. Emission quenching of CT-DNA bound EthBr by complexes 
[C36H34N60i3Cu](N03)2 and [Ci6H32N40i2Zn](NOs)2. 
Complex Emission Excitation Monitored at Ksv 
[C36H34N407Cu](N03)2 520 525 580 6.71x10' 
[C36H32N406Zn](N03)2 520 525 580 1.89x10^ 
The high Ksv value for copper relative to zinc complex show that copper complex 
exhibit much higher binding affinity with CT-DNA compared to zinc complex 
(Table 18). Thus, the ability to hinder the DNA induced emission decreases in the 
order [C36H34N407Cu](N03)2 > [C36H32N406Zn](N03)2; which is consistent with the 
decrease in the binding constant of the complexes as illustrated above. 
Viscosity studies 
The changes in the relative viscosity of CT-DNA in presence of increasing amount 
of the complexes [C36H34N407Cu](N03)2 and [C36H32N406Zn](N03)2 and 1-thBr (a 
classical intercalators) are presented in Figure 79, Ethidium bromide (EthBr), a 
known DNA classical intercalator, increases the relative specific viscosity of DNA 
double helix due to lengthening of helix axis owing to its intercalative binding mode. 
In presence of increasing amount of ethidium bromide (EB) and complexes 
[C36H34N4CM:U}(N(>3)2, [C36H32N406Zn](N03)2, the relative viscosity of CT-DNA 
increases steadily [269]. However, this increase is rather less as compared to 
classical intercalators EthBr. The increasing degree of viscosity follows the order EB 
> [C36H34N407Cu](N03)2>[C36H32N406Zn](N03)2. On the basis of viscosity results, 
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at first glance, the increase in the viscosity of CT-DNA appears to result from the 
intercalative interactions but the increase is quiet less than that for potential 
intercalator viz; EthBr with the same concentration ranges of CT-DNA. 
Figure 79. Effect of addition of (a) EthBr and complexes (b) 
[C36H34N407CuJ(NOs)2, (c) [C36H32N406Zn](NOj)! on the relative viscosity of CT-
DNA. [DNAJ=1.45xlO"^M, r ([Complex]/[DNA]) = 1-5, respectively. 
Thus, we conclude that, although the complexes exhibit affinity for the intercalative 
site on DNA but the binding affinity to a lower extent than EthBr. These results 
indicate that the complexes bring conformational changes in a manner, probably due 
to the steric matching of the DNA grooves and the complexes 
[C36H34N407Cu](N03)2, [C36H32N406Zn](N03)2 resulting in some partial 
intercalation of the complexes within the hydrophobic DNA pockets through ihe 
aromatic rings. This aggregation of the complexes into the groove of DNA helix 
inducing partial intercalative interactions causes an extension of the DNA helix with 
concomitant increase in its viscosity. Thus, the above resuhs cumulatively indicate 
that the complexes [C36H34N407Cu](N03)2 and [C36H32N406Zn](N03)2 bind to CT-
DNA in the groove regions [270]. Moreover, the increase in viscosity observed tor 
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[C36H34N407Cu](N03)2 coiTiplex (Figure 79b) is more pronounced as compared to 
[C36H32N406Zn](N03)2 complex (Figure 79c), indicating that 
[C36H34N407Cu](N03)2 complcx bind more avidly with CT-DNA than 
[C36H32N406Zn](N03)2 complex. 
Circular dichroic studies 
The CD spectra of CT-DNA on addition complexes [C36H34N407Cu](N03)2 and 
[C36H32N406Zn](N03)2 depicted in Figure 80, exhibit significant perturbations both 
in negative and positive bands. The complex [C36H34N407Cu](N03)2 exhibit increase 
in both the positive and negative bands with respect to unbound CT-DNA which was 
attributed to partial insertion of planar aromatic chromophores in between the DNA 
base pairs causing stabilization of base stacking consequently, leading to 
conformational transition of B-form of DNA into more A-like conformation. 
However, complex [C36H32N406Zn](N03)2 displays small change in the positive 
band with respect to DNA accompanied by a large increase in the negative band as 
exhibited by complex [C36H34N407Cu](N03)2. This corroborates well with the 
hypothesis in literature that simple groove binding and electrostatic interaction oi the 
complexes with DNA shows less or no perturbation on the base stacking and helicity 
bands while intercalator enhances the intensities of both the bands [271]. These 
results supports groove binding nature of the complexes [C36l-l34N407Cu](N03)2 and 
[C36H32N406Zn](N03)2 probably due to some partial intercalative interactions which 
modifies the CT-DNA morphology during drug-DNA interactions. It is conceivable 
that the bigger size of the complex is critical for promoting B—vA conformational 
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transitions. The nucleobases in the deep major groove of DNA double helix were 
preferably accessible to the multivalent positively charged transition metal 
complexes. These positively charged transition metal complexes neutralize the two 
closely associated negatively charged sugar phosphate backbone along the major 
groove in A-DNA and results in B—»A conformational transitions. 
230 240 250 2M 270 
WiV8leiig0i(im) 
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Figure 80. Circular dichroism spectra ofCT-DNA in the (a) absence and presence 
of complex (b) [Ci6H34N407Cu](NOi)2 (blue line) (c) [C}6H32N40^n](NOi)2 (red 
line) in Tris-HCl buffer at 25 "C. [Complex]= Ixlff^ Mand [DNAJ=1.4 3x10" M. 
Gel electrophoresis 
Since the complex [C36H34N407Cu](N03)2 shows maximum binding propensity with 
CT-DNA, therefore, the cleavage activity has been evaluated for complex 
[C36H34N407Cu](N03)2. It has been well established in literature that copper(li) 
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complexes are selective for the cleavage of DNA either through oxidative or 
hydrolytic mechanism. 
The nuclease activity of complex [C36H34N407Cu](N03)2 have been studied using 
supercoiled pBR322 DNA as a substrate (Figure 81). To ascertain the DNA cleavage 
ability of complex, supercoiled pBR322 DNA was incubated with different 
concentration of complex in aqueous buffer solution (5mM Tris-HCl/40 mM NaCl, 
pH 7.42) without addition of any reductant. 
^ Form n 
> Form i n 
^ Form I 
Figure 81. The cleavage patterns of the agarose gel electrophoresis for pBR322 
plasmidDNA (300ng) by [C36H34N407Cu](N03)2; Lane 1: DNA control; Lane 2: 10 
//M complex + DNA; Lane 3: 20 /uM complex + DNA; Lane 4: 30 juM complex + 
DNA; Lane 5: 40 [xMcomplex + DNA. 
As observed from the Figure, that there is a gradual decrease in the amount of Form 1 
with a simultaneous increase in Form II (Lanes 2 and 3) on increasing the 
concentration of the complex. A notable cleavage feature observed for this complex 
is the appearance of Form III before the disappearance of Form 1 (Lanes 3 and 4). 
This phenomenon indicates that the complex is capable of performing direct strand 
scission, as a consequence, this complex is better suited for therapeutic applications 
particularly, in cancer chemotherapeutics, while many complexes are only able to 
cleave single strand successively [272]. 
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Figure 82. Agarose gel electrophoresis pattern for the cleavage pattern of pBR322 
plasmid DNA (SOOng) by complex fC36f^34N407CuJ{N03)2 (20 ^M) in presence of 
different activating agent at 312 K after incubation for 30 min. Lane 1, DNA control; 
Lane 2, DNA + lCi(fii4N407Cu](N03)2 + GSH (40 nM); Lane 3, DNA f 
[C36H34N407Cu](N03)2 + Asc (40 fjM); Lane 4, DNA + [C36H34N407Cu](N03j2 + MP A 
(40 ^ M); Lane 5, DNA + lCi^34N40TCu](N03)2 + H2O2 (40 iiM) 
In the presence of activators viz; glutathione (GSH), ascorbic acid (Asc), hydrogen 
peroxide (H2O2) and mercaptoprop ionic acid (MPA), the complex 
[C36H34N407Cu](N03)2 showed significant increase in the cleavage of the DNA and 
follows the order H2O2 > MPA > GSH > Asc (Figure 82). 
The mechanistic pathway for the cleavage of plasmid DNA followed by complex 
was investigated by gel electrophoresis in the presence of various radical scavengers 
such as NaNj, DMSO, tert-butyl alcohol, NaNs (Figure 83, Lane 2-5). The DNA 
cleavage of the plasmid was inhibited in the presence of NaNs suggesting that 'O2 is 
likely to be the reactive species responsible for the nuclease activity (Lane 2). When 
hydroxyl radical scavenger, DMSO and tert-butyl alcohol were added to the reaction 
mixture, they were found to diminish the nuclease activity which was indicative of 
the involvement of OH' radicals in the cleavage process (Lane 3 and 4). Similarly, in 
the presence of SOD, the cleavage was repressed which indicate that O2" might be 
an inhibitor in the cleavage process and reducing the amount of O2' can improve the 
cleavage effect (Lane 5). Thus, the results suggested the oxidative pathway of the 
complex to cleave the DNA. 
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^ Form I 
Figure 83. Agarose gel electrophoresis pattern for the cleavage of pBR322 plasmid 
DNA (SOOng) by complex [C36H34N407CuJ(N03)2 (20 fiM) in presence of standard 
radical scavengers at 310 K after incubation for 30 min. Lane 1, DNA control; Lane 
2, DNA + [C36Hs4N407CuJ(N03)2 + NaN3 (40 /uM); Lane 3, DNA + 
[C36H34N407Cu](N03)2 + DMSO (40 nM); Lane 4, DNA + [C3dii4N407Cu](N03)2 + 
tert-butyl alcohol (40 /xM); Lane 5, DNA + [C36H34N407Cu](N03)2 + Superoxide 
dismutase (15 Units). 
When supercoiled pBR322 DNA was treated with DAPI, the cleavage reaction 
mediated by complex was not quenched (Figure 84, Lane 2). This clearly suggests 
that the complex prefers to bind to DNA major groove. Further support to this 
observation was provided by complete inhibition of the cleavage by the complex in 
presence of methyl green, a major groove binding agent (Figure 84, Lane 3). 
Form II 
> Form I 
•if X villi 11 
> Form I 
Figure 84. Agarose gel electrophoresis pattern for the clevage of pBR322 plasmid 
DNA (300ng) by complex [C36H34N407Cu](N03)2 (20 juMj in the presence of DNA 
minor binding agent DAPL and major binding agent methyl green at 310 K after 
incubation for 30 min. Lane 1, DNA control; Lane 2, DNA + 
[C36H34N407Cu](N03)2^ DAPI (8 nM); Lane 3, DNA + [C36H34N407Cu](N03)2+ 
Methyl green (2.5 //Z of a O.Olmg/ml solution) 
Conclusions 
Two new transition metal complexes [C36H34N407Cu](N03)2 and 
[C36H32N406Zn](N03)2 have been synthesized and characterized. The comparative 
binding propensities of the two complexes with CT-DNA were also investigated by 
absorption, emission, circular dichroism and viscosity measurements. Experimental 
results indicate that the two complexes bind to CT-DNA by electrostatic groove 
binding mechanism. As observed for gel electrophoretic mobility assay, the complex 
[C36H34N407Cu](N03)2 displays efficient cleavage activity of plasmid pBR322 DNA 
converting the Form I to Form II and uhimately to leading to the formation of 
linearized Form III with increasing concentrations of the complex. Singlet oxygen 
('O2) and hydroxyl radicals ('OH) is likely to be the reactive species responsible for 
the nuclease activity of plasmid DNA. Additionally, the most notable evidence for 
the groove binding of the complexes was provided by gel electrophoresis of plasmid 
DNA in presence of groove recognition agents DAPI and methyl green suggesting a 
major groove selectivity of the complex. 
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